0001753926-20-000051.txt : 20200327 0001753926-20-000051.hdr.sgml : 20200327 20200327164729 ACCESSION NUMBER: 0001753926-20-000051 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 57 CONFORMED PERIOD OF REPORT: 20191231 FILED AS OF DATE: 20200327 DATE AS OF CHANGE: 20200327 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Canfield Medical Supply, Inc. CENTRAL INDEX KEY: 0001553788 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HOME HEALTH CARE SERVICES [8082] IRS NUMBER: 341720075 STATE OF INCORPORATION: CO FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-55114 FILM NUMBER: 20752465 BUSINESS ADDRESS: STREET 1: 4120 BOARDMAN-CANFIELD ROAD CITY: CANFIELD STATE: OH ZIP: 44406 BUSINESS PHONE: (330) 533-1914 MAIL ADDRESS: STREET 1: 4120 BOARDMAN-CANFIELD ROAD CITY: CANFIELD STATE: OH ZIP: 44406 10-K 1 g081940_10k.htm 10-K

U.S. SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-K

☒		ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

		For the fiscal year ended December 31, 2019

☐		TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _________to _________

Commission File Number 000-55114

Canfield Medical Supply, Inc.

(Exact name of registrant as specified in its charter)

Colorado		34-1720075
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

4120 Boardman-Canfield Road, Canfield, Ohio		44406
(Address of principal executive offices)		(Zip Code)

Registrant's Telephone Number, including area code: (330) 533-1914

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
None

Securities registered pursuant to Section 12(g) of the Act:

Common Stock, No Par Value

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. ☐ Yes ☒ No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

☐ Yes ☒ No

Indicate by check mark whether the registrant (i) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

Indicate by checkmark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No

Indicate by checkmark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and “emerging growth company,” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Indicate by check mark whether the registrant is a shell company (as defined in rule 12b-2 of the Act). ☐ Yes ☒ No

The aggregate market value of the Registrant's common equity held by non-affiliates computed by reference to the price at which the common equity was last sold as of the last business day of the Registrant's most recently completed second fiscal quarter was $3,683,160.

On March 27, 2020, there were 11,813,200 shares of the Registrant's common stock outstanding.

CANFIELD MEDICAL SUPPLY, INC.

FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2019

TABLE OF CONTENTS

		Page
PART I

Item 1.	Business	3
Item 1A.	Risk Factors	9
Item 1B.	Unresolved Staff Comments	9
Item 2.	Properties	9
Item 3.	Legal Proceedings	9
Item 4.	Mine Safety Disclosures	9

PART II

Item 5.	Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	10
Item 6.	Selected Financial Data	10
Item 7.	Management's Discussion and Analysis of Financial Condition and Results of Operations	10
Item 7A.	Quantitative and Qualitative Disclosures about Market Risk	13
Item 8.	Financial Statements and Supplementary Data	13
Item 9.	Changes in and Disagreements With Accountants on Accounting and Financial Disclosure	15
Item 9A.	Controls and Procedures	15
Item 9B.	Other Information	16

PART III

Item 10.	Directors, Executive Officers and Corporate Governance	17
Item 11.	Executive Compensation	20
Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	21
Item 13.	Certain Relationships and Related Transactions and Director Independence	21
Item 14.	Principal Accounting Fees and Services	21

PART IV

Item 15.	Exhibits, Financial Statement Schedules	23
	Signatures	24

PART I

Item 1. Business.

General Information

Canfield Medical Supply, Inc. ("the Company," "it", "we', "us" or "our") was incorporated in the State of Ohio on September 3, 1992. On April 18, 2012 it changed its domicile to the State of Colorado by merging with a newly formed Colorado subsidiary.

We commenced our operations in September 1992. Initially we operated as a compounding pharmacy providing Intradialytic Parenteral Nutrition (a means of providing additional nutrition to patients on dialysis) to patients with End Stage Renal Disease who had experienced excessive weight loss due to intestinal malabsorption. We also provided pharmacy services to patients who required intravenous antibiotic therapy, home total parenteral nutrition and home enteral nutrition. (Enteral nutrition involves absorption of the drug through the gastrointestinal tract and parenteral nutrition involves administering the drug/nutrition in some way other than the digestive tract.) We also provided various nebulizer medications for patients with chronic obstructive pulmonary disease. (A nebulizer is a device used to administer medication in the form of a mist inhaled into the lungs.) We ceased pharmacy operations in May 2002 in response to significant reductions in reimbursement by Medicare, Medicaid and Private Insurance Companies, and changed our focus to providing quality home medical equipment and supplies to patients in our geographical area. We have never been involved in any bankruptcy, receivership, or similar proceeding.

Effective June 21, 2019 WesBev LLC, a Nevada limited liability company ("WesBev"), acquired 8,000,000 shares of common stock from Michael J. West, a founder, director and former principal shareholder of the Company, consisting of approximately 69.7% of the issued and outstanding shares of the Company at the time of the purchase. As part of his agreement with WesBev, Mr. West undertook to appoint or cause the appointment of up to three persons nominated by WesBev to the board of directors of the Company. Effective June 21, 2019 the Company sold 336,000 shares of common stock to WesBev for $100,000. Following these stock purchases WesBev beneficially owned 8,336,000 shares, or approximately 71% of the issued and outstanding shares of the Company.

On December 31, 2019, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with SBG Acquisition Inc. (“Merger Sub”), a Nevada Corporation wholly-owned by the Company, and Splash Beverage Group, Inc. a Nevada corporation (“Splash”) pursuant to which Merger Sub shall be merged with and into Splash (the “Merger”) with Splash as the surviving company and a wholly-owned subsidiary of the Company. The closing of the Merger shall take place on the first business day following satisfaction or waiver of the closing terms and conditions set forth in the Merger Agreement.

Completion of the Merger is subject to customary closing terms and conditions including, among others:

	•	the adoption of the Merger Agreement by Splash’s stockholders;
	•	the representations and warranties of the respective parties being true and correct in all material respects as of the closing day of the Merger;
	•	since June 1, 2019 through the closing of the Merger, Splash shall have raised from the aggregate sale of its equity securities not less than $1,500,000 which shall be available or was utilized for inventory purchases, reductions to accounts payable and for other general working capital purposes;
	•	on the closing of the Merger liabilities of Splash debt shall not exceed $500,000;
	•	Splash shall have entered into note conversion agreements with substantially all holders of its debt pursuant to which such debt is converted into shares Splash’s common stock at a conversion price of $1.00 per share;
	•	designated shareholders of Splash shall have entered into lock-up/leak out agreements by which they will agree to restrict post-Merger sales of Canfield securities for a period of up to one year following the Merger, as more particularly described within the Merger Agreement;
	•	the Company and Michael West, the Company’s former Chief Executive Officer, and a current director, shall have entered into a Business Transfer and Indemnity Agreement pursuant to which all operations, assets and liabilities of the Company’s home health services business shall be transferred and conveyed to Mr. West or an entity designated by Mr. West in exchange for his indemnifying the Company for certain liabilities and claims;
	•	the Company shall not have any liabilities exceeding $50,000 in the aggregate;
	•	the Company’s directors and officers shall have tendered their resignations;
	•	Robert Nistico, Chief Executive Officer of Splash, shall be appointed as chief executive officer of the Company; and
	•	the composition of the Company’s board of directors shall be as set forth in the Merger Agreement.

As of the date of this annual report, all conditions to closing have been completed, except for the fourth, and the seventh through eleventh bulleted conditions listed above. The items listed in the seventh, ninth and tenth bulleted conditions above have been finalized, but will not be delivered until the closing date.

At the closing of the Merger, each outstanding share of common stock, Series A Preferred Stock and Series B Preferred Stock of Splash, shall be converted into such amount of fully paid and non-assessable shares of common stock of the Company. Upon completion of the merger, shareholders of Splash as a group will own on a fully diluted basis approximately 85% of the Company and the current shareholders of the Company as a group will own on a fully diluted basis approximately 15% of the Company.

Business

We are a provider of home medical equipment, supplies and services (which relate to the equipment sales) in Ohio's Mahoning Valley, with an emphasis on providing for patients with mobility related limitations. We also sell to patients in Western Pennsylvania and Northern West Virginia. We typically provide equipment, supplies and services to people who have had strokes, hip or knee replacements, and other surgeries after they are discharged from a hospital or rehab center. We provide almost any medical equipment and supplies these persons need to enable them to remain in their homes. We have been in the home health care business since 1992 and have developed relationships with many of the local physicians, discharge planners for hospitals and rehab facilities, nursing services, and home health agencies.

We operate in only one segment, which is home medical equipment and supplies. We also provide the services described below along with the equipment and supplies, but most of our revenue is derived from the sale of equipment and supplies. Most of the equipment and supplies that we sell are prescribed by a physician and are part of a care plan. We provide substantial benefits to both patients and payors by allowing patients to receive necessary care and services in the comfort of their own home while reducing the cost of treatment. Our services include:

	1.	Providing in-home delivery, set-up, and maintenance of equipment;
	2.	Providing patients and caregivers with written instructions about home safety, self-care, and the proper use of equipment;
	3.	Processing claims to third-party payors and billing/collecting patient co-pays and deductibles.

We supply a wide range of home medical equipment to help improve the quality of life for patients with special needs, particularly those who face unique mobility challenges as they try to remain independent in their homes. The use of home medical equipment provides a significant relative cost advantage to our patients and payors. The basic categories of equipment we carry are:

	1.	Electric wheelchairs, scooters, and lift chairs
	2.	Manual wheelchairs and ambulatory equipment, such as wheeled walkers, canes, and crutches;
	3.	Hospital beds;
	4.	Bathroom equipment, such as bedside commodes, shower chairs, grab bars, and toilet risers;
	5.	Support surfaces, such as pressure pads and mattresses, for patients at risk for developing pressure sores or decubitus ulcers;
	6.	Threshold ramps, folding ramps, and lift systems for cars or vans that make it easy to exit the home or transport electric wheelchairs or scooters.

Our Competitive Strength

Our principal competitive strength is that we are an established local company in the Mahoning Valley with a reputation for good service and good quality. If a patient has any problems with a piece of equipment they purchase from us, they can call us and we will take care of the problem. Historically we have not experienced significant returns or refunds. We contract with Medicare, Medicaid, most major health insurance companies, and a number of other payors. We are especially known as a business that can provide almost anything a patient with reduced mobility needs, including home modifications necessary to remain independent in the home.

We also qualify as a "small supplier" under the Medicare competitive bidding program, since our annual revenues are less than $3.5 million. The Medicare regulations have established a 30 percent target for small supplier participation, which improves our chances of winning small bids from Medicare. As a supplier in the Medicare program, we are required to meet and adhere to certain standards set by Medicare.

We also participate in the Ohio Medicaid program. Our agreement with the Ohio Department of Jobs and Family Services expires on July 31, 2020 at which time we must apply for a new agreement.

Organization and Operations

Organization. Our only facility is our office/showroom located at 4120 Boardman-Canfield Road in Canfield, Ohio, about eight miles southwest of Youngstown, Ohio. From this location we deliver our home healthcare products and services to patients in their homes and to other care sites using our delivery vehicles and our employees.

Payors. We derive substantially all of our revenues from third-party payors, including private insurers, Medicare, Medicaid, and managed care organizations. For the year ended December 31, 2019, approximately 29% of our net revenues were derived from Medicare and Medicaid. Generally, each third-party payor has specific requirements, which must be met before claim submission will result in payment. We have procedures in place to manage the claims submission process, including verification procedures to facilitate complete and accurate documentation. Notwithstanding these measures, violation of these requirements may still occur and could result in the termination of a contract with a payor, the repayment of amounts previously received, or other potentially significant liability. When the third-party payor is a governmental entity, violations of these requirements could subject us to civil, administrative, and criminal enforcement actions. We are subject to periodic audits by Medicare and Medicaid, the results of which have not identified any violations by us of these governmental entities' claim submission requirements.

Medicare Claims. Most Medicare claims are paid within 30 to 60 days of submission. High dollar claims such as power chairs and pressure reduction surfaces require increased scrutiny by Medicare. Such high dollar claims frequently are singled out for pre-payment audits, which require all hard copy documentation of the patient's condition by the physician be sent in to Medicare prior to receiving payment. These claims take a minimum of 60 days to process and denials must be appealed. All subsequent claims to Medicare for rental payments for the denied equipment continue to be denied until the appeal process is finished. All of these claims require additional time to be completed and sometimes require phone calls to patients and doctors to reconcile. Management is constantly reviewing unpaid claims to determine their status and claims are not written off until all attempts to collect payment from Medicare have been exhausted. We historically write off approximately 5% of Medicare payments due to unsuccessful collection attempts.

Medicaid Claims. Based on our results for the last three years, approximately 70% of our Medicaid claims are paid within 30 days. Any claims not paid within 30 days usually have a billing error that has not been resolved by management and end up getting resolved and paid within an additional 30 to 60 days.

Self-pay Claims. Approximately 12% of our business during the year ended December 31, 2019 was comprised of self-pay business. This business represents persons who come into our store and purchase items not covered by insurance and patients who already may be purchasing something from us that is covered by insurance and they desire to purchase something additional that is not covered by insurance. Some of these customers pay for their product at the time of purchase and we send or deliver invoices to the others. These invoices request payment on receipt of the invoice. We consider these receivables delinquent once they are 180 days late. We rely on our past collection experience with other patients for similar or different products to determine if any of such receivables are still collectible. At December 31, 2019, we determined that no allowance for such items was necessary.

With respect to our claims submitted to third party payors, our billing system generates contractual adjustments based on fee schedules for the patient's insurance plan for each claim.

Receivables Management. We operate in an environment with complex requirements governing billing and reimbursement for our products and services. We are expanding our use of technology in areas such as electronic claims submission and electronic funds transfer whenever we can to more efficiently process business transactions. This use of technology can expedite claims processing and reduce the administrative cost associated with this activity for both us and our customers/payors. Our policy is to collect co-payments from the patient or applicable secondary payor. In the absence of a secondary payor, we generally require the co-payment at the time the patient is initially established with the product/service. Subsequent months' co-payments are billed to the patient.

With respect to rentals of power chairs, once initial delivery of rental equipment is made to the patient, a monthly billing cycle is established based on the initial date of delivery. The Company recognizes rental revenue ratably over the 13-month service period. Routine maintenance and servicing of the equipment is the responsibility of the Company.

Marketing

We market our products and services primarily to physicians, discharge planners for hospitals and rehab facilities, nursing services, companies that provide home care companions and aides, home health agencies, and case managers. Our marketing is primarily done by Michael West, our former President who has developed relationships with many of the persons to whom we market in the course of his dealings with prior patients who purchased our products or services over the past 25 years that we have been in business. Most of our marketing consists of face-to-face meetings and in-service education with the staff at facilities to which we provide services. We also provide educational pamphlets and product specific brochures to go along with marketing materials such as pens, scratch pads, calendars, and prescription pads.

One of the marketing steps we have taken is to be accredited by The Joint Commission, which is a nationally recognized organization that develops standards for various healthcare industry segments and monitors compliance with those standards through voluntary surveys of participating providers. We have been accredited by The Joint Commission since 2008, with on-site accreditation renewal every three years and online recertification every year. As the home healthcare industry has grown and accreditation has become a mandatory requirement for Medicare DMEPOS providers, the need for objective quality measurements has increased. Accreditation is also widely considered a prerequisite for entering into contracts with managed care organizations and is required for Medicare competitive bidding. Because accreditation is expensive and time consuming, not all providers choose to undergo the process.

Sales

Our President has primary responsibility for generating new referrals and for maintaining existing relationships for our products and services. Our customers are typically the patients who purchase and utilize our products and services, but these patients are usually referred to us by physicians and their staffs, the discharge planners in hospitals and rehab facilities, nursing services and services that provide home care companions, and aides. We have several rehabilitation facilities that refer a significant amount of patients to us that account for in excess of 25% of our gross revenues. These facilities include Park Vista Rehabilitation, Sunrise Senior Living, and Whispering Pines Village Assisted & Independent Living. However, these facilities also refer business to other providers.

Website

We currently have a website which shows pictures of most of the products we sell with links to the manufacturers/suppliers of the products. This allows viewers to obtain more information on the products. The website is not designed to be used for online sales, and instead it is used more to show new or existing patients what products we can obtain and sell to them. There is also no product pricing on the website.

We intend to enhance this website so that online sales can be made on the website once we have funding available. We intend to contract with a leading web store builder program that offers a wealth of features to expand our business and provide support as our business grows. This program will make it easy to launch and maintain our web store. We hope to build a state-of-the-art e-commerce site that reflects our brands and puts our Company on a fast track to leveraging the sales opportunities on the Internet. This whole process could be accomplished in only a manner of weeks once funding is available, and will not require the purchase of new computers or software licenses, or hiring of additional staff.

Competition

The segment of the healthcare market in which we compete is highly competitive. In our line of products and services, there are a limited number of national providers and numerous regional and local providers. The competitive factors most important in our local market are:

	1.	Reputation with referral sources, including local physicians and hospital-based professionals;
	2.	Price of products and services;
	3.	Accessibility and overall ease of doing business;
	4.	Quality of patient care and associated services;
	5.	Range of home healthcare products and services;
	6.	Ability to provide local maintenance service on products sold.

The primary national provider with which we compete is Apria Healthcare Group, Inc., and the primary regional providers with which we compete in Northeastern Ohio and Western Pennsylvania are Boardman Medical Supply, Inc., Community Home Medical, Inc., and Seeley Medical, Inc. Depending on their business strategies and financial position, a very large percentage of our competitors have access to significantly greater financial and marketing resources than we do. This may increase pricing pressure and limit our ability to maintain or increase our market share.

Government Regulation

We are subject to extensive government regulation, including numerous laws directed at regulating reimbursement of our products and services under various government programs and preventing fraud and abuse, as more fully described below. We maintain certain safeguards intended to reduce the likelihood that we will engage in conduct or enter into arrangements in violation of these restrictions. All contracts with Insurance Companies are fairly standard and do not require legal opinions, and all our policies and procedures have been reviewed by The Joint Commission and meet Industry standards and requirements. Federal and state laws require that we obtain facility and other regulatory licenses and that we enroll as a supplier with federal and state health programs. Notwithstanding these measures, due to changes in and new interpretations of such laws and regulations, and changes in our business, among other factors, violations of these laws and regulations may still occur, which could subject us to civil and criminal enforcement actions; licensure revocation, suspension, or non-renewal; severe fines and penalties; and even the termination of our ability to provide services, including those provided under certain government programs such as Medicare and Medicaid.

Medicare and Medicaid Revenues. In the years ended December 31, 2019 and 2018, approximately 29% of our net revenues were reimbursed by the Medicare and state Medicaid programs, respectively. No other third-party payor represented more than 10% of our total net revenues for the year ended December 31, 2019. The majority of our revenues are derived from sales of equipment and supplies we sell to patients for patient care under fee-for-service arrangements. Fee-for-service is a payment model where services are unbundled and paid for separately, and occurs when doctors and other health care providers receive a fee for each service, such as an office visit, test, or procedure. Since most of the manufacturers of the products we sell do not provide direct patient care, our services primarily involve providing in-home-delivery, set-up, and maintenance of home medical equipment. All of these services are included in our service under a single claim, and cannot be billed separately. We do not have ongoing arrangements with patients or medical providers, other than rental agreements that we have for wheel chairs and hospital beds.

Medicare Reimbursement. There are a number of legislative and regulatory initiatives in Congress and at CMS that affect or may affect Medicare reimbursement policies for products and services we provide. Specifically, a number of important legislative changes that affect our business were included in the Medicare Prescription Drug, Improvement and Modernization Act of 2003 ("MMA"); the Deficit Reduction Act of 2005 ("DRA"); MIPPA, which became law in 2008; and the comprehensive healthcare reform law signed in March 2010 ("the Reform Package"). These Acts and their implementing regulations and guidelines contain numerous provisions that are significant to us and continue to have an impact on our operations today.

Employees

As of December 31, 2019, we had four full-time and five part-time employees.

Item 1A. Risk Factors.

As a smaller reporting company, we are not required to provide the information required by this item.

Item 1B. Unresolved Staff Comments.

None.

Item 2. Properties.

Our offices are located at 4120 Boardman-Canfield Road, Canfield, Ohio 44406. We rent our offices pursuant to a three-year lease extension which expires in September 2020. Our monthly rent is approximately $2,700, plus costs.

Item 3. Legal Proceedings.

No legal proceedings are currently pending or threatened to the best of our knowledge.

Item 4. Mine Safety Disclosures.

Not applicable.

PART II

Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

Price Ranges of Common Stock

Our stock is quoted on the OTCQB under the symbol “CNMF.” We were listed on July 10, 2018. There are 11,813,200 shares outstanding as of March 27, 2020. The below table provides the high and low bid prices of our common stock for each quarterly period during the previous two fiscal years.

	Year ended December 31, 2019
	High		Low
Fourth Quarter	$	1.50	$	0.54
Third Quarter	$	8.99	$	0.60
Second Quarter	$	1.37	$	0.45
First Quarter	$	0.07	$	0.01

	Year ended December 31, 2018
	High			Low
Fourth Quarter		$	0.70			$	0.01
Third Quarter		$	0.01			$	0.01
Second Quarter		$	N/A		$		N/A
First Quarter		$	N/A		$		N/A

Aggregate Number of Holders of Common Stock

The number of record holders of our common stock on December 31, 2019 was 133.

Dividends

Holders of our common stock are entitled to receive dividends as may be declared from time to time by our Board of Directors. We have not paid any cash dividends on our common stock and do not anticipate paying any in the foreseeable future. Management's current policy is to retain earnings, if any, for use in our operations and for expansion of the business.

Securities Authorized for Issuance under Equity Compensation Plans

None.

Equity Compensation Plan Information

We do not have any compensation plans or stock option plans.

Recent Sales of Unregistered Securities

In June 2019, the Company received net proceeds of $100,000 from the sale of 336,000 shares of no-par value common stock at $0.298 per share.

In July 2018, the Company received net proceeds of $2,000 from the sale of 200,000 shares of no-par value common stock at $0.01 per share.

The above listed sales were made pursuant to the exemption from registration available under Section 4(a)(2) of the Securities Act of 1933.

Item 6. Selected Financial Data.

This item is not required for Smaller Reporting Companies.

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis should be read in conjunction with the Financial Statements and Notes to Financial Statements filed herein.

Business Overview

We primarily provide services to the rehabilitation market, which consists primarily of home medical equipment and supplies. More than 50% of our revenues are derived from the sale and rental of durable home medical equipment including such items as wheeled walkers, manual and power wheelchairs, hospital beds, ramps, bedside commodes, and miscellaneous bathroom equipment. The balance of our revenue is from the sale of various home medical supplies including diabetic testing, incontinence, ostomy, wound care, and catheter care. Our emphasis is on helping patients with mobility related limitations, but our overall business is aimed at helping patients remain in their homes instead of having to go to hospitals, rehab centers, and other similar facilities. Most of the equipment and supplies that we sell are prescribed by a physician as part of an overall care plan.

Effective June 21, 2019, WesBev LLC, a Nevada limited liability company ("WesBev"), acquired 8,000,000 shares of common stock from Michael J. West, a founder, director and former principal shareholder of the Company, consisting of approximately 69.7% of the issued and outstanding shares of the Company at the time of the purchase. As part of his agreement with WesBev, Mr. West undertook to appoint or cause the appointment of up to three persons nominated by WesBev to the board of directors of the Company. Effective June 21, 2019 the Company sold 336,000 shares of common stock to WesBev for $100,000. Following these stock purchases WesBev beneficially owned 8,336,000 shares, or approximately 71% of the issued and outstanding shares of the Company.

Completion of the Merger is subject to customary closing terms and conditions including, among others:

	●	the adoption of the Merger Agreement by Splash’s stockholders;
	●	the representations and warranties of the respective parties being true and correct in all material respects as of the closing day of the Merger;
	●	since June 1, 2019 through the closing of the Merger, Splash shall have raised from the aggregate sale of its equity securities not less than $1,500,000 which shall be available or was utilized for inventory purchases, reductions to accounts payable and for other general working capital purposes;
	●	on the closing of the Merger liabilities of Splash debt shall not exceed $500,000;
	●	Splash shall have entered into note conversion agreements with substantially all holders of its debt pursuant to which such debt is converted into shares Splash’s common stock at a conversion price of $1.00 per share;
	●	designated shareholders of Splash shall have entered into lock-up/leak out agreements by which they will agree to restrict post-Merger sales of Canfield securities for a period of up to one year following the Merger, as more particularly described within the Merger Agreement;
	●	the Company and Michael West, the Company’s former Chief Executive Officer, and a current director, shall have entered into a Business Transfer and Indemnity Agreement pursuant to which all operations, assets and liabilities of the Company’s home health services business shall be transferred and conveyed to Mr. West or an entity designated by Mr. West in exchange for his indemnifying the Company for certain liabilities and claims;
	●	the Company shall not have any liabilities exceeding $50,000 in the aggregate;
	●	the Company’s directors and officers shall have tendered their resignations;
	●	Robert Nistico, Chief Executive Officer of Splash, shall be appointed as chief executive officer of the Company; and
	●	the composition of the Company’s board of directors shall be as set forth in the Merger Agreement.

Results of Operation for the year ended December 31, 2019 as compared to the year ended December 31, 2018

Revenues for the year ended December 31, 2019 were $1,017,833 as compared to the revenues of $1,309,178 for the year ended December 31, 2018. The $291,345 decrease in sales is due to a decrease in the number of expensive complex rehab powerchairs sold as well as custom manual wheelchairs sold in the year ended December 31, 2019 as compared to the year ended December 31, 2018.

Cost of goods sold for the year ended December 31, 2019 were $508,874 as compared to cost of goods sold for the year ended December 31, 2018 of $605,273. The $96,399 decrease in cost of goods sold during the year ended December 31, 2019 is primarily due to our decreased sales of powerchairs and manual wheelchairs. As our sales of those products decreased, our costs associated with the sale of those products correspondingly decreased.

Operating expenses for the year ended December 31, 2019 were $927,209 as compared to $637,230 for the year ended December 31, 2018. The $289,979 increase in operating expenses was primarily due to an $82,026 increase in our professional fees due to change in control, a $36,469 increase in salaries and wages, and issuance of stock options valued at $160,786.

Our net loss for the year ended December 31, 2019 was $477,234 as compared to net income of $68,206 for the year ended December 31, 2018. The primary reasons for the change to a net loss for 2019 versus net income in 2018 was our $291,349 decrease in revenue for the year ended December 31, 2019, coupled with our $342,125 increase in operating expenses during the period.

Liquidity and Capital Resources

As of December 31, 2019, we had a working capital deficit of $260,888 compared to a working capital deficit of $55,788 as of December 31, 2018.

Net cash used for operating activities during the year ended December 31, 2019 was $228,405 as compared to net cash provided by operating activities for the year ended December 31, 2018 of $62,392. The primary reasons for the change in our cash related to operating activities was the decrease in revenue and the increase in operating expenses as explained above.

Net cash used for investing activities during the year ended December 31, 2019 was $47,939, which consisted of $54,385 used for the purchase of equipment which was offset by $6,446 received from the sale of equipment as compared to net cash used for investing activities of $67,569 for the year ended December 31, 2018, which consisted of $75,633 used for the purchase of equipment offset by $8,064 received from the sale of equipment.

Net cash provided by financing activities during the year ended December 31, 2019 was $292,679 as compared to $5,764 used for financing activities for the year ended December 31, 2018. The Company sold shares of its common stock during the years ended December 31, 2019 and 2018 for proceeds of $100,000 and $2,000, respectively. The Company also paid $8,523 and $11,567 in debt principal during the years ended December 31, 2019 and 2018, respectively. In addition, during the year ended December 31, 2019, an officer lent the Company net proceeds of $197,849 in cash to be used for working capital.

We believe that our recent public and private offerings will provide sufficient capital in the short term for our current level of operations. Additional resources will be needed to build our web store and to otherwise increase advertising and marketing.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

Critical Accounting Policies and Estimates

See Note 1 to the accompanying financial statements for complete disclosure of our critical accounting policies and estimates.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity of three months or less as cash equivalents.

Accounts Receivable

The majority of the Company’s revenues are received from Medicare, Medicaid, and private insurance companies. As such, the Company records revenues at allowable amounts, net of estimated allowances and discounts based on contracted prices and historical collection rates. The Company reviews accounts receivable periodically for collectability and establishes an allowance for doubtful accounts and records bad debt expense when deemed necessary. At December 30, 2019 and December 31, 2018, the Company has determined that no allowance for doubtful accounts is necessary.

Revenue recognition

It is the Company’s policy that revenues from product sales is recognized in accordance with ASC 606, "Revenue Recognition." Five basic steps must be followed before revenue can be recognized; (1) Identifying the contract(s) with a customer that creates enforceable rights and obligations; (2) Identifying the performance obligations in the contract, such as promising to transfer goods or services to a customer; (3) Determining the transaction price, meaning the amount of consideration in a contract to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer; (4) Allocating the transaction price to the performance obligations in the contract, which requires the Company to allocate the transaction price to each performance obligation on the basis of the relative standalone selling prices of each distinct good or services promised in the contract; and (5) Recognizing revenue when (or as) the entity satisfies a performance obligation by transferring a promised good or service to a customer. The amount of revenue recognized is the amount allocated to the satisfied performance obligation. For sales of our Company products, a purchase arrangement is evidenced by a written order, with delivery considered as made after physical customer acceptance. Although rare, defective products may be returned, with other return issues considered on a case by case basis. Services such as periodic scheduled deliveries are contracted in writing, and generally billed monthly. Any service revenue earned by the Company for services such as safety and set up consulting or claims processing is recorded after the service is performed. Rental of durable home medical equipment is evidenced by written contract, with revenue recognized when rent is earned.

Income Tax

The Company accounts for income taxes pursuant to ASC 740. Under ASC 740, deferred taxes are provided for using the liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss carryforwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

Net Income (Loss) per Share

Basic net income per common share ("Basic EPS'') excludes dilution and is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share ("Diluted EPS'') reflects the potential dilution that could occur if stock options or other contracts to issue shares of common stock were exercised or converted into common stock. The computation of Diluted EPS does not assume exercise or conversion of securities that would have an anti-dilutive effect on net income per common share.

Long-Lived Assets

In accordance with ASC 350, the Company regularly reviews the carrying value of intangible and other long-lived assets for the existence of facts or circumstances, both internally and externally, that suggest impairment. If impairment testing indicates a lack of recoverability, an impairment loss is recognized by the Company if the carrying amount of a long-lived asset exceeds its fair value.

Leases

In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02, “Lease (Topic 842),” a new lease standard requiring lessees to recognize lease assets and lease liabilities for most leases classified as operating leases under previous U.S. GAAP. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset (“ROU” asset) representing its right to use the underlying asset for the lease term. The guidance is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company has adopted this standard effective January 1, 2019. The Company elected the optional transition method that permits adoption of the new standard prospectively, as of the effective date, without adjusting comparative periods presented. See Note 1 to the accompanying financial statements for disclosure required by ASC 842.

Item 7A. Quantitative and Qualitative Disclosures about Market Risk.

Not applicable for smaller reporting companies.

Item 8. Financial Statements and Supplementary Data.

CANFIELD MEDICAL SUPPLY, INC.

Financial Statements

TABLE OF CONTENTS

	Page

REPORTS OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRMS	F-1

FINANCIAL STATEMENTS

Balance Sheets	F-2
Statements of Operations	F-3
Statements of Changes in Stockholders' Deficit	F-4
Statements of Cash Flows	F-5
Notes to Financial Statements	F-6 - F-13

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Stockholders

Canfield Medical Supply, Inc.

Canfield, OH

Opinion on the Financial Statements

We have audited the accompanying balance sheets of Canfield Medical Supply, Inc. (the Company) as of December 31, 2019 and 2018, and the related statements of operations, stockholders’ equity (deficit), and cash flows for the years then ended, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2019 and 2018, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.

Consideration of the Company’s Ability to Continue as a Going Concern

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has suffered recurring losses and has working capital and stockholders' equity deficits, which raise substantial doubt about its ability to continue as a going concern. Management's plans regarding these matters are described in Note 8. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

/s/ Pinnacle Accountancy Group of Utah

We have served as the Company’s auditor since 2018.

Pinnacle Accountancy Group of Utah

(a DBA of Heaton & Co., PLLC)

Farmington, Utah

March 27, 2019

F-1

CANFIELD MEDICAL SUPPLY, INC.

BALANCE SHEETS

	December 31,			December 31,
	2019			2018
ASSETS
Current Assets
Cash	$	23,315		$	6,980
Accounts receivable		309,622			300,993
Inventory		30,559			41,695
Right-of-use asset		18,718			—
Total Current Assets		382,214			349,668


Other Assets
Equipment, net of accumulated depreciation of $95,488 and $92,907		43,845			58,627
Total Assets	$	426,059		$	408,295

LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

Current Liabilities
Accounts payable and accrued liabilities	$	353,849		$	331,034
Line of credit		69,534			66,181
Due to officer		197,849			—
Lease liability		18,718			—
Current portion of long-term debt		3,152			8,241
Total Current Liabilities		643,102			405,456
Long-term liabilities
Long-term debt		2,064			5,498
Total Long-term Liabilities		2,064			5,498
Total Liabilities		645,166			410,954

Stockholders' Equity (Deficit)
Preferred stock, no par value; 5,000,000 shares authorized; no shares issued and outstanding		—			—
Common stock, no par value; 100,000,000 shares authorized; 11,813,200 (December 31, 2019) and 11,477,200 (December 31, 2018) shares issued and outstanding		345,515			245,515
Additional paid-in capital		160,786			—
Accumulated deficit		(725,408	)		(248,174	)
Total Stockholders' Equity (Deficit)		(219,107	)		(2,659	)
Total Liabilities and Stockholders' Equity (Deficit)	$	426,059		$	408,295

The accompanying footnotes are an integral part of these financial statements.

F-2

CANFIELD MEDICAL SUPPLY, INC.

STATEMENTS OF OPERATIONS

	Year Ended			Year Ended
	December 31, 2019			December 31, 2018

Sales (net of returns)	$	1,017,833		$	1,309,178
Cost of goods sold		508,874			605,273
Gross profit		508,959			703,905

Operating expenses:
Salaries and wages		517,725			320,470
Professional fees		193,797			59,625
Depreciation		63,758			62,825
Other selling, general and administrative		204,075			194,310
Total operating expenses		979,355			637,230

Income (loss) from operations		(470,396	)		66,675

Other income (expense):
Interest income		501			—
Interest expense		(8,376	)		(5,715	)
Gain on sale of fixed assets		1,037			7,246
Total other income (expense)		(6,838	)		1,531

Income (loss) before provision for income taxes		(477,234	)		68,206
Provision for income tax		—			—

Net income (loss)	$	(477,234	)	$	68,206

Net income (loss) per share applicable to common shareholders - basic	$	(0.04	)	$	0.01
Net income (loss) per share applicable to common shareholders - diluted		(0.04	)	$	0.01

Weighted average number of common shares outstanding - basic		11,635,534			11,385,693
Weighted average number of common shares outstanding - diluted		11,935,534			11,385,693

The accompanying footnotes are an integral part of these financial statements.

F-3

CANFIELD MEDICAL SUPPLY, INC.

STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

	Common Stock (No Par)				Additional Paid-in		Accumulated			Stockholders'
	Shares		Amount		Capital		Deficit			Equity (Deficit)

Balances at December 31, 2017		11,277,200	$	243,515	$	—	$	(316,380	)	$	(72,865	)

Common stock issued for cash		200,000		2,000							2,000

Net income for the year								68,206			68,206

Balances at December 31, 2018		11,477,200	$	245,515	$	—	$	(248,174	)	$	(2,659	)

Common stock issued for cash		336,000		100,000							100,000

Stock options granted and vested						160,786					160,786

Net (loss) for the year								(477,234	)		(477,234	)

Balances at December 31, 2019		11,813,200	$	345,515	$	160,786	$	(725,408	)	$	(219,107	)

The accompanying footnotes are an integral part of these financial statements

F-4

CANFIELD MEDICAL SUPPLY, INC.

STATEMENTS OF CASH FLOWS

	December 31,			December 31,
	2019			2018

Cash Flows from Operating Activities:
Net income (loss)	$	(477,234	)	$	68,206
Adjustments to reconcile net income (loss) to net cash provided by (used for) operating activities:
Gain on disposal of fixed assets		(1,037	)		(7,246	)
Depreciation		63,758			62,825
Stock-based compensation		160,786			—
Changes in current assets and liabilities
Increase in accounts receivable		(8,629	)		(149,731	)
(Increase) decrease in inventory		11,136			(16,486	)
Increase in accounts payable and accrued liabilities		22,815			104,824
Net cash provided by (used for) operating activities		(228,405	)		62,392

Cash Flows From Investing Activities:
Proceeds from sale of fixed assets		6,446			8,064
Purchase of property and equipment		(54,385	)		(75,633	)
Net cash (used for) investing activities		(47,939	)		(67,569	)

Cash Flows from Financing Activities:
Net borrowings on line of credit		3,353			3,803
Proceeds from officer		276,550			—
Payments to officer		(78,701	)		—
Payments on long-term debt		(8,523	)		(11,567	)
Proceeds from sales of common stock.		100,000			2,000
Net cash provided by (used for) financing activities		292,679			(5,764	)

Net Increase (Decrease) in Cash		16,335			(10,941	)
Cash at the Beginning of the Period		6,980			17,921
Cash at the End of the Period	$	23,315		$	6,980

Schedule Of Non-Cash Investing And Financing Activities
Recognition of right-of use asset and lease liability	$	43,677		$	—
Amortization of right-of-use asset	$	24,959		$	—

Supplemental Disclosure
Cash paid for interest	$	8,376		$	5,715
Cash paid for income taxes	$	—		$	—

The accompanying footnotes are an integral part of these financial statements.

F-5

CANFIELD MEDICAL SUPPLY, INC.

NOTES TO FINANCIAL STATEMENTS

December 31, 2019 and 2018

NOTE 1. ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Canfield Medical Supply, Inc. (the “Company”), was incorporated in the State of Ohio on September 3, 1992, and changed domicile to Colorado on April 18, 2012. The Company is in the business of home health services, primarily the selling of durable medical equipment and medical supplies to the public, nursing homes, hospitals and other end users.

Effective June 21, 2019 WesBev LLC, a Nevada limited liability company ("WesBev"), acquired 8,000,000 shares of common stock from Michael J. West, a founder, director and former principal shareholder of the Company, consisting of approximately 69.7% of the issued and outstanding shares of the Company at the time of the purchase. As part of his agreement with WesBev, Mr. West undertook to appoint or cause the appointment of up to three persons nominated by WesBev to the board of directors of the Company. Effective June 21, 2019 the Company sold 336,000 shares of common stock to WesBev for $100,000. Following these stock purchases WesBev beneficially owns 8,336,000 shares, or approximately 71% of the issued and outstanding shares of the Company and may be deemed to be in control of the registrant.

Completion of the Merger is subject to customary closing terms and conditions including, among others:

	●	the adoption of the Merger Agreement by Splash’s stockholders;
	●	the representations and warranties of the respective parties being true and correct in all material respects as of the closing day of the Merger;
	●	since June 1, 2019 through the closing of the Merger, Splash shall have raised from the aggregate sale of its equity securities not less than $1,500,000 which shall be available or was utilized for inventory purchases, reductions to accounts payable and for other general working capital purposes;
	●	on the closing of the Merger liabilities of Splash debt shall not exceed $500,000;
	●	Splash shall have entered into note conversion agreements with substantially all holders of its debt pursuant to which such debt is converted into shares Splash’s common stock at a conversion price of $1.00 per share;
	●	designated shareholders of Splash shall have entered into lock-up/leak out agreements by which they will agree to restrict post-Merger sales of Canfield securities for a period of up to one year following the Merger, as more particularly described within the Merger Agreement;
	●	the Company and Michael West, the Company’s former Chief Executive Officer, and a current director, shall have entered into a Business Transfer and Indemnity Agreement pursuant to which all operations, assets and liabilities of the Company’s home health services business shall be transferred and conveyed to Mr. West or an entity designated by Mr. West in exchange for his indemnifying the Company for certain liabilities and claims;
	●	the Company shall not have any liabilities exceeding $50,000 in the aggregate;
	●	the Company’s directors and officers shall have tendered their resignations;
	●	Robert Nistico, Chief Executive Officer of Splash, shall be appointed as chief executive officer of the Company; and
	●	the composition of the Company’s board of directors shall be as set forth in the Merger Agreement.

Use of Estimates

The preparation of financial statements in conformity with U.S. Generally Accepted Accounting Principles (“U.S. GAAP”) requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity of three months or less as cash equivalents.

Accounts Receivable

F-6

CANFIELD MEDICAL SUPPLY, INC.

NOTES TO FINANCIAL STATEMENTS

December 31, 2019 and 2018

NOTE 1. ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued):

Property and Equipment

Property and equipment are recorded at cost and depreciated under straight line methods over each item's estimated useful life.

Inventory

The Company carries inventory of durable medical equipment and medical supplies for resale. Inventory is accounted for on a first–in first-out basis. Inventory consists of the following:

	December 31, 2019		December 31, 2018
Durable medical equipment	$	22,759	$	33,570
Medical supplies		249		1,076
Enteral		7,551		7,049
TOTALS	$	30,559	$	41,695

Revenue recognition

It is the Company’s policy that revenues from product sales is recognized in accordance with ASC 606 "Revenue Recognition." Five basic steps must be followed before revenue can be recognized; (1) Identifying the contract(s) with a customer that creates enforceable rights and obligations; (2) Identifying the performance obligations in the contract, such as promising to transfer goods or services to a customer; (3) Determining the transaction price, meaning the amount of consideration in a contract to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer; (4) Allocating the transaction price to the performance obligations in the contract, which requires the company to allocate the transaction price to each performance obligation on the basis of the relative standalone selling prices of each distinct good or services promised in the contract; and (5) Recognizing revenue when (or as) the entity satisfies a performance obligation by transferring a promised good or service to a customer. The amount of revenue recognized is the amount allocated to the satisfied performance obligation. For sales of our Company products, a purchase arrangement is evidenced by a written order, with delivery considered as made after physical customer acceptance. Although rare, defective products may be returned, with other return issues considered on a case by case basis. Services such as periodic scheduled deliveries are contracted in writing, and generally billed monthly. Any service revenue earned by the Company for services such as safety and set up consulting or claims processing is recorded after the service is performed. Rental of durable home medical equipment is evidenced by written contract, with revenue recognized when rent is earned.

F-7

CANFIELD MEDICAL SUPPLY, INC.

NOTES TO FINANCIAL STATEMENTS

December 31, 2019 and 2018

NOTE 1. ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued):

The Company’s primary source of revenue is reimbursement from Medicare, Medicaid, and private insurance companies for the procurement and sale of medical equipment and supplies to patients. The amount of revenue earned from each classification as a percent of total revenues is as follows:

	December 31,
	2019			2018
Medicare		19	%		29	%
Medicaid		7	%		9	%
Private pay/private insurance		73	%		58	%
Other		1	%		4	%
Total		100	%		100	%

Advertising Costs

Advertising costs are expensed as incurred. The Company had advertising costs during the years ended December 31, 2019 and 2018 of $13,453 and $18,129, respectively.

Income Tax

Through February 2012, the Company was an S-Corporation for income tax purposes, and therefore a pass-through entity paying no income tax at the corporate level. The Company had no material loss carryforwards as of December 31, 2011. Included in the Company’s accumulated deficit from February 2012 forward is approximately $99,000 in undistributed S-Corporation losses. At December 31, 2019 and 2018 the Company had net operating loss carryforwards (NOL’s) of approximately $462,000 and $144,000 respectively, which may be applied against future taxable income. However, if certain substantial changes in the Company’s ownership should occur, there could be an annual limitation on the amount of net operating loss carryforwards that can be utilized. The amount of and ultimate realization of the benefits from the operating loss carryforwards for income tax purposes is dependent, in part, upon the tax laws in effect, the future earnings of the Company, and other future events, the effects of which cannot be determined. Because of the uncertainty surrounding the realization of the loss carryforwards, the Company has established a valuation allowance equal to the tax effect (2019 and 2018: 21% federal and 5% state) of the loss carryforwards of approximately $120,000 and $37,440 at December 31, 2019 and 2018, respectively, and therefore, no deferred tax asset has been recognized for the loss carryforwards. The change in valuation allowance is approximately $82,560 and ($19,760) for the periods ended December 31, 2019 and 2018, respectively. The tax effect of remaining NOL’s and resulting deferred tax assets of $120,000 remain fully reserved by valuation allowance, due to continued uncertainty as to their utilization.

F-8

CANFIELD MEDICAL SUPPLY, INC.

NOTES TO FINANCIAL STATEMENTS

December 31, 2019 and 2018

NOTE 1. ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued):

Net Income (Loss) per Share

	Year Ended December 31, 2019			Year Ended December 31, 2018
Numerator
Net income (loss) applicable to common shareholders	$	(477,234	)	$	68,206

Denominator
Weighted average common shares outstanding, basic		11,635,534			11,385,693
Stock options		300,000			—
Weighted average common shares outstanding, diluted		11,935,534			11,385,693
Net Income per share - Basic	$	(0.04	)	$	0.01
Income per shares - Diluted	$	(0.04	)	$	0.01

Financial Instruments

The carrying value of the Company’s financial instruments, as reported in the accompanying balance sheets, approximates fair value.

Concentrations

Financial instruments that potentially subject the Company to concentrations of credit risk include cash and cash equivalents. The Company places its cash and cash equivalents at well-known financial institutions, where at times, such balances may exceed FDIC insurance limits.

The Company receives a significant amount of its revenues in reimbursements from Medicare and Medicaid through competitive bidding processes. There is no guarantee that the Company will be selected as a winning contract supplier under future bidding rounds.

Other Selling, General and Administrative Expenses

Other selling, general and administrative expenses included the following:

	December 31,
	2019		2018
Rent	$	27,504	$	27,504
Office expenses		25,765		40,727
Other SG&A		150,806		126,079
Total	$	204,075	$	194,310

F-9

CANFIELD MEDICAL SUPPLY, INC.

NOTES TO FINANCIAL STATEMENTS

December 31, 2019 and 2018

NOTE 1. ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued):

Long-Lived Assets

Products and Services, Geographic Areas and Major Customers

The Company’s business of medical supply sales constitutes one operating segment. All revenues each year were domestic and to external customers.

Leases

NOTE 2. EQUIPMENT

Property and equipment are recorded at cost and consist of the following:

	December 31,
	2019			2018
Office equipment	$	2,934		$	2,934
Vehicles		70,208			70,208
Wheelchair rental pool		66,191			78,392
Total property and equipment		139,333			151,534
Accumulated depreciation		(95,488	)		(92,907	)
Net property and equipment	$	43,845		$	58,627

Depreciation is computed using the straight-line method based upon estimated useful lives as follows:

Office equipment	7 years
Vehicles	5 years
Wheelchair rental pool	13 months

Depreciation for 2019 and 2018 was $63,758 and $62,825, respectively.

The wheelchair rental pool consists of wheelchairs rented to customers over the shorter of the 13 month use period as mandated by Medicare and Medicaid, or the period over which the customer requires use of a wheelchair. At the end of the use period, the chair is either returned to the pool to be rented to another customer, or title of the chair is transferred to the customer.

NOTE 3. LINE OF CREDIT

At December 31, 2019 and December 31, 2018, the Company owed a bank $69,534 and $66,181, respectively, under a revolving line of credit. The line of credit is secured by all Company assets, is capped at $100,000, is due on demand, and bears interest at variable rates approximating 7% on average. Interest expense under the note totaled $5,410 and $4,327 during the years ended December 31, 2019 and 2018, respectively. During 2019 and 2018, the Company made net borrowings $3,353 and $3,803, respectively.

F-10

CANFIELD MEDICAL SUPPLY, INC.

NOTES TO FINANCIAL STATEMENTS

December 31, 2019 and 2018

NOTE 4. RELATED PARTY LOAN

On June 21, 2019, the Company entered into a short-term loan with Michael West, an officer of the Company, for $276,550. The loan has a one-year term from June 21, 2019, and is non-interest bearing. The Company made payments of $78,701 on this loan, resulting in a loan balance of $197,849 and $0 as of December 31, 2019 and December 31, 2018, respectively.

NOTE 5. LONG-TERM DEBT

Long-term debt consists of the following vehicle loans, which are collateralized by their underlying vehicles with net carrying values exceeding the outstanding loan amounts:

	December 31, 2019			December 31, 2018

3.53% installment note payable $352 monthly, including interest, through July 2019	$	—		$	2,782

3.79% installment note payable $299 monthly, including
interest, through July 2021		5,216			8,532


2.99% installment note payable $350 monthly, including interest, through August 2019		—			2,425
Total		5,216			13,739

Less principal due within one year		(3,152	)		(8,241	)

TOTAL LONG-TERM DEBT	$	2,064		$	5,498

Principal payments due on long-term debt subsequent to December 31, 2019, are as follows:

2020	$	3,152
2021		2,064
TOTAL	$	5,216

F-11

CANFIELD MEDICAL SUPPLY, INC.

NOTES TO FINANCIAL STATEMENTS

December 31, 2019 and 2018

NOTE 6. STOCKHOLDERS’ EQUITY

Common Stock

In June 2019, the Company received net proceeds of $100,000 from the sale of 336,000 shares of no-par value common stock at $0.298 per share.

In July 2018, the Company received net proceeds of $2,000 from the sale of 200,000 shares of no-par value common stock at $0.01 per share.

2019 Stock Options Granted

On November 26, 2019, the Board granted stock options to each of two officers, one director, and one advisor for the purchase of 300,000 shares of the common stock of the Company. The options expire in five years from the issuance date, have an exercise price of $0.55, and were immediately vested and exercisable. On the grant date, total recognized compensation of $160,786 was recorded as salaries and wages.

	For the year ended December 31, 2019
Number of shares		300,000
Fair market value per share	$	0.54
Stock based compensation recognized	$	160,786

As of December 31, 2019, total unrecognized compensation remaining to be recognized in future periods totaled $0. The fair value of each option award above is estimated using the Black-Scholes option-pricing model with the following assumptions at the measurement date, which was deemed to be the November 26, 2019 grant date:

	Measurement date
Dividend yield		0	%
Expected volatility		314.95	%
Risk-free interest rate		1.58	%
Expected life (years)		2
Stock Price	$	0.55
Exercise Price	$	0.55

A summary of the activity for the Company's stock options is as follows:

	December 31, 2019
	Shares		Weighted Average Exercise Price
Outstanding, beginning of year		0	$	0
Granted		300,000	$	0.55
Exercised		0	$	0
Canceled		0	$	0
Outstanding, end of year		300,000	$	0.55
Weighted average fair value of options granted			$	0.55

F-12

CANFIELD MEDICAL SUPPLY, INC.

NOTES TO FINANCIAL STATEMENTS

December 31, 2019 and 2018

NOTE 7. LEASE COMMITMENTS

The Company rents office space under a non-cancellable lease through September 2020 with monthly payments of approximately $2,292. Pursuant to ASC 842, an operating lease right-of-use (“ROU”) asset and liability were recognized at January 1, 2019 based on the present value of lease payments over the remaining lease term. The ROU asset represents the Company’s right to use the underlying office space asset for the lease term, and the lease liability represents the Company’s obligation to make lease payments arising from the lease. Generally, the implicit rate of interest in arrangements is not readily determinable and the Company utilizes its incremental borrowing rate in determining the present value of lease payments. The operating lease ROU asset includes any lease payments made and excludes lease incentives. The Company recognized $27,504 in lease expense during each of the years ended December 31, 2019 and 2018.

Remaining lease term at December 31, 2019 (in months)			9
Discount rate			5	%

	Year Ended December 31, 2019
Operating lease expense	$	27,504
Cash paid for amounts included in measurement of lease liability	$	27,504

The supplemental balance sheet information related to leases for the period is as follows:

Right-of-Use Asset
ROU Asset, January 1, 2019	$	43,677
Amortization of ROU Asset		(24,959	)
ROU Asset, December 31, 2019	$	18,718

Maturities of the Company’s lease liabilities are as follows:

Year Ending		Payments
	2020	$	20,628
	Less: Imputed interest/present value discount		(1,910	)
	Present value of lease liability at December 31, 2019	$	18,718

NOTE 8. GOING CONCERN

The Company has suffered losses from operations and has working capital and stockholders’ equity deficits. In all likelihood, the Company will be required to make significant future expenditures in connection with marketing efforts along with general administrative expenses. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.

The Company may raise additional capital through the sale of its equity securities, through an offering of debt securities, or through borrowings from financial institutions or related parties. By doing so, the Company hopes to generate sufficient capital to execute its business plan of selling medical supplies on an ongoing basis. Management believes that actions presently being taken to obtain additional funding provide the opportunity for the Company to continue as a going concern.

NOTE 9. SUBSEQUENT EVENTS

The Company has evaluated subsequent events through the date these financial statements were issued and determined that there are no reportable subsequent events.

F-13

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

None.

Item 9A. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rule 13a-l5(e) under the Exchange Act) that are designed to ensure that information that would be required to be disclosed in Exchange Act reports is recorded, processed, summarized and reported within the time period specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including to our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Our management, under the supervision and with the participation of our CEO and Chief Financial Officer ("CFO"), has evaluated the effectiveness of our disclosure controls and procedures as defined in SEC Rules 13a-15(e) and 15d-15(e) as of the end of the period covered by this report. Based on such evaluation, management identified deficiencies that were determined to be a material weakness.

Management’s Annual Report on Internal Controls over Financial Reporting

The Company’s management is responsible for establishing and maintaining effective internal control over financial reporting (as defined in Rule 13a-l5(f) of the Securities Exchange Act). Management assessed the effectiveness of the Company’s internal control over financial reporting as of December 31, 2019. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) (2013). Based on that assessment, management believes that, as of December 31, 2019, the Company’s internal control over financial reporting was ineffective based on the COSO criteria, due to the following material weaknesses listed below.

The specific material weaknesses identified by the company’s management as of end of the period covered by this report include the following:

	•	we have not performed a risk assessment and mapped our processes to control objectives;
	•	we have not implemented comprehensive entity-level internal controls;
	•	we have not implemented adequate system and manual controls; and
	•	we do not have sufficient segregation of duties.

Despite the material weaknesses reported above, our management believes that our consolidated financial statements included in this report fairly present in all material respects our financial condition, results of operations and cash flows for the periods presented and that this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

This report does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by our registered public accounting firm pursuant to rules of the Commission that permit us to provide only management’s report in this report.

Management's Remediation Plan

The weaknesses and their related risks are not uncommon in a company of our size because of the limitations in the size and number of staff. Due to our size and nature, segregation of all conflicting duties has not always been possible and may not be economically feasible.

However, we plan to take steps to enhance and improve the design of our internal control over financial reporting. During the period covered by this annual report on Form 10-K, we have not been able to remediate the material weaknesses identified above. To remediate such weaknesses, we plan to implement the following changes in the current fiscal year as resources allow:

(i)

appoint additional qualified personnel to address inadequate segregation of duties and implement modifications to our financial controls to address such inadequacies;

The remediation efforts set out herein will be implemented in the current 2020 fiscal year. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within our company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake.

Management believes that despite our material weaknesses set forth above, our consolidated financial statements for the year ended December 31, 2019 are fairly stated, in all material respects, in accordance with U.S. GAAP.

Changes in Internal Control over Financial Reporting

There were no changes to our internal control over financial reporting that occurred during our fourth fiscal quarter of our fiscal year ended December 31, 2019.

Item 9B. Other Information.

None.

PART III

Item 10. Directors, Executive Officers and Corporate Governance.

Each of our directors is elected by the stockholders to a term of one year and serves until his successor is elected and qualified. Each of our officers is elected by the board of directors to a term of one year and serves until his or her successor is duly elected and qualified, or until he or she is removed from office.

The name, age and position of our officers and directors is set forth below:

Name	Age		Position(s) with the Company
Amy Joanne Atkinson		57	Director
Heather Kearns(1)		41	Former Principal Executive Officer, Former Principal Financial Officer and Former Principal Accounting Officer
John Matthias Lepo		78	Principal Executive Officer, Principal Financial Officer Director
Michael Long		66	Director
Michael J. West		65	Director
Stephen H. West		63	Director

(1)

Heather Kearns resigned from all officer positions with the Company effective November 19, 2019.

The persons named above are expected to hold said offices/positions until the next annual meeting of our stockholders. These officers and directors are our only officers, directors, promoters and control persons.

Background Information about Our Officers and Directors

Amy Joanne Atkinson

Ms Atkinson has since 2005 been Fund Manager/Director of Operations of Kirby Enterprise Capital Management, LLC where since 2012 she has managed a special situations fund and coordinates private placements and monitors investment activity. She has been responsible for integrating and updating accounting systems, developing operating procedures, preparing financial reporting, managing quarterly partnership reporting, coordinating private placements and ensuring compliance in all areas. Ms Atkinson attended Colorado State University.

Heather Kearns, CPA, MBA

Ms. Kearns has since 2011 been an independent certified public accountant specializing in corporate accounting matters and finance services for those companies needing financial expertise to meet critical business objectives. Ms Kearns received Bachelor of Science in Business Administration and a Master of Business Administration degrees from Auburn University. She is licensed as a CPA in Colorado.

John Matthias Lepo

Mr. Lepo has since 1998 been President of Battersea Capital Inc. offering consulting services to small businesses including corporate finance and advisory functions as well as advising on businesses entering the public markets. Mr. Lepo has a Bachelor of Science in Economics from Saint Mary’s University of Minnesota.

Michael Long

Mr. Long has been the chief executive officer of AnyDATA Corporation, from 2017 to the present. AnyDATA Corporation designs and manufactures OBD-2 devices for consumer automotive, commercial fleet and automotive manufacturing markets. From 2013 to 2014 he was vice president of Giant Magellan Telescope Organization (GMTO) a scientific partnership established to build and operate a 25-meter telescope at the Las Campana Observatory in Chile. From 1992 to 2013 he was president and founder of Premier Wireless, Inc. which designed and manufactured wireless communications products for the broadcast, security and military markets. He has since 2012 been a member of the Board of Trustees of Carnegie Institute of Science and received an AB, majoring in physics, from University of Chicago.

Michael J. West

Mr. West co-founded our Company with his wife in September 1992 and served as Vice-President, Secretary and a Director until September 2004 when he became the President and sole Director. He also founded Medical Billing Assistance, Inc. ("Medical Billing") in 1994. Medical Billing was involved in electronic billing of medical claims to Medicare. Medical Billing completed an acquisition of FCID Medical, Inc. in December 2010 and Mr. West resigned from all positions with Medical Billing at that time. Mr. West received a Bachelor of Arts Degree in Biology from Wittenberg University in 1977. Mr. West resigned from all executive officer positions with the Company on June 28, 2019, but is currently a member of our board of directors, and serves as the president of our medical supply business division. We believe that Mr. Michael West's 24 years of experience serving as either our President or Vice President enables him to make valuable contributions to our Board of Directors.

Stephen H. West

Mr. West served as Secretary, Treasurer, CFO and a Director of our company since September 2011, until his resignation from his officer positions on June 28, 2019. He is the brother of Michael J. West. He has been involved in the computer data storage market since 1978. He spent twenty-two years at Storage Technology Corporation where he held positions as Director of Sales for their telecommunications region, Vice President and General Manager of the Western Region and Vice President of Global Accounts. He co-founded PeakData Inc., a computer data storage company which focuses on sales and integration of enterprise storage solutions for Fortune 1000 companies in March 2001 and served as its Executive Vice president of Sales until January 2009. Since January 2009, he has served as Director of Sales of Net Source, a computer storage company. From May 2007 until December 2010 he served as Secretary and a Director of Medical Billing Assistance, Inc. and he continued as a Director until April 2011. Mr. West graduated from the University of Cincinnati with a BBA in 1978. He plans to devote approximately 5 to 10 hours per month to our affairs. We believe that Mr. Stephen West's 38 years of sales and executive experience in the technology industry and his knowledge of our Company's history qualify him to serve as a member of our Board of Directors.

Family Relationships

Except for Michael J. West, a director and our former CEO, and Stephen West, a director and our former CFO, Secretary and Treasurer, who are brothers, there are no family relationships among any of our directors, executive officers or key employees.

Committees of the Board of Directors

Our shares are currently quoted on the OTCQB under the symbol “CNFM.” We have no separately designated standing audit committee, compensation committee, nominating committee, executive committee or any other committees of our Board of Directors. The functions of those committees are currently undertaken by our Board of Directors.

Our Board of Directors believes that, considering our size, decisions relating to director nominations can be made on a case-by-case basis by all members of the Board of Directors without the formality of a nominating committee or a nominating committee charter. To date, we have not engaged third parties to identify or evaluate or assist in identifying potential nominees, although we reserve the right to do so in the future.

The Board of Directors does not have an express policy with regard to the consideration of any director candidates recommended by stockholders since the Board of Directors believes that it can adequately evaluate any such nominees on a case-by-case basis; however, the Board of Directors will evaluate stockholder recommended candidates under the same criteria as internally generated candidates. Although the Board of Directors does not currently have any formal minimum criteria for nominees, substantial relevant business and industry experience would generally be considered important, as would the ability to attend and prepare for board, committee and stockholder meetings. Any candidate must state in advance his or her willingness and interest in serving on the board of directors.

Meetings of the Board of Directors

Our Board held one meeting during the year ended December 31, 2019 and also acted via board consent. We held no annual meeting of stockholders during the year ended December 31, 2019.

Director Independence

The OTCQB imposes no director independence requirements. For purposes of determining director independence, we have applied the definitions set out in NASDAQ Rule 5605(a)(2). The NASDAQ definition of “Independent Director” means a person other than an Executive Officer or employee of the Company or any other individual having a relationship which, in the opinion of the Company's Board of Directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director.

Involvement in Certain Legal Proceedings

During the past ten years no current or incoming director, executive officer, promoter or control person of the Company has to its knowledge been involved in any of the following:

(1) A petition under the Federal bankruptcy laws or any state insolvency law which was filed by or against, or a receiver, fiscal agent or similar officer was appointed by a court for the business or property of such person, or any partnership in which he was a general partner at or within two years before the time of such filing, or any corporation or business association of which he was an executive officer at or within two years before the time of such filing;

(2) Such person was convicted in a criminal proceeding or is a named subject of a pending criminal proceeding (excluding traffic violations and other minor offenses);

(3) Such person was the subject of any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining him from, or otherwise limiting, the following activities:

i. Acting as a futures commission merchant, introducing broker, commodity trading advisor, commodity pool operator, floor broker, leverage transaction merchant, any other person regulated by the Commodity Futures Trading Commission, or an associated person of any of the foregoing, or as an investment adviser, underwriter, broker or dealer in securities, or as an affiliated person, director or employee of any investment company, bank, savings and loan association or insurance company, or engaging in or continuing any conduct or practice in connection with such activity;

ii. Engaging in any type of business practice; or

iii. Engaging in any activity in connection with the purchase or sale of any security or commodity or in connection with any violation of federal or state securities laws or Federal commodities laws;

(4) Such person was the subject of any order, judgment or decree, not subsequently reversed, suspended or vacated, of any Federal or State authority barring, suspending or otherwise limiting for more than 60 days the right of such person to engage in any activity described in paragraph (f)(3)(i) of this section, or to be associated with persons engaged in any such activity;

(5) Such person was found by a court of competent jurisdiction in a civil action or by the Commission to have violated any federal or state securities law, and the judgment in such civil action or finding by the Commission has not been subsequently reversed, suspended, or vacated;

(6) Such person was found by a court of competent jurisdiction in a civil action or by the Commodity Futures Trading Commission to have violated any federal commodities law, and the judgment in such civil action or finding by the Commodity Futures Trading Commission has not been subsequently reversed, suspended or vacated;

(7) Such person was the subject of, or a party to, any federal or state judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated, relating to an alleged violation of:

i. Any federal or state securities or commodities law or regulation; or

ii. Any law or regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order; or

iii. Any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or

(8) Such person was the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization (as defined in Section 3(a)(26) of the Exchange Act (15 U.S.C. 78c(a)(26))), any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange Act (7 U.S.C. 1(a)(29))), or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.

Board leadership structure and role in risk oversight

Our Board consists of five directors, Michael J. West, our former CEO, Stephen J. West, our former CFO, Amy Atkinson, John M. Lepo, our current CEO and CFO, and Michael Long.

Item 11. Executive Compensation.

The following table sets forth information for our two most recently completed fiscal years concerning all of the compensation awarded to, earned by or paid to the executive officers named below. No other employees earned a salary over $100,000 in the last two completed fiscal years.

Name and Principal Position	Year		Salary ($)		Bonus ($)		Stock Awards($)		Option Awards($)		Non-Equity Incentive Plan Compensation ($)		Nonqualified Deferred Compensation Earnings($)		All Other Compensation ($)		Total($)

Michael West		2019		72,908		—		—		—		—		—		—	$	72,908
		2018		72,775		—		—		—		—		—		—	$	72,775

Steve West		2019		—		—		—		—		—		—		—	$	—
		2018		—		—		—		—		—		—		—	$	—

Amy J. Atkinson		2019		—		—		—		24,118		—		—		—	$	24,118
		2018		—		—		—		—		—		—		—	$	—

John M. Lepo		2019		—		—		—		64,315		—		—		—	$	64,315
		2018

Michael Long		2019		—		—		—		24,118		—		—		—	$	24,118
		2018		—		—		—		—		—		—		—	$	—

Heather Kearns(1)		2019		—		—		—		—		—		—		—	$	—
		2018		—		—		—		—		—		—		—	$	—

(1)

Heather Kearns resigned from all officers positions with the Company effective November 19, 2019.

Directors Compensation

Our directors have not been paid any compensation for serving as Directors of the Company and there are no present plans or understandings with respect to future compensation.

Outstanding Equity Awards at Fiscal Year-End

Option Awards							Stock Awards
Name	Number of Securities Underlying Unexercised Options (#) Exercisable	Number of Securities Underlying Unexercised Options (#) Unexercisable	Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#)		Option Exercise Price ($)	Option Expiration Date	Number of Shares or Units of Stock That Have Not Vested (#)	Market Value of Shares or Units of Stock That Have Not Vested ($)	Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#)	Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested
J. Matthias Lepo	120,000	—	—	$	0.55	11/28/24
Amy Joanne Atkinson	45,000	—	—	$	0.55	11/28/24
Michael Long	45,000	—	—	$	0.55	11/28/24

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

The following table sets forth the beneficial ownership of our common stock as of March 27, 2020, by (i) each person or entity who is known by us to own beneficially more than 5% of the outstanding shares of common stock, (ii) each of our Directors, (iii) each of the Executive Officers named in the Summary Compensation Table, and (iv) all of our Officers and Directors as a Group. Unless otherwise listed, the address for each of our offices and directors is 4120 Boardman-Canfield Road, Canfield, OH 44406.

Name and Address of Beneficial Owner	Beneficial Ownership(1)(2)		Approximate Percent Owned

Michael J. West		344,000		2.9	%
Stephen H. West		300,000		2.5	%
Amy J. Atkinson		344		*
John M. Lepo		—		—
Michael Long		—		—
Heather Kerns(3)		—		—
All Officers and Directors as a group (5 persons)		644,344		5.5	%

5% or greater owners:
WesBev LLC(4)		8,336,000		70.6	%

* less than one percent.

(1)	This table is based upon 11,813,200 shares of common stock issued and outstanding as of March 27, 2020.

(2)	Beneficial ownership is determined in accordance with the rules of the Securities and Exchange Commission and includes voting and investment power with respect to the shares. Shares of Common Stock subject to options or warrants currently exercisable or exercisable within 60 days are deemed outstanding for computing the percentage of the person holding such options or warrants, but are not deemed outstanding for computing the percentage of any other person.

(3)	Heather Kearns resigned from all officer positions with the Company effective November 19, 2019.

(4)	WesBev LLC is controlled by Justin Yorke. The address for WesBev LLC is 4 Richland Place, Pasadena, CA 91103.

Item 13. Certain Relationships and Related Transactions and Director Independence.

Effective June 21, 2019 WesBev LLC, a Nevada limited liability company ("WesBev"), acquired 8,000,000 shares of common stock from Michael J. West, a founder, director and former principal shareholder of the Company, consisting of approximately 69.7% of the issued and outstanding shares of the Company at the time of the purchase. As part of his agreement with WesBev, Mr. West undertook to appoint or cause the appointment of up to three persons nominated by WesBev to the board of directors of the Company. Effective June 21, 2019, the Company sold 336,000 shares of common stock to WesBev for $100,000. Following these stock purchases WesBev beneficially owned 8,336,000 shares.

On June 21, 2019, the Company entered into a short-term loan with Michael West, an officer of the company for $276,550. The Company made payments of $78,701 on this loan. The loan has a one-year term from June 21, 2019, and is non-interest bearing. As of December 31, 2019 and December 31, 2018 the loan had a balance of $197,849 and $0, respectively

Item 14. Principal Accounting Fees and Services.

Approval of Services

Pending establishment of an audit committee, the Board of Directors pre-approves all engagements for audit and non-audit services provided by the Company's principal registered accounting firm, Pinnacle Accountancy Group of Utah, a dba of Heaton & Company, PLLC.

Audit Fees

The aggregate fees billed during the fiscal years ended December 31, 2019 and 2018 for professional services rendered by our principal accounting firm, Pinnacle Accountancy Group of Utah (a DBA of Heaton & Co., PLLC), for the audit of the financial statements included in Form 10-K, and for the review of the interim condensed financial statements included in Form 10-Q, were approximately $34,600 and $34,500, respectively.

Audit Related Fees

The aggregate fees billed during the fiscal years ended December 31, 2019 and 2018 for audit related services rendered by our principal accounting firm, Pinnacle Accountancy Group of Utah (a DBA of Heaton & Co., PLLC), were approximately $0 and $0, respectively.

Tax Compliance/Preparation Fees

The aggregate fees billed during the fiscal years ended December 31, 2019 and 2018 for professional services rendered by our principal accounting firm, Pinnacle Accountancy Group of Utah, a dba of Heaton & Company, PLLC, for tax compliance, tax advice, and tax planning were approximately $0 and $0, respectively. Tax compliance services include the preparation of income tax returns filed with the Internal Revenue Service. Tax advice and planning services included assistance with implementation of tax planning strategies and consultation on other tax matters.

All Other Fees

The aggregate fees billed during the fiscal years ended December 31, 2019 and 2018 for all other professional services rendered by our principal accounting firm, Pinnacle Accountancy Group of Utah, a dba of Heaton & Company, were $0 and $0, respectively.

Board of Directors Pre-Approval Process, Policies and Procedures

Our principal auditors have performed their audit procedures in accordance with pre-approved policies and procedures established by our Board of Directors. Our principal auditors have informed our Board of Directors of the scope and nature of each service provided. With respect to the provisions of services other than audit, review, or attest services, our principal accountants brought such services to the attention of our Board of Directors prior to commencing such services.

PART IV

Item 15. Exhibits and Financial Statement Schedules.

The following documents are filed as part of this Annual Report on Form 10-K:

1. Financial Statements. See the Financial Statements starting on page 14.

2. Exhibits. The exhibits listed in the Exhibit Index, which appears immediately following the signature page and is incorporated herein by reference, and filed as part of this Annual Report on Form 10-K.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		CANFIELD MEDICAL SUPPLY, INC. (Registrant)


Date: March 27, 2020		By: /s/ John Mathias Lepo
		Name: John Mathias Lepo Title: President and CEO (Principal Executive Officer), CFO (Principal Financial Officer, Principal Accounting Officer)

Pursuant to the requirements of the Securities Act of 1934 this Annual Report on Form 10-K was signed by the following persons on behalf of the Registrant and in the capacities and on the dates stated:

Name	Title	Date


/s/ Michael J. West	Director	March 27, 2020
Michael J. West

/s/ Stephen H. West	Director	March 27, 2020
Stephen H. West

/s/ John Mathias Lepo	President, CEO, CFO, Director	March 27, 2020
John Mathias Lepo

/s/ Michael Long		Director	March 27, 2020
Michael Long

/s/ Amy Joanne Atkinson		Director	March 27, 2020
Amy Joanne Atkinson

EXHIBIT INDEX

Exhibit Number	Description

2.1	Agreement and Plan of Merger dated December 31, 2019 by and among Canfield Medical Supply, Inc., SBG Acquisition, Inc., and Splash Beverage Group, Inc. (incorporated by reference to Exhibit 2.1 to the Registrant's Form 8-K dated January 6, 2020)

3.1	Articles of Incorporation (incorporated herein by reference to Exhibit 3.1 filed with Form S-1 filed with the SEC on July 12, 2012)

3.2	Bylaws (incorporated by reference herein to Exhibit 3.2 filed with Form S-1 filed with the SEC on July 12, 2012)

31.1	Certification by CEO (filed herewith electronically)

31.2	Certification by CFO (filed herewith electronically)

32.1	Certification of CEO pursuant to 18. U.S.C. Section 1350 as adopted, pursuant to Section 906 of Sarbanes-Oxley Act of 2002 (filed herewith electronically)

32.2	Certification of CFO pursuant to 18. U.S.C. Section 1350 as adopted, pursuant to Section 906 of Sarbanes-Oxley Act of 2002 (filed herewith electronically)

*101.INS			Inline XBRL Instance Document (filed herewith)
*101.SCH			Inline XBRL Taxonomy Extension Schema (filed herewith)
*101.CAL			Inline XBRL Taxonomy Extension Calculation Linkbase (filed herewith)
*101.LAB			Inline XBRL Taxonomy Extension Label Linkbase (filed herewith)
*101.PRE			Inline XBRL Taxonomy Extension Presentation Linkbase (filed herewith)
*101.DEF			Inline XBRL Taxonomy Definition Linkbase (filed herewith)
*104			Cover Page Interactive Data File (embedded within the Inline XBRL document filed as Exhibit 101)



*		Interactive data files are furnished but not filed for purposes of Sections 11 and 12 of the Securities Act of 1933, as amended, and Section 18 of the Securities Exchange Act of 1934, as amended.

EX-31.1 2 g081940_ex31-1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, John Lepo, certify that:

1. I have reviewed this annual report on Form 10-K of Canfield Medical Supply, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in the Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

(a) Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within the registrant, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: March 27, 2020

/s/ John Lepo

John Lepo

President, CEO, CFO, Director

EX-31.2 3 g081940_ex31-2.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, John Lepo, certify that:

1. I have reviewed this annual report on Form 10-K of Canfield Medical Supply, Inc.;

3. Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the of the registrant as of, and for, the periods presented in this report;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: March 27, 2020

/s/ John Lepo

John Lepo

President, CEO, CFO, Director

EX-32.1 4 g081940_ex32-1.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Form 10-K of Canfield Medical Supply, Inc., a company duly formed under the laws of Colorado (the "Company"), for the fiscal year ended December 31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), John Lepo, President CEO, CFO, Director of the Company, hereby certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of his knowledge, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 27, 2020

/s/ John Lepo

John Lepo

President, CEO, CFO, Director

This certification accompanies this Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

A signed original of this written statement required by Section 906 has been provided to Canfield Medical Supply, Inc. and will be retained by Canfield Medical Supply, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 5 g081940_ex32-2.htm EXHIBIT 32.2

Exhibit 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Form 10-K of Canfield Medical Supply, Inc., a company duly formed under the laws of Colorado (the "Company"), for the quarter ended December 31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), John Lepo, President, CEO, CFO, Director of the Company, hereby certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of his knowledge, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 27, 2020

/s/ John Lepo

John Lepo

President, CEO, CFO, Director

EX-101.INS 6 cmds-20191231.xml XBRL INSTANCE FILE 0001553788 2018-12-31 0001553788 2019-12-31 0001553788 2019-01-01 2019-12-31 0001553788 2018-01-01 2018-12-31 0001553788 2019-06-30 0001553788 2017-12-31 0001553788 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001553788 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0001553788 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001553788 us-gaap:CommonStockMember 2018-01-01 2018-12-31 0001553788 us-gaap:CommonStockMember 2018-12-31 0001553788 us-gaap:CommonStockMember 2019-12-31 0001553788 us-gaap:CommonStockMember 2017-12-31 0001553788 us-gaap:RetainedEarningsMember 2018-12-31 0001553788 us-gaap:RetainedEarningsMember 2019-12-31 0001553788 us-gaap:RetainedEarningsMember 2017-12-31 0001553788 cmds:MedicareMember 2019-01-01 2019-12-31 0001553788 cmds:MedicaidMember 2019-01-01 2019-12-31 0001553788 cmds:PrivatePayPrivateInsuranceMember 2019-01-01 2019-12-31 0001553788 cmds:OtherMember 2019-01-01 2019-12-31 0001553788 cmds:MedicareMember 2018-01-01 2018-12-31 0001553788 cmds:MedicaidMember 2018-01-01 2018-12-31 0001553788 cmds:PrivatePayPrivateInsuranceMember 2018-01-01 2018-12-31 0001553788 cmds:OtherMember 2018-01-01 2018-12-31 0001553788 us-gaap:OfficeEquipmentMember 2019-12-31 0001553788 us-gaap:OfficeEquipmentMember 2018-12-31 0001553788 us-gaap:VehiclesMember 2019-12-31 0001553788 us-gaap:VehiclesMember 2018-12-31 0001553788 cmds:WheelchairRentalPoolMember 2019-12-31 0001553788 us-gaap:OfficeEquipmentMember 2019-01-01 2019-12-31 0001553788 us-gaap:VehiclesMember 2019-01-01 2019-12-31 0001553788 cmds:WheelchairRentalPoolMember 2019-01-01 2019-12-31 0001553788 cmds:LongTermDebtOneMember 2019-12-31 0001553788 cmds:LongTermDebtTwoMember 2019-12-31 0001553788 cmds:LongTermDebtThreeMember 2019-12-31 0001553788 cmds:LongTermDebtOneMember 2018-12-31 0001553788 cmds:LongTermDebtTwoMember 2018-12-31 0001553788 cmds:LongTermDebtThreeMember 2018-12-31 0001553788 2020-03-27 0001553788 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001553788 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001553788 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001553788 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001553788 cmds:DurableMedicalEquipmentMember 2019-12-31 0001553788 cmds:MedicalSuppliesMember 2019-12-31 0001553788 cmds:EnteralMember 2019-12-31 0001553788 cmds:DurableMedicalEquipmentMember 2018-12-31 0001553788 cmds:MedicalSuppliesMember 2018-12-31 0001553788 cmds:EnteralMember 2018-12-31 0001553788 cmds:WesBevMember 2019-06-01 2019-06-21 0001553788 cmds:WesBevMember 2019-06-21 0001553788 cmds:WheelchairRentalPoolMember 2018-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

5000000

100000000

11477200

11813200

11477200

11813200

-248174

-725408

-2659

-219107

-72865

245515

345515

243515

-248174

-725408

-316380

160786

204075

194310

336000

200000

336000

13453

18129

144000

462000

82560

-19760

120000

151534

139333

2934

70208

66191

78392

P7Y

P5Y

P13M

5410

4327

352

299

350

13739

5216

2782

8532

2425

5498

2064

3152

2064

0.01

0.298

2292

92907

95488

8241

3152

5216

CANFIELD MEDICAL SUPPLY, INC. 0001553788 10-K 2019-12-31 false --12-31 No No Yes Non-accelerated Filer true true true false 3683160 11813200 FY 2019

27504

37440

120000

Yes 000-55114 CO

P9M

0.05

27504 43677 18718

24959

20628

-1910

18718

410954

645166

349668

382214

18718

41695

30559

300993

309622

408295

426059

58627

43845

405456

643102

8241

3152

18718

197849

66181

69534

331034

353849

5498

2064

5498

2064

408295

426059

160786

245515

345515

508959

703905

508874

605273

1017833

1309178

-470396

66675

979355

637230

204075

194310

63758

62825

193797

59625

517725

320470

11935534

11385693

11635534

11385693

-0.04

0.01

-0.04

0.01

-6838

1531

1037

7246

8376

5715

501

-477234

68206

11477200

11813200

11277200

336000

200000

100000

2000

100000

2000

-477234

68206

-477234

68206

160786

-228405

62392

22815

104824

-11136

16486

8629

149731

63758

62825

1037

7246

-477234

68206

160786

-47939

-67569

54385

75633

6446

8064

292679

-5764

100000

2000

100000

8523

11567

276550

3353

3803

6980

23315

17921

16335

-10941

24959 0 43677 0

8376

5715

78701

300000

160786

0.54

0.00

3.1495

0.0158

P2Y

0.55

300000

0.55

P1Y

100000

0.07

41695

30559

22759

249

7551

33570

1076

7049

1.00 1.00 0.19 0.07 0.73 0.01 0.29 0.09 0.58 0.04

-477234

68206

300000

150806

126079

25765 40727

27504

8000000

0.697

8336000

0.21

0.05

NOTE 2.  EQUIPMENT   Property and equipment are recorded at cost and consist of the following:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="7" style="text-align: center; border-bottom: Black 1.5pt solid">December 31,</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="text-align: center"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1.5pt solid">2018</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Office equipment</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,934</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,934</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Vehicles</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">70,208</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">70,208</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Wheelchair rental pool</td><td> </td> <td style="text-align: left; border-bottom: Black 1pt solid"> </td><td style="text-align: right; border-bottom: Black 1pt solid">66,191</td><td style="text-align: left; border-bottom: Black 1pt solid"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: Black 1pt solid"> </td><td style="text-align: right; border-bottom: Black 1pt solid">78,392</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total property and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">139,333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">151,534</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accumulated depreciation</td><td> </td> <td style="text-align: left; border-bottom: Black 1pt solid"> </td><td style="text-align: right; border-bottom: Black 1pt solid">(95,488</td><td style="text-align: left; border-bottom: Black 1pt solid">)</td><td> </td> <td style="text-align: left; border-bottom: Black 1pt solid"> </td><td style="text-align: right; border-bottom: Black 1pt solid">(92,907</td><td style="text-align: left; border-bottom: Black 1pt solid">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net property and equipment</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">43,845</td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">58,627</td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>    Depreciation is computed using the straight-line method based upon estimated useful lives as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top; text-align: left"> <td style="width: 30%; padding-left: 30pt">Office equipment</td> <td style="width: 70%">7 years</td></tr> <tr style="vertical-align: top; text-align: left"> <td style="padding-left: 30pt">Vehicles</td> <td> 5 years</td></tr> <tr style="vertical-align: top; text-align: left"> <td style="padding-left: 30pt">Wheelchair rental pool</td> <td>13 months</td></tr> </table>    Depreciation for 2019 and 2018 was $63,758 and $62,825, respectively.   The wheelchair rental pool consists of wheelchairs rented to customers over the shorter of the 13 month use period as mandated by Medicare and Medicaid, or the period over which the customer requires use of a wheelchair. At the end of the use period, the chair is either returned to the pool to be rented to another customer, or title of the chair is transferred to the customer.

NOTE 3.  LINE OF CREDIT   At December 31, 2019 and December 31, 2018, the Company owed a bank $69,534 and $66,181, respectively, under a revolving line of credit. The line of credit is secured by all Company assets, is capped at $100,000, is due on demand, and bears interest at variable rates approximating 7% on average. Interest expense under the note totaled $5,410 and $4,327 during the years ended December 31, 2019 and 2018, respectively.  During 2019 and 2018, the Company made net borrowings $3,353 and $3,803, respectively.

NOTE 5.  LONG-TERM DEBT   Long-term debt consists of the following vehicle loans, which are collateralized by their underlying vehicles with net carrying values exceeding the outstanding loan amounts:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1.5pt solid">December 31, 2019</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1.5pt solid">December 31, 2018</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left; padding-left: 5.4pt">3.53% installment note payable $352 monthly,  including    interest, through July 2019</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left; border-bottom: Black 1pt solid">$</td><td style="width: 12%; text-align: right; border-bottom: Black 1pt solid">—  </td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left; border-bottom: Black 1pt solid">$</td><td style="width: 12%; text-align: right; border-bottom: Black 1pt solid">2,782</td><td style="width: 1%; text-align: left; border-bottom: Black 1pt solid"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">3.79% installment note payable $299 monthly, including</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt">interest, through July 2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,216</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,532</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">2.99% installment note payable $350 monthly, including    interest, through August 2019</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left; border-bottom: Black 1pt solid"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,425</td><td style="padding-bottom: 1pt; text-align: left; border-bottom: Black 1pt solid"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt">Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,216</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,739</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Less principal due within one year</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,152</td><td style="padding-bottom: 1pt; text-align: left; border-bottom: Black 1pt solid">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(8,241</td><td style="padding-bottom: 1pt; text-align: left; border-bottom: Black 1pt solid">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">     TOTAL LONG-TERM DEBT</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,064</td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,498</td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   Principal payments due on long-term debt subsequent to December 31, 2019, are as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 50%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left"> </td><td style="width: 66%; text-align: left">2020</td><td style="width: 1%; text-align: left"> </td><td style="width: 10%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">3,152</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: left">2021</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,064</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td style="text-align: center">TOTAL</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5,216</td><td style="text-align: left"> </td></tr></table>

NOTE 6.  STOCKHOLDERS’ EQUITY   Common Stock   In June 2019, the Company received net proceeds of $100,000 from the sale of 336,000 shares of no-par value common stock at $0.298 per share.   In July 2018, the Company received net proceeds of $2,000 from the sale of 200,000 shares of no-par value common stock at $0.01 per share.    2019 Stock Options Granted   On November 26, 2019, the Board granted stock options to each of two officers, one director, and one advisor for the purchase of 300,000 shares of the common stock of the Company. The options expire in five years from the issuance date, have an exercise price of $0.55, and were immediately vested and exercisable.  On the grant date, total recognized compensation of $160,786 was recorded as salaries and wages.   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1.5pt solid">For the year ended December 31, 2019</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Number of shares</td><td style="width: 10%; padding-bottom: 1pt"> </td> <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"> </td><td style="width: 18%; border-bottom: Black 1pt solid; text-align: right">300,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Fair market value per share</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">0.54</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Stock based compensation recognized</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">160,786</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>   As of December 31, 2019, total unrecognized compensation remaining to be recognized in future periods totaled $0. The fair value of each option award above is estimated using the Black-Scholes option-pricing model with the following assumptions at the measurement date, which was deemed to be the November 26, 2019 grant date:    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1.5pt solid">Measurement date</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left; padding-left: 5.4pt">Dividend yield</td><td style="width: 10%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">0</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">314.95</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.58</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">Expected life (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt">Stock Price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.55</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt">Exercise Price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.55</td><td style="text-align: left"> </td></tr> </table>   A summary of the activity for the Company's stock options is as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="7" style="text-align: center; border-bottom: Black 1.5pt solid">December 31, 2019</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center">Shares</td><td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: justify; padding-left: 5.4pt">Outstanding, beginning of year</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">0</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">0</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 5.4pt">Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">300,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.55</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-left: 5.4pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 5.4pt">Canceled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-left: 5.4pt">Outstanding, end of year</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">300,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.55</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 5.4pt">Weighted average fair value of options granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.55</td><td style="text-align: left"> </td></tr></table>

NOTE 7.  LEASE COMMITMENTS   The Company rents office space under a non-cancellable lease through September 2020 with monthly payments of approximately $2,292. Pursuant to ASC 842, an operating lease right-of-use (“ROU”) asset and liability were recognized at January 1, 2019 based on the present value of lease payments over the remaining lease term. The ROU asset represents the Company’s right to use the underlying office space asset for the lease term, and the lease liability represents the Company’s obligation to make lease payments arising from the lease. Generally, the implicit rate of interest in arrangements is not readily determinable and the Company utilizes its incremental borrowing rate in determining the present value of lease payments. The operating lease ROU asset includes any lease payments made and excludes lease incentives. The Company recognized $27,504 in lease expense during each of the years ended December 31, 2019 and 2018.   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%">Remaining lease term at December 31, 2019 (in months)</td><td style="width: 10%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">9</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Discount rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5</td><td style="text-align: left">%</td></tr> </table>     <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-size: 12pt; text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended December 31, 2019</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: justify">Operating lease expense</td><td style="width: 10%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">27,504</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Cash paid for amounts included in measurement of lease liability</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">27,504</td><td style="text-align: left"> </td></tr> </table>   The supplemental balance sheet information related to leases for the period is as follows: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> Right-of-Use Asset </td><td> </td> <td colspan="3" style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: justify"> ROU Asset, January 1, 2019</td><td style="width: 10%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">43,677</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt"> Amortization of ROU Asset</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(24,959</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt"> ROU Asset, December 31, 2019</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">18,718</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>    Maturities of the Company’s lease liabilities are as follows: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="3" style="text-align: left"> Year Ending</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: right">Payments</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left"> </td><td style="width: 66%; text-align: left">2020</td><td style="width: 1%; text-align: left"> </td><td style="width: 10%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">20,628</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: left; padding-left: 10pt">Less: Imputed interest/present value discount</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,910</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: left; padding-left: 20pt">Present value of lease liability at December 31, 2019</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">18,718</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

NOTE 8.  GOING CONCERN   The Company has suffered losses from operations and has working capital and stockholders’ equity deficits. In all likelihood, the Company will be required to make significant future expenditures in connection with marketing efforts along with general administrative expenses. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.   The Company may raise additional capital through the sale of its equity securities, through an offering of debt securities, or through borrowings from financial institutions or related parties. By doing so, the Company hopes to generate sufficient capital to execute its business plan of selling medical supplies on an ongoing basis. Management believes that actions presently being taken to obtain additional funding provide the opportunity for the Company to continue as a going concern.

NOTE 9.  SUBSEQUENT EVENTS   The Company has evaluated subsequent events through the date these financial statements were issued and determined that there are no reportable subsequent events.

Use of Estimates   The preparation of financial statements in conformity with U.S. Generally Accepted Accounting Principles (“U.S. GAAP”) requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and Cash Equivalents   The Company considers all highly liquid investments with an original maturity of three months or less as cash equivalents.

Accounts Receivable   The majority of the Company’s revenues are received from Medicare, Medicaid, and private insurance companies. As such, the Company records revenues at allowable amounts, net of estimated allowances and discounts based on contracted prices and historical collection rates. The Company reviews accounts receivable periodically for collectability and establishes an allowance for doubtful accounts and records bad debt expense when deemed necessary. At December 30, 2019 and December 31, 2018, the Company has determined that no allowance for doubtful accounts is necessary.

Property and Equipment   Property and equipment are recorded at cost and depreciated under straight line methods over each item's estimated useful life.

Inventory   The Company carries inventory of durable medical equipment and medical supplies for resale.  Inventory is accounted for on a first–in first-out basis. Inventory consists of the following:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1.5pt solid">December 31, 2019</td><td> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1.5pt solid">December 31, 2018</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left; padding-left: 5.4pt">Durable medical equipment</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">22,759</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">33,570</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">Medical supplies</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">249</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,076</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt">Enteral</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,551</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,049</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">TOTALS</td><td> </td> <td style="text-align: left; border-top: Black 1pt solid; border-bottom: Black 2pt double">$</td><td style="text-align: right; border-top: Black 1pt solid; border-bottom: Black 2pt double">30,559</td><td style="text-align: left; border-top: Black 1pt solid; border-bottom: Black 2pt double"> </td><td style="padding-bottom: 2pt"> </td> <td style="text-align: left; border-top: Black 1pt solid; border-bottom: Black 2pt double">$</td><td style="text-align: right; border-top: Black 1pt solid; border-bottom: Black 2pt double">41,695</td><td style="text-align: left; border-top: Black 1pt solid; border-bottom: Black 2pt double"> </td></tr></table>

Revenue recognition   It is the Company’s policy that revenues from product sales is recognized in accordance with ASC 606 "Revenue Recognition."  Five basic steps must be followed before revenue can be recognized; (1) Identifying the contract(s) with a customer that creates enforceable rights and obligations; (2) Identifying the performance obligations in the contract, such as promising to transfer goods or services to a customer; (3) Determining the transaction price, meaning the amount of consideration in a contract to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer; (4) Allocating the transaction price to the performance obligations in the contract, which requires the company to allocate the transaction price to each performance obligation on the basis of the relative standalone selling prices of each distinct good or services promised in the contract; and (5) Recognizing revenue when (or as) the entity satisfies a performance obligation by transferring a promised good or service to a customer.  The amount of revenue recognized is the amount allocated to the satisfied performance obligation.  For sales of our Company products, a purchase arrangement is evidenced by a written order, with delivery considered as made after physical customer acceptance. Although rare, defective products may be returned, with other return issues considered on a case by case basis. Services such as periodic scheduled deliveries are contracted in writing, and generally billed monthly. Any service revenue earned by the Company for services such as safety and set up consulting or claims processing is recorded after the service is performed. Rental of durable home medical equipment is evidenced by written contract, with revenue recognized when rent is earned.    The Company’s primary source of revenue is reimbursement from Medicare, Medicaid, and private insurance companies for the procurement and sale of medical equipment and supplies to patients. The amount of revenue earned from each classification as a percent of total revenues is as follows:   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="7" style="text-align: center; border-bottom: Black 1.5pt solid">December 31,</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1.5pt solid">2019</td><td> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1.5pt solid">2018</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; padding-left: 5.4pt">Medicare</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">19</td><td style="width: 1%; text-align: left">%</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">29</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt">Medicaid</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">Private pay/private insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">73</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">58</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt">Other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Total</td><td> </td></tr></table>

Advertising Costs   Advertising costs are expensed as incurred. The Company had advertising costs during the years ended December 31, 2019 and 2018 of $13,453 and $18,129, respectively.

Income Tax   The Company accounts for income taxes pursuant to ASC 740. Under ASC 740, deferred taxes are provided for using the liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss carryforwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.    Through February 2012, the Company was an S-Corporation for income tax purposes, and therefore a pass-through entity paying no income tax at the corporate level. The Company had no material loss carryforwards as of December 31, 2011. Included in the Company’s accumulated deficit from February 2012 forward is approximately $99,000 in undistributed S-Corporation losses. At December 31, 2019 and 2018 the Company had net operating loss carryforwards (NOL’s) of approximately $462,000 and $144,000 respectively, which may be applied against future taxable income. However, if certain substantial changes in the Company’s ownership should occur, there could be an annual limitation on the amount of net operating loss carryforwards that can be utilized. The amount of and ultimate realization of the benefits from the operating loss carryforwards for income tax purposes is dependent, in part, upon the tax laws in effect, the future earnings of the Company, and other future events, the effects of which cannot be determined. Because of the uncertainty surrounding the realization of the loss carryforwards, the Company has established a valuation allowance equal to the tax effect (2019 and 2018: 21% federal and 5% state) of the loss carryforwards of approximately $120,000 and $37,440 at December 31, 2019 and 2018, respectively, and therefore, no deferred tax asset has been recognized for the loss carryforwards. The change in valuation allowance is approximately $82,560 and ($19,760) for the periods ended December 31, 2019 and 2018, respectively. The tax effect of remaining NOL’s and resulting deferred tax assets of $120,000 remain fully reserved by valuation allowance, due to continued uncertainty as to their utilization.

Net Income (Loss) per Share   Basic net income per common share ("Basic EPS'') excludes dilution and is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share ("Diluted EPS'') reflects the potential dilution that could occur if stock options or other contracts to issue shares of common stock were exercised or converted into common stock. The computation of Diluted EPS does not assume exercise or conversion of securities that would have an anti-dilutive effect on net income per common share.   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended December 31, 2019</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended December 31, 2018</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: left">Numerator</td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left; padding-left: 5.4pt">Net income (loss) applicable to common shareholders</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(477,234</td><td style="width: 1%; text-align: left">)</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">68,206</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-left: 5.4pt">Denominator</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt">Weighted average common shares outstanding, basic</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,635,534</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,385,693</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">Stock options</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">300,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt">Weighted average common shares outstanding, diluted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,935,534</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,385,693</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt">Net Income per share - Basic</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.04</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.01</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt">Income per shares - Diluted</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.04</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.01</td><td style="text-align: left"> </td></tr></table>

Financial Instruments   The carrying value of the Company’s financial instruments, as reported in the accompanying balance sheets, approximates fair value.

Concentrations   Financial instruments that potentially subject the Company to concentrations of credit risk include cash and cash equivalents. The Company places its cash and cash equivalents at well-known financial institutions, where at times, such balances may exceed FDIC insurance limits.   The Company receives a significant amount of its revenues in reimbursements from Medicare and Medicaid thru competitive bidding processes. There is no guarantee that the Company will be selected as a winning contract supplier under future bidding rounds.

Other Selling, General and Administrative Expenses   Other selling, general and administrative expenses included the following:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="7" style="text-align: center; border-bottom: Black 1.5pt solid">December 31,</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="text-align: center"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1.5pt solid">2018</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%">Rent</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">27,504</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">27,504</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Office expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,765</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,727</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other SG&A</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">150,806</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">126,079</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Total</td><td> </td> <td style="text-align: left; border-top: Black 1pt solid; border-bottom: Black 2pt double">$</td><td style="text-align: right; border-top: Black 1pt solid; border-bottom: Black 2pt double">204,075</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left; border-top: Black 1pt solid; border-bottom: Black 2pt double">$</td><td style="text-align: right; border-top: Black 1pt solid; border-bottom: Black 2pt double">194,310</td><td style="text-align: left"> </td></tr></table>

Long-Lived Assets   In accordance with ASC 350, the Company regularly reviews the carrying value of intangible and other long-lived assets for the existence of facts or circumstances, both internally and externally, that suggest impairment. If impairment testing indicates a lack of recoverability, an impairment loss is recognized by the Company if the carrying amount of a long-lived asset exceeds its fair value. No impairment was noted during the years ended December 31, 2019 and 2018.

Products and Services, Geographic Areas and Major Customers   The Company’s business of medical supply sales constitutes one operating segment. All revenues each year were domestic and to external customers.

Leases   In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02, “Lease (Topic 842),” a new lease standard requiring lessees to recognize lease assets and lease liabilities for most leases classified as operating leases under previous U.S. GAAP. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset (“ROU” asset) representing its right to use the underlying asset for the lease term. The guidance is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company has adopted this standard effective January 1, 2019. The Company elected the optional transition method that permits adoption of the new standard prospectively, as of the effective date, without adjusting comparative periods presented. See Note 6 for disclosure required by ASC 842.

The Company carries inventory of durable medical equipment and medical supplies for resale.  Inventory is accounted for on a first–in first-out basis. Inventory consists of the following:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1.5pt solid">December 31, 2019</td><td> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1.5pt solid">December 31, 2018</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left; padding-left: 5.4pt">Durable medical equipment</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">22,759</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">33,570</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">Medical supplies</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">249</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,076</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt">Enteral</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,551</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,049</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">TOTALS</td><td> </td> <td style="text-align: left; border-top: Black 1pt solid; border-bottom: Black 2pt double">$</td><td style="text-align: right; border-top: Black 1pt solid; border-bottom: Black 2pt double">30,559</td><td style="text-align: left; border-top: Black 1pt solid; border-bottom: Black 2pt double"> </td><td style="padding-bottom: 2pt"> </td> <td style="text-align: left; border-top: Black 1pt solid; border-bottom: Black 2pt double">$</td><td style="text-align: right; border-top: Black 1pt solid; border-bottom: Black 2pt double">41,695</td><td style="text-align: left; border-top: Black 1pt solid; border-bottom: Black 2pt double"> </td></tr></table>

The amount of revenue earned from each classification as a percent of total revenues is as follows:   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="7" style="text-align: center; border-bottom: Black 1.5pt solid">December 31,</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1.5pt solid">2019</td><td> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1.5pt solid">2018</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; padding-left: 5.4pt">Medicare</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">19</td><td style="width: 1%; text-align: left">%</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">29</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt">Medicaid</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">Private pay/private insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">73</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">58</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt">Other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Total</td><td> </td> <td style="text-align: left; border-top: Black 1pt solid; border-bottom: Black 2pt double"> </td><td style="text-align: right; border-top: Black 1pt solid; border-bottom: Black 2pt double">100</td><td style="text-align: left; vertical-align: middle">%</td><td style="padding-bottom: 2pt"> </td> <td style="text-align: left; border-top: Black 1pt solid; border-bottom: Black 2pt double"> </td><td style="text-align: right; border-top: Black 1pt solid; border-bottom: Black 2pt double">100</td><td style="text-align: left; vertical-align: middle">%</td></tr></table>

The computation of Diluted EPS does not assume exercise or conversion of securities that would have an anti-dilutive effect on net income per common share.   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended December 31, 2019</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended December 31, 2018</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: left">Numerator</td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left; padding-left: 5.4pt">Net income (loss) applicable to common shareholders</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(477,234</td><td style="width: 1%; text-align: left">)</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">68,206</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-left: 5.4pt">Denominator</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt">Weighted average common shares outstanding, basic</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,635,534</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,385,693</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">Stock options</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">300,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt">Weighted average common shares outstanding, diluted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,935,534</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,385,693</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt">Net Income per share - Basic</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.04</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.01</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt">Income per shares - Diluted</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.04</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.01</td><td style="text-align: left"> </td></tr></table>

Other selling, general and administrative expenses included the following:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="7" style="text-align: center; border-bottom: Black 1.5pt solid">December 31,</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="text-align: center"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1.5pt solid">2018</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%">Rent</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">27,504</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">27,504</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Office expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,765</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,727</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other SG&A</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">150,806</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">126,079</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Total</td><td> </td> <td style="text-align: left; border-top: Black 1pt solid; border-bottom: Black 2pt double">$</td><td style="text-align: right; border-top: Black 1pt solid; border-bottom: Black 2pt double">204,075</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left; border-top: Black 1pt solid; border-bottom: Black 2pt double">$</td><td style="text-align: right; border-top: Black 1pt solid; border-bottom: Black 2pt double">194,310</td><td style="text-align: left"> </td></tr></table>

Property and equipment are recorded at cost and consist of the following:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="7" style="text-align: center; border-bottom: Black 1.5pt solid">December 31,</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="text-align: center"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1.5pt solid">2018</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Office equipment</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,934</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,934</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Vehicles</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">70,208</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">70,208</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Wheelchair rental pool</td><td> </td> <td style="text-align: left; border-bottom: Black 1pt solid"> </td><td style="text-align: right; border-bottom: Black 1pt solid">66,191</td><td style="text-align: left; border-bottom: Black 1pt solid"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: Black 1pt solid"> </td><td style="text-align: right; border-bottom: Black 1pt solid">78,392</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total property and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">139,333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">151,534</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accumulated depreciation</td><td> </td> <td style="text-align: left; border-bottom: Black 1pt solid"> </td><td style="text-align: right; border-bottom: Black 1pt solid">(95,488</td><td style="text-align: left; border-bottom: Black 1pt solid">)</td><td> </td> <td style="text-align: left; border-bottom: Black 1pt solid"> </td><td style="text-align: right; border-bottom: Black 1pt solid">(92,907</td><td style="text-align: left; border-bottom: Black 1pt solid">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net property and equipment</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">43,845</td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">58,627</td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

Depreciation is computed using the straight-line method based upon estimated useful lives as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top; text-align: left"> <td style="width: 30%; padding-left: 30pt">Office equipment</td> <td style="width: 70%">7 years</td></tr> <tr style="vertical-align: top; text-align: left"> <td style="padding-left: 30pt">Vehicles</td> <td> 5 years</td></tr> <tr style="vertical-align: top; text-align: left"> <td style="padding-left: 30pt">Wheelchair rental pool</td> <td>13 months</td></tr></table>

Long-term debt consists of the following vehicle loans, which are collateralized by their underlying vehicles with net carrying values exceeding the outstanding loan amounts:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1.5pt solid">December 31, 2019</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1.5pt solid">December 31, 2018</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left; padding-left: 5.4pt">3.53% installment note payable $352 monthly,  including    interest, through July 2019</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left; border-bottom: Black 1pt solid">$</td><td style="width: 12%; text-align: right; border-bottom: Black 1pt solid">—  </td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left; border-bottom: Black 1pt solid">$</td><td style="width: 12%; text-align: right; border-bottom: Black 1pt solid">2,782</td><td style="width: 1%; text-align: left; border-bottom: Black 1pt solid"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">3.79% installment note payable $299 monthly, including</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt">interest, through July 2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,216</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,532</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">2.99% installment note payable $350 monthly, including    interest, through August 2019</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left; border-bottom: Black 1pt solid"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,425</td><td style="padding-bottom: 1pt; text-align: left; border-bottom: Black 1pt solid"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt">Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,216</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,739</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Less principal due within one year</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,152</td><td style="padding-bottom: 1pt; text-align: left; border-bottom: Black 1pt solid">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(8,241</td><td style="padding-bottom: 1pt; text-align: left; border-bottom: Black 1pt solid">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">     TOTAL LONG-TERM DEBT</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,064</td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,498</td></tr></table>

Principal payments due on long-term debt subsequent to December 31, 2019, are as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 50%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left"> </td><td style="width: 66%; text-align: left">2020</td><td style="width: 1%; text-align: left"> </td><td style="width: 10%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">3,152</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: left">2021</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,064</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td style="text-align: center">TOTAL</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5,216</td><td style="text-align: left"> </td></tr></table>

On the grant date, total recognized compensation of $160,786 was recorded as salaries and wages.   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1.5pt solid">For the year ended December 31, 2019</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Number of shares</td><td style="width: 10%; padding-bottom: 1pt"> </td> <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"> </td><td style="width: 18%; border-bottom: Black 1pt solid; text-align: right">300,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Fair market value per share</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">0.54</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt">Stock based compensation recognized</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">160,786</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr></table>

The fair value of each option award above is estimated using the Black-Scholes option-pricing model with the following assumptions at the measurement date, which was deemed to be the November 26, 2019 grant date:    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1.5pt solid">Measurement date</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left; padding-left: 5.4pt">Dividend yield</td><td style="width: 10%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">0</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">314.95</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.58</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">Expected life (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt">Stock Price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.55</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt">Exercise Price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.55</td><td style="text-align: left"> </td></tr></table>

A summary of the activity for the Company's stock options is as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="7" style="text-align: center; border-bottom: Black 1.5pt solid">December 31, 2019</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center">Shares</td><td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: justify; padding-left: 5.4pt">Outstanding, beginning of year</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">0</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">0</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 5.4pt">Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">300,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.55</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-left: 5.4pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 5.4pt">Canceled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-left: 5.4pt">Outstanding, end of year</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">300,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.55</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 5.4pt">Weighted average fair value of options granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.55</td><td style="text-align: left"> </td></tr></table>

The Company recognized $27,504 in lease expense during each of the years ended December 31, 2019 and 2018.   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%">Remaining lease term at December 31, 2019 (in months)</td><td style="width: 10%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">9</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Discount rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5</td><td style="text-align: left">%</td></tr> </table>     <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-size: 12pt; text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended December 31, 2019</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: justify">Operating lease expense</td><td style="width: 10%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">27,504</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Cash paid for amounts included in measurement of lease liability</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">27,504</td><td style="text-align: left"> </td></tr></table>

The supplemental balance sheet information related to leases for the period is as follows: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> Right-of-Use Asset </td><td> </td> <td colspan="3" style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: justify"> ROU Asset, January 1, 2019</td><td style="width: 10%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">43,677</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt"> Amortization of ROU Asset</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(24,959</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt"> ROU Asset, December 31, 2019</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">18,718</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

Maturities of the Company’s lease liabilities are as follows: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="3" style="text-align: left"> Year Ending</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: right">Payments</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left"> </td><td style="width: 66%; text-align: left">2020</td><td style="width: 1%; text-align: left"> </td><td style="width: 10%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">20,628</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: left; padding-left: 10pt">Less: Imputed interest/present value discount</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,910</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: left; padding-left: 20pt">Present value of lease liability at December 31, 2019</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">18,718</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

NOTE 1. ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES   Canfield Medical Supply, Inc. (the “Company”), was incorporated in the State of Ohio on September 3, 1992, and changed domicile to Colorado on April 18, 2012. The Company is in the business of home health services, primarily the selling of durable medical equipment and medical supplies to the public, nursing homes, hospitals and other end users.   Effective June 21, 2019 WesBev LLC, a Nevada limited liability company ("WesBev"), acquired 8,000,000 shares of common stock from Michael J. West, a founder, director and former principal shareholder of the Company, consisting of approximately 69.7% of the issued and outstanding shares of the Company at the time of the purchase. As part of his agreement with WesBev, Mr. West undertook to appoint or cause the appointment of up to three persons nominated by WesBev to the board of directors of the Company. Effective June 21, 2019 the Company sold 336,000 shares of common stock to WesBev for $100,000. Following these stock purchases WesBev beneficially owns 8,336,000 shares, or approximately 71% of the issued and outstanding shares of the Company and may be deemed to be in control of the registrant.   On December 31, 2019, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with SBG Acquisition Inc. (“Merger Sub”), a Nevada Corporation wholly-owned by the Company, and Splash Beverage Group, Inc. a Nevada corporation (“Splash”) pursuant to which Merger Sub shall be merged with and into Splash (the “Merger”) with Splash as the surviving company and a wholly-owned subsidiary of the Company. The closing of the Merger shall take place on the first business day following satisfaction or waiver of the closing terms and conditions set forth in the Merger Agreement.   Completion of the Merger is subject to customary closing terms and conditions including, among others:  <table cellspacing="0" cellpadding="0" style="width: 100%; background-color: white"> <tr style="vertical-align: top"> <td style="font: 12pt Times New Roman, Times, Serif; width: 24px"> </td> <td style="font: 12pt Times New Roman, Times, Serif; width: 24px">●</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">the adoption of the Merger Agreement by Splash’s stockholders;</td></tr> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify"> </td> <td style="width: 24px; text-align: justify">●</td> <td style="text-align: justify">the representations and warranties of the respective parties being true and correct in all material respects as of the closing day of the Merger;</td></tr> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify"> </td> <td style="width: 24px; text-align: justify">●</td> <td style="text-align: justify">since June 1, 2019 through the closing of the Merger, Splash shall have raised from the aggregate sale of its equity securities not less than $1,500,000 which shall be available or was utilized for inventory purchases, reductions to accounts payable and for other general working capital purposes;</td></tr> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify"> </td> <td style="width: 24px; text-align: justify">●</td> <td style="text-align: justify">on the closing of the Merger liabilities of Splash debt shall not exceed $500,000;</td></tr> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify"> </td> <td style="width: 24px; text-align: justify">●</td> <td style="text-align: justify">Splash shall have entered into note conversion agreements with substantially all holders of its debt pursuant to which such debt is converted into shares Splash’s common stock at a conversion price of $1.00 per share;</td></tr> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify"> </td> <td style="width: 24px; text-align: justify">●</td> <td style="text-align: justify">designated shareholders of Splash shall have entered into lock-up/leak out agreements by which they will agree to restrict post-Merger sales of Canfield securities for a period of up to one year following the Merger, as more particularly described within the Merger Agreement;</td></tr> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify"> </td> <td style="width: 24px; text-align: justify">●</td> <td style="text-align: justify">the Company and Michael West, the Company’s former Chief Executive Officer, and a current director, shall have entered into a Business Transfer and Indemnity Agreement  pursuant to which all operations, assets and liabilities of the Company’s home health services business shall be transferred and conveyed to Mr. West or an entity designated by Mr. West in exchange for his indemnifying the Company for certain liabilities and claims;</td></tr> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify"> </td> <td style="width: 24px; text-align: justify">●</td> <td style="text-align: justify">the Company shall not have any liabilities exceeding $50,000 in the aggregate;</td></tr> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify"> </td> <td style="width: 24px; text-align: justify">●</td> <td style="text-align: justify">the Company’s directors and officers shall have tendered their resignations;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify">●</td> <td style="text-align: justify">Robert Nistico, Chief Executive Officer of Splash, shall be appointed as chief executive officer of the Company; and</td></tr> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify"> </td> <td style="width: 24px; text-align: justify">●</td> <td style="text-align: justify">the composition of the Company’s board of directors shall be as set forth in the Merger Agreement.</td></tr> </table>   As of the date of this annual report, all conditions to closing have been completed, except for the fourth, and the seventh through eleventh bulleted conditions listed above. The items listed in the seventh, ninth and tenth bulleted conditions above have been finalized, but will not be delivered until the closing date.  Use of Estimates   The preparation of financial statements in conformity with U.S. Generally Accepted Accounting Principles (“U.S. GAAP”) requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.   Cash and Cash Equivalents   The Company considers all highly liquid investments with an original maturity of three months or less as cash equivalents.   Accounts Receivable   The majority of the Company’s revenues are received from Medicare, Medicaid, and private insurance companies. As such, the Company records revenues at allowable amounts, net of estimated allowances and discounts based on contracted prices and historical collection rates. The Company reviews accounts receivable periodically for collectability and establishes an allowance for doubtful accounts and records bad debt expense when deemed necessary. At December 30, 2019 and December 31, 2018, the Company has determined that no allowance for doubtful accounts is necessary.   Property and Equipment   Property and equipment are recorded at cost and depreciated under straight line methods over each item's estimated useful life.   Inventory   The Company carries inventory of durable medical equipment and medical supplies for resale.  Inventory is accounted for on a first–in first-out basis. Inventory consists of the following:   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2019</td><td> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2018</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left; padding-left: 5.4pt">Durable medical equipment</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">22,759</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">33,570</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">Medical supplies</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">249</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,076</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt">Enteral</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,551</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,049</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">TOTALS</td><td> </td> <td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: left">$</td><td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: right">30,559</td><td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: left"> </td><td style="padding-bottom: 2pt"> </td> <td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: left">$</td><td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: right">41,695</td><td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: left"> </td></tr> </table>   Revenue recognition   It is the Company’s policy that revenues from product sales is recognized in accordance with ASC 606 "Revenue Recognition."  Five basic steps must be followed before revenue can be recognized; (1) Identifying the contract(s) with a customer that creates enforceable rights and obligations; (2) Identifying the performance obligations in the contract, such as promising to transfer goods or services to a customer; (3) Determining the transaction price, meaning the amount of consideration in a contract to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer; (4) Allocating the transaction price to the performance obligations in the contract, which requires the company to allocate the transaction price to each performance obligation on the basis of the relative standalone selling prices of each distinct good or services promised in the contract; and (5) Recognizing revenue when (or as) the entity satisfies a performance obligation by transferring a promised good or service to a customer.  The amount of revenue recognized is the amount allocated to the satisfied performance obligation.  For sales of our Company products, a purchase arrangement is evidenced by a written order, with delivery considered as made after physical customer acceptance. Although rare, defective products may be returned, with other return issues considered on a case by case basis. Services such as periodic scheduled deliveries are contracted in writing, and generally billed monthly. Any service revenue earned by the Company for services such as safety and set up consulting or claims processing is recorded after the service is performed. Rental of durable home medical equipment is evidenced by written contract, with revenue recognized when rent is earned.    The Company’s primary source of revenue is reimbursement from Medicare, Medicaid, and private insurance companies for the procurement and sale of medical equipment and supplies to patients. The amount of revenue earned from each classification as a percent of total revenues is as follows:   <table cellpadding="0" cellspacing="0" align="center" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="7" style="border-bottom: Black 1.5pt solid; text-align: center">December 31,</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center">2018</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; padding-left: 5.4pt">Medicare</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">19</td><td style="width: 1%; text-align: left">%</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">29</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt">Medicaid</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">Private pay/private insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">73</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">58</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt">Other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Total</td><td> </td> <td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: left"> </td><td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: right">100</td><td style="text-align: left; vertical-align: middle">%</td><td style="padding-bottom: 2pt"> </td> <td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: left"> </td><td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: right">100</td><td style="text-align: left; vertical-align: middle">%</td></tr> </table>     Advertising Costs   Advertising costs are expensed as incurred. The Company had advertising costs during the years ended December 31, 2019 and 2018 of $13,453 and $18,129, respectively.   Income Tax   The Company accounts for income taxes pursuant to ASC 740. Under ASC 740, deferred taxes are provided for using the liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss carryforwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.    Through February 2012, the Company was an S-Corporation for income tax purposes, and therefore a pass-through entity paying no income tax at the corporate level. The Company had no material loss carryforwards as of December 31, 2011. Included in the Company’s accumulated deficit from February 2012 forward is approximately $99,000 in undistributed S-Corporation losses. At December 31, 2019 and 2018 the Company had net operating loss carryforwards (NOL’s) of approximately $462,000 and $144,000 respectively, which may be applied against future taxable income. However, if certain substantial changes in the Company’s ownership should occur, there could be an annual limitation on the amount of net operating loss carryforwards that can be utilized. The amount of and ultimate realization of the benefits from the operating loss carryforwards for income tax purposes is dependent, in part, upon the tax laws in effect, the future earnings of the Company, and other future events, the effects of which cannot be determined. Because of the uncertainty surrounding the realization of the loss carryforwards, the Company has established a valuation allowance equal to the tax effect (2019 and 2018: 21% federal and 5% state) of the loss carryforwards of approximately $120,000 and $37,440 at December 31, 2019 and 2018, respectively, and therefore, no deferred tax asset has been recognized for the loss carryforwards. The change in valuation allowance is approximately $82,560 and ($19,760) for the periods ended December 31, 2019 and 2018, respectively. The tax effect of remaining NOL’s and resulting deferred tax assets of $120,000 remain fully reserved by valuation allowance, due to continued uncertainty as to their utilization.   Net Income (Loss) per Share   Basic net income per common share ("Basic EPS'') excludes dilution and is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share ("Diluted EPS'') reflects the potential dilution that could occur if stock options or other contracts to issue shares of common stock were exercised or converted into common stock. The computation of Diluted EPS does not assume exercise or conversion of securities that would have an anti-dilutive effect on net income per common share.   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31, 2019</td><td style="font-weight: bold"> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31, 2018</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: left">Numerator</td><td> </td> <td colspan="3" style="text-align: right"> </td><td> </td> <td colspan="3" style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left; padding-left: 5.4pt">Net income (loss) applicable to common shareholders</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(477,234</td><td style="width: 1%; text-align: left">)</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">68,206</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-left: 5.4pt">Denominator</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt">Weighted average common shares outstanding, basic</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,635,534</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,385,693</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">Stock options</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">300,000</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt">Weighted average common shares outstanding, diluted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,935,534</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,385,693</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt">Net Income per share - Basic</td><td> </td> <td style="border-top: Black 2pt double; border-bottom: Black 2pt double; text-align: left">$</td><td style="border-top: Black 2pt double; border-bottom: Black 2pt double; text-align: right">(0.04</td><td style="text-align: left">)</td><td> </td> <td style="border-top: Black 2pt double; border-bottom: Black 2pt double; text-align: left">$</td><td style="border-top: Black 2pt double; border-bottom: Black 2pt double; text-align: right">0.01</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt">Income per shares - Diluted</td><td> </td> <td style="border-bottom: Black 2pt double; text-align: left">$</td><td style="border-bottom: Black 2pt double; text-align: right">(0.04</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2pt double; text-align: left">$</td><td style="border-bottom: Black 2pt double; text-align: right">0.01</td><td style="text-align: left"> </td></tr> </table>   Financial Instruments   The carrying value of the Company’s financial instruments, as reported in the accompanying balance sheets, approximates fair value.   Concentrations   Financial instruments that potentially subject the Company to concentrations of credit risk include cash and cash equivalents. The Company places its cash and cash equivalents at well-known financial institutions, where at times, such balances may exceed FDIC insurance limits.   The Company receives a significant amount of its revenues in reimbursements from Medicare and Medicaid thru competitive bidding processes. There is no guarantee that the Company will be selected as a winning contract supplier under future bidding rounds.   Other Selling, General and Administrative Expenses   Other selling, general and administrative expenses included the following:   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="7" style="border-bottom: Black 1.5pt solid; text-align: center">December 31,</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="text-align: center"> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center">2018</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%">Rent</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">27,504</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">27,504</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Office expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,765</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,727</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other SG&A</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">150,806</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">126,079</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Total</td><td> </td> <td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: left">$</td><td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: right">204,075</td><td style="text-align: left"> </td><td> </td> <td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: left">$</td><td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: right">194,310</td><td style="text-align: left"> </td></tr> </table>   Long-Lived Assets   In accordance with ASC 350, the Company regularly reviews the carrying value of intangible and other long-lived assets for the existence of facts or circumstances, both internally and externally, that suggest impairment. If impairment testing indicates a lack of recoverability, an impairment loss is recognized by the Company if the carrying amount of a long-lived asset exceeds its fair value. No impairment was noted during the years ended December 31, 2019 and 2018.   Products and Services, Geographic Areas and Major Customers   The Company’s business of medical supply sales constitutes one operating segment. All revenues each year were domestic and to external customers.   Leases   In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02, “Lease (Topic 842),” a new lease standard requiring lessees to recognize lease assets and lease liabilities for most leases classified as operating leases under previous U.S. GAAP. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset (“ROU” asset) representing its right to use the underlying asset for the lease term. The guidance is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company has adopted this standard effective January 1, 2019. The Company elected the optional transition method that permits adoption of the new standard prospectively, as of the effective date, without adjusting comparative periods presented. See Note 6 for disclosure required by ASC 842.

NOTE 4. RELATED PARTY LOAN   On June 21, 2019, the Company entered into a short-term loan with Michael West, an officer of the Company, for $276,550. The loan has a one-year term from June 21, 2019, and is non-interest bearing. The Company made payments of $78,701 on this loan, resulting in a loan balance of $197,849 and $0 as of December 31, 2019 and December 31, 2018, respectively.

EX-101.SCH 7 cmds-20191231.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - LINE OF CREDIT link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - RELATED PARTY LOAN link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - LONG-TERM DEBT link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - LEASE COMMITMENTS link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - GOING CONCERN link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - LONG-TERM DEBT (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - STOCKHOLDERS' EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - LEASE COMMITMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - EQUIPMENT (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - EQUIPMENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - LINE OF CREDIT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - RELATED PARTY LOAN (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - LONG-TERM DEBT (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - LONG-TERM DEBT (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - STOCKHOLDERS' EQUITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - STOCKHOLDERS' EQUITY (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - STOCKHOLDERS' EQUITY (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - STOCKHOLDERS’ EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - LEASE COMMITMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - LEASE COMMITMENTS (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - LEASE COMMITMENTS (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - LEASE COMMITMENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 cmds-20191231_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 cmds-20191231_def.xml XBRL DEFINITION FILE EX-101.LAB 10 cmds-20191231_lab.xml XBRL LABEL FILE Equity Components [Axis] Accumulated Deficit Common Stock (no par) Concentration Risk Type [Axis] Medicare Medicaid Private pay/private insurance Other Property, Plant and Equipment, Type [Axis] Office Equipment [Member] Vehicles [Member] Wheelchair rental pool [Member] Extinguishment of Debt [Axis] Long-term Debt One [Member] Long-term Debt Two [Member] Long-term Debt Three [Member] Additional Paid-In Capital Inventory [Axis] Durable medical equipment Medical supplies Enteral Business Acquisition [Axis] WesBev Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Filer Category Entity Emerging Growth Company Entity Small Business Entity Ex Transition Period Entity Shell Company Entity Interactive Data Current Entity File Number Entity Incorporation, State or Country Code Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS Current Assets Cash Accounts receivable Inventory Right-of-use asset Total Current Assets Equipment, net of accumulated depreciation of $95,488 and $92,907 Total Assets LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Current Liabilities Accounts payable and accrued liabilities Line of credit Due from officer Lease liability Current portion of long-term debt Total Current liabilities Long-term Liabilities Long-term debt Total Long-term liabilities Total liabilities Stockholders' Equity (Deficit) Preferred stock, no par value; 5,000,000 shares authorized; no shares issued and outstanding Common stock, no par value; 100,000,000 shares authorized; 11,813,200 (December 31, 2019) and 11,477,200 (December 31, 2018) shares issued and outstanding Additional paid-in capital Accumulated deficit Total Stockholders' Equity (Deficit) Total Liabilities and Stockholders' Equity (Deficit) Preferred stock, no par value Preferred stock, authorized shares Preferred stock, issued shares Preferred stock, outstanding shares Common stock, no par value Common stock, authorized shares Common stock, issued shares Common stock, outstanding shares Accumulated depreciation Income Statement [Abstract] Sales (net of returns) Cost of goods sold Gross profit Operating expenses: Salaries and wages Professional fees Depreciation Other selling, general and administrative Total operating expenses Income (loss) from operations Other income (expense): Interest income Interest expense Gain on sale of fixed assets Total other income (expense) Income (loss) before provision for income taxes Provision for income tax Net income (loss) Net income (loss) per share applicable to common shareholders - basic Net income (loss) per share applicable to common shareholders - diluted Weighted average number of common shares outstanding - basic Weighted average number of common shares outstanding - diluted Statement [Table] Statement [Line Items] Beginning Balance Beginning Balance, in Shares Common stock issued for cash Common stock issued for cash, in Shares Stock options granted and vested Net income (loss) for the year Ending Balance Ending Balance, in Shares Statements Of Cash Flows Cash Flows From Operating Activities: Net income (loss) Adjustments to reconcile net income (loss) to net cash provided by (used for) operating activities: Gain on disposal of fixed assets Depreciation Stock-based compensation Changes in current assets and liabilities: Increase in accounts receivable (Increase) decrease in inventory Increase in accounts payable and accrued liabilities Net cash provided by (used for) operating activities Cash Flows From Investing Activities: Proceeds from sale of fixed assets Purchase of property and equipment Net cash provided by (used for) investing activities Cash Flows From Financing Activities: Net borrowings (payments) on line of credit Proceeds from officer Payments to officer Payments on long-term debt Proceeds from sales of common stock Net cash provided by (used for) financing activities Net Increase (Decrease) in Cash Cash at the Beginning of the Period Cash at the End of the Period Schedule Of Non-Cash Investing And Financing Activities Lease liability and right-of-use-asset Amortization of right-of-use asset Supplemental Disclosure Cash paid for interest Cash paid for income taxes Accounting Policies [Abstract] ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Property, Plant and Equipment [Abstract] EQUIPMENT Debt Disclosure [Abstract] LINE OF CREDIT Related Party Transactions [Abstract] RELATED PARTY LOAN LONG-TERM DEBT Equity [Abstract] STOCKHOLDERS' EQUITY Leases [Abstract] LEASE COMMITMENTS Organization, Consolidation and Presentation of Financial Statements [Abstract] GOING CONCERN Subsequent Events [Abstract] SUBSEQUENT EVENTS Use of Estimates Cash and Cash Equivalents Accounts Receivable Property and Equipment Inventory Revenue recognition Advertising Costs Income Tax Net Income (Loss) per Share Financial Instruments Concentrations Other selling, general and administrative expenses Long-Lived Assets Products and Services, Geographic Areas and Major Customers Leases Schedule of Inventory Classification of percent of total revenues Schedule of Earnings Per Share, Basic and Diluted Schedule of selling, general and administrative expenses Equipment Tables Schedule of Property and equipment Schedule of estimated useful lives of equipment Schedule of Long Term Debt Schedule of Principal amount due to Long Term Assets Schedule of compensation Schedule of Valuation Assumptions Schedule of Stock Options Activity Components of lease expense and supplemental information related to lease Supplemental balance sheet information related to leases EX-101.PRE 11 cmds-20191231_pre.xml XBRL PRESENTATION FILE XML 12 R7.htm IDEA: XBRL DOCUMENT

ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 1. ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Effective June 21, 2019 WesBev LLC, a Nevada limited liability company ("WesBev"), acquired 8,000,000 shares of common stock from Michael J. West, a founder, director and former principal shareholder of the Company, consisting of approximately 69.7% of the issued and outstanding shares of the Company at the time of the purchase. As part of his agreement with WesBev, Mr. West undertook to appoint or cause the appointment of up to three persons nominated by WesBev to the board of directors of the Company. Effective June 21, 2019 the Company sold 336,000 shares of common stock to WesBev for $100,000. Following these stock purchases WesBev beneficially owns 8,336,000 shares, or approximately 71% of the issued and outstanding shares of the Company and may be deemed to be in control of the registrant.

Completion of the Merger is subject to customary closing terms and conditions including, among others:

	●	the adoption of the Merger Agreement by Splash’s stockholders;
	●	the representations and warranties of the respective parties being true and correct in all material respects as of the closing day of the Merger;
	●	since June 1, 2019 through the closing of the Merger, Splash shall have raised from the aggregate sale of its equity securities not less than $1,500,000 which shall be available or was utilized for inventory purchases, reductions to accounts payable and for other general working capital purposes;
	●	on the closing of the Merger liabilities of Splash debt shall not exceed $500,000;
	●	Splash shall have entered into note conversion agreements with substantially all holders of its debt pursuant to which such debt is converted into shares Splash’s common stock at a conversion price of $1.00 per share;
	●	designated shareholders of Splash shall have entered into lock-up/leak out agreements by which they will agree to restrict post-Merger sales of Canfield securities for a period of up to one year following the Merger, as more particularly described within the Merger Agreement;
	●	the Company and Michael West, the Company’s former Chief Executive Officer, and a current director, shall have entered into a Business Transfer and Indemnity Agreement pursuant to which all operations, assets and liabilities of the Company’s home health services business shall be transferred and conveyed to Mr. West or an entity designated by Mr. West in exchange for his indemnifying the Company for certain liabilities and claims;
	●	the Company shall not have any liabilities exceeding $50,000 in the aggregate;
	●	the Company’s directors and officers shall have tendered their resignations;
	●	Robert Nistico, Chief Executive Officer of Splash, shall be appointed as chief executive officer of the Company; and
	●	the composition of the Company’s board of directors shall be as set forth in the Merger Agreement.

Use of Estimates

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity of three months or less as cash equivalents.

Accounts Receivable

Property and Equipment

Property and equipment are recorded at cost and depreciated under straight line methods over each item's estimated useful life.

Inventory

The Company carries inventory of durable medical equipment and medical supplies for resale. Inventory is accounted for on a first–in first-out basis. Inventory consists of the following:

	December 31, 2019		December 31, 2018
Durable medical equipment	$	22,759	$	33,570
Medical supplies		249		1,076
Enteral		7,551		7,049
TOTALS	$	30,559	$	41,695

Revenue recognition

	December 31,
	2019			2018
Medicare		19	%		29	%
Medicaid		7	%		9	%
Private pay/private insurance		73	%		58	%
Other		1	%		4	%
Total		100	%		100	%

Advertising Costs

Advertising costs are expensed as incurred. The Company had advertising costs during the years ended December 31, 2019 and 2018 of $13,453 and $18,129, respectively.

Income Tax

Net Income (Loss) per Share

	Year Ended December 31, 2019			Year Ended December 31, 2018
Numerator
Net income (loss) applicable to common shareholders	$	(477,234	)	$	68,206

Denominator
Weighted average common shares outstanding, basic		11,635,534			11,385,693
Stock options		300,000			—
Weighted average common shares outstanding, diluted		11,935,534			11,385,693
Net Income per share - Basic	$	(0.04	)	$	0.01
Income per shares - Diluted	$	(0.04	)	$	0.01

Financial Instruments

The carrying value of the Company’s financial instruments, as reported in the accompanying balance sheets, approximates fair value.

Concentrations

The Company receives a significant amount of its revenues in reimbursements from Medicare and Medicaid thru competitive bidding processes. There is no guarantee that the Company will be selected as a winning contract supplier under future bidding rounds.

Other Selling, General and Administrative Expenses

Other selling, general and administrative expenses included the following:

	December 31,
	2019		2018
Rent	$	27,504	$	27,504
Office expenses		25,765		40,727
Other SG&A		150,806		126,079
Total	$	204,075	$	194,310

Long-Lived Assets

Products and Services, Geographic Areas and Major Customers

The Company’s business of medical supply sales constitutes one operating segment. All revenues each year were domestic and to external customers.

Leases

XML 13 R3.htm IDEA: XBRL DOCUMENT

BALANCE SHEETS (Parenthetical) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Preferred stock, no par value	$ 0	$ 0
Preferred stock, authorized shares	5,000,000	5,000,000
Preferred stock, issued shares	0	0
Preferred stock, outstanding shares	0	0
Common stock, no par value	$ 0	$ 0
Common stock, authorized shares	100,000,000	100,000,000
Common stock, issued shares	11,813,200	11,477,200
Common stock, outstanding shares	11,813,200	11,477,200
Accumulated depreciation	$ 95,488	$ 92,907

XML 14 R38.htm IDEA: XBRL DOCUMENT

LEASE COMMITMENTS (Details) - USD ($)	12 Months Ended
LEASE COMMITMENTS (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Leases [Abstract]
Remaining lease term (in months)	9 months
Discount rate	5.00%
Operating lease expense	$ 27,504	$ 27,504
Cash paid for amounts included in measurement of lease liability	$ 27,504

XML 15 R30.htm IDEA: XBRL DOCUMENT

LINE OF CREDIT (Details Narrative) - USD ($)	12 Months Ended
LINE OF CREDIT (Details Narrative) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Debt Disclosure [Abstract]
Line of credit	$ 69,534	$ 66,181
Secured line of credit	$ 100,000
Interest rate	7.00%
Interest expense	$ 5,410	4,327
Proceeds from (Repayments of) Lines of Credit	$ 3,353	$ 3,803

- Definition

The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.

+ References + Details

XML 16 R34.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY (Details)	12 Months Ended
STOCKHOLDERS' EQUITY (Details)	Dec. 31, 2019 USD ($) $ / shares shares
Equity [Abstract]
Number of shares \| shares	300,000
Fair market value per share \| $ / shares	$ 0.54
Stock based compensation recognized \| $	$ 160,786

XML 17 R17.htm IDEA: XBRL DOCUMENT

ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Schedule of Inventory

The Company carries inventory of durable medical equipment and medical supplies for resale. Inventory is accounted for on a first–in first-out basis. Inventory consists of the following:

	December 31, 2019		December 31, 2018
Durable medical equipment	$	22,759	$	33,570
Medical supplies		249		1,076
Enteral		7,551		7,049
TOTALS	$	30,559	$	41,695

Classification of percent of total revenues

The amount of revenue earned from each classification as a percent of total revenues is as follows:

	December 31,
	2019			2018
Medicare		19	%		29	%
Medicaid		7	%		9	%
Private pay/private insurance		73	%		58	%
Other		1	%		4	%
Total		100	%		100	%

Schedule of Earnings Per Share, Basic and Diluted

The computation of Diluted EPS does not assume exercise or conversion of securities that would have an anti-dilutive effect on net income per common share.

	Year Ended December 31, 2019			Year Ended December 31, 2018
Numerator
Net income (loss) applicable to common shareholders	$	(477,234	)	$	68,206

Denominator
Weighted average common shares outstanding, basic		11,635,534			11,385,693
Stock options		300,000			—
Weighted average common shares outstanding, diluted		11,935,534			11,385,693
Net Income per share - Basic	$	(0.04	)	$	0.01
Income per shares - Diluted	$	(0.04	)	$	0.01

Schedule of selling, general and administrative expenses

Other selling, general and administrative expenses included the following:

	December 31,
	2019		2018
Rent	$	27,504	$	27,504
Office expenses		25,765		40,727
Other SG&A		150,806		126,079
Total	$	204,075	$	194,310

XML 18 R13.htm IDEA: XBRL DOCUMENT

LEASE COMMITMENTS

12 Months Ended

Dec. 31, 2019

Leases [Abstract]

LEASE COMMITMENTS

NOTE 7. LEASE COMMITMENTS

Remaining lease term at December 31, 2019 (in months)			9
Discount rate			5	%

	Year Ended December 31, 2019
Operating lease expense	$	27,504
Cash paid for amounts included in measurement of lease liability	$	27,504

The supplemental balance sheet information related to leases for the period is as follows:

Right-of-Use Asset
ROU Asset, January 1, 2019	$	43,677
Amortization of ROU Asset		(24,959	)
ROU Asset, December 31, 2019	$	18,718

Maturities of the Company’s lease liabilities are as follows:

Year Ending		Payments
	2020	$	20,628
	Less: Imputed interest/present value discount		(1,910	)
	Present value of lease liability at December 31, 2019	$	18,718

XML 19 R25.htm IDEA: XBRL DOCUMENT

ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Rent	$ 27,504	$ 27,504
Office expenses	25,765	40,727
Other SG&A	150,806	126,079
Total	$ 204,075	$ 194,310

XML 20 R21.htm IDEA: XBRL DOCUMENT

LEASE COMMITMENTS (Tables)

12 Months Ended

Dec. 31, 2019

Leases [Abstract]

Components of lease expense and supplemental information related to lease

The Company recognized $27,504 in lease expense during each of the years ended December 31, 2019 and 2018.

Remaining lease term at December 31, 2019 (in months)			9
Discount rate			5	%

	Year Ended December 31, 2019
Operating lease expense	$	27,504
Cash paid for amounts included in measurement of lease liability	$	27,504

Supplemental balance sheet information related to leases

The supplemental balance sheet information related to leases for the period is as follows:

Right-of-Use Asset
ROU Asset, January 1, 2019	$	43,677
Amortization of ROU Asset		(24,959	)
ROU Asset, December 31, 2019	$	18,718

Maturities of lease liabilities

Maturities of the Company’s lease liabilities are as follows:

Year Ending		Payments
	2020	$	20,628
	Less: Imputed interest/present value discount		(1,910	)
	Present value of lease liability at December 31, 2019	$	18,718

XML 21 R29.htm IDEA: XBRL DOCUMENT

EQUIPMENT (Details Narrative) - USD ($)	12 Months Ended
EQUIPMENT (Details Narrative) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Depreciation	$ 63,758	$ 62,825

ZIP 23 0001753926-20-000051-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001753926-20-000051-xbrl.zip M4$L#!!0 ( .V%>U =D:=Q/FL /9N! 1 8VUD#5J2?33'EK22//WV?CD! D42 M8Q#@X")9\^O?S*S"E0 )D" )4NQSIILB@:JLJJRLK+P\^=?_\VMF2D_,<0W; M^OV-),FGK>_..'#\_/S^<3_L"8_WZNV3/I["S> MV!>#F?I'Z=+6SJZML?U)NE%G[*/T8/N.QCY)_U!-'_[49KI[_FOL?)(NH>N/ M4K/1;/S6O&RTX%_-WJ/2_=CH?FSU_E_!QCW5\]VP\<:O?H/_PU__ZZ^18QH? M\=\23(_E?OSE&K^_B8WJN75N.Y,/S49#^?#_??_VH$W93#TS+-=3+8V]"=Z" M,?_,>D\9# 8?Z-?@T84GL?.@C]8'_'FDNE'+2."2YQ<#][+G'V A\[@*>886OC>ZI>2+P -^'4V=?1+!G6:[5N>\Y*]).)'?*V7 M?,UUO,5NX,NL'F 7AL]JJC7&[35CNJ&I)FYM>D5IP@O!)D3&_>C2]KAG8XEX M_N.4. $;.PM>./_EZF_$SSB^W]^XQFQN @-_")KBFU*S+8_]\B1#__W-T+T= M0P/],Z5Y%O49/LHLS_!>PF_#[PT=?P':'8DH8XFU"2;LXOJ_WOP-1(+2Z;1Z M_?Y?/Z1?CKK[D-F?Z&T.ZVKK&530%O7^%@T@[$+\DFX_T5+PI9B/E9,T./1) M&FQSDKXX]BQ@]X;BV0<[83 ICH='Y-^BX00M1;\MO,8L/7HI,<_!+Y7.Y>Q/SW%]GGOO;G.=PTS>Z9ZW&@KM1S+^MU"N M_ON>>:IA,?U*=2Q4\K^SV8@Y>YO/:(^RR8S%)B+\20=B?LU-0S,\3JND&_ D MOP*)47W$.P+#]Z_^Y0/=%_9L;EOPISO\9;AO_A8\ECWXOW[(["=.XX=L(E^9 MV#\Q44V9J'YG6@%)!/,[LZT'S]9^OBK^61CW2?Z4E3\GUJD#Z]1/ZB1M#"=V MV3>[[,=L?FR/G3M63OUY(]2_P3!]2) _8A M^T\<4"<.V)>U4_-=SY[]]W?R=CKL.)C@PK8T>-M1/?CZWG!_?GYY?)DSS@+H MH/V8'._)KK 6NQCZZV*78+PG=BG)+G>.\03]W:DOXM.UY?H.1O*\%@9:-0,G MEBK)4K?>E#FOA7MB@STQ2E$3^$FSV3>[U,_L791=3IK-B5T*LT-+#X<7Y)7@X<>R%;-.]LV7Q$+D+Z8/P?'*@,*Q >?M(%:: .'82I=QDBG@Z4..0H' MQ3JGLZF&9U/-V2E;O?EF6Y-'YLPNVR/S_:K6_9PS*]XV:<.>WW[/3;J(U_Z_DG0UTW0[\)\L6393X+^ M=2[[2= ?\](W&V>-UEFS=["8(\$ ]F;)&^JZ@;YRN#RJAGYM7:AS VZ2Q[%E M"J9F+)V#TTVZB(/HQ$8U8Z,].XI/_%!??MA'ZM^)'^K+#[M(!T_98BY]1QV9 MC(<"F\?F1_1'\,0/SS!AN9E[;3U!6[;S$E/6EX[_R$5#9F*?^>#/8;!'XPA< MS0*9XWY=2W\%#SC'<@@46/+$>(]\J?LG@7$ G\/YKF3P*^'P-_#TI\$_A$N M=61D[$9&1OC&M:K;U?.2[C>KX>#WQ"P4F- [Z&;%DLWA8_$% MB[8A&S/'83K!:_(U&_K>U':,?S-=$JQZC[624I6.)&R.?A K+>E,,V:JZ?[^ MYOKFRYN_=7@YL[]^*-;7YI0-]DC9M>OZ&\[7"GIX#YO14GB&*J/EUO=0,F(I MOVU.3JR;"JBJ:IJ64!7#M*UTTRFBB&",LB5=;4A5X7FJF*JJF$I1VKU>K*)2<.(#C7-G_DFEA&]9&/4'XM- M$FIH,:(:;_YVUFSWE5X[HFAU5]40MSAI&<3UFIUVH[$<32U4]O4F>-R1^WZ M,]7M#")2%AM>K^M"\]!4!DJC5WWGO6*+T.]VJN][=4V(950UVYV.L@6J5EWOX#53A(SL=@WE@9W5'-H MZ4,=[N*&2_!63^SJUYQ9+DN0M:3^ZE*YT&@W>G&Y4*CGZNC-JF.Z=#D'[9;2 MV)A>7&*N9EWZ#KQ_1Y8NKG[=L&?ZR2T_OSDZ7ZO53=P>BG5?'='+)SF'Z&;J MRK-KHHNZE78T^T/]B3F>X<+S%6X_!;2%5D3:8B?KD5%Z5_65YJ ,&;=S-$K" M[]]LU[U0'>=E;#O/JJ.[ZZK62KN=6*7\'C:CITQ]TY]P7CC K(G&QMCJ6FS$]N_\=XJI"2":UA^$ ZV3TD,06#Y MK#2*T8*-7ENNY_C([W2/@&7,T*++Z(&M7FL05TOSN]B4G$*[J:ET=TK-^LS< MV#N=Q5B]%E-:="_L:%(+H?PLE1^]?G/OI!9;_WZG50-2"ZY_L]WLK$=LO+=U MA6&G/8BI\O$6R_96S'3>;9?O#50>X1KXQE27W8Y,8T*F#O>>S=47G"@@XU_! M7BLD-G/>\XEMQO?CFM3>B67X8M/=HA*G5S-Q$4UVL"0(Z,8&HHG8S1Y >R1.X+/)R(QMZ7#J.9[Q M;_H^]PZ\[L$W: [BH4%5D;/+81;9MX-.N]_?_C ?IO 2GA4YM_H2"]-OMF/R M.J/A-?LN?^ 7Z+O8$5G-U;!87P&%.C,PI1).C7LV(>>^Y=VHL\(NV+]=#&^^ M7%]]NY2^7UU>7PR_20\_[NZ^_2E+US<7YW_]D-?^8O\7#&N,@2*@LU__Q5X* M$Q!/3LIM+=[=I:V1UHSI1(5[41IG_\7;C[^>U2SW>5_Q1+_"[<?!U!^46Y:$]3/_.*]_8G91:M:6^R5J+F Z9[83O$M=6-;9ZJF,1.=\TR7 MJ)5X]XEF%WN]FC%G@K%#( Z]*6(WJ5;QWC%R*]Y99FN+G3Z /#2#?-&U.TNT MDC&R7X\@P7@B*M^:ZP]KH:F,,4V!B\O.7VR/+[:RV ?/N?]BVFJ.]M#HGK4: MR\_#;K^E8)1!9JL9>Z% %0EO'"W^X&W_.VR>J62U%V"7()!W6/!::9HQ6^ MIE)R![?/29UDRL)RU MO=G/8_E5G2:6[7HV]SUD*Q[V,(=_P2-D=POVRMI)=)A#)Y:R0#?+9S)[JY5G MK!6M+UAIQ \&6_NL;RN-02?N&XF:+-E;D6%VVQVEVRW4&S_$EW!B(4VF/>AV MXV;">*.E>RQD:>LWFTJ[8(_)9:Y()&8&JV>TOS$Q&_/U"H)",+6-HJ/;2G<0 M.W^3C9;OLA /-#IQZ;R\RZ%&\L6]9QHSGC!6Z(9YF[)]HS$8M!+6\=P^-J6G MV(0,NLWFFO30!EI[]1O]9GSY>6O%^RB4(M+L-A*G<68?N2Z'G$R$0D$._6X\ M.G!9%YN24V@B6OUV9SUR8@?!AKS?;G3:G>PC)H?#BO5=['AK*8UFJ;YCOH\- M!Y[T+V4TO&;?FP64%#KY0@5GPRG(/?K2'6Q.3G5*70Y)H!$_VO>,7)IWJE/! MSH@;2W(;WXR,0K,RZ/7;@W5H^698['9\X3!]?8"3;E?IQ[=)K,FRW162"(-$ M:M:R[H)#440,;ZH"@"2*]YS=^OHT%)(*G59BI8O1$!.:-[:E;38-J3# K*;7 M[G^-P+-"_<>D9^43D-GV^A1L%GN73T$RV*9<7%&^U,MH=K?C M>_;$++\2_R>,NA\'64IT4+KWLB.'?=_LM0KV+KZN)+U/:2B]?CPI/6B\3*>E MX31:C0%TN[K3\'; 802^I>U/:P[ZK(V"4S,N@-6ITL.H).UJ*B]&2T>LU6UGTUEPIT9^\/#*I$]Q53OBDLU :4QT.) MJYA46/1.3!3$FR_;=6E^:_:3Z5CY7>,IQ%R7E(\OK"+9.VCU!DE39:*/=6@H M.P6=0;?9*4["@VJJ#E='_U GU4Q#1^GUXC2D^UB'AK+3T(*MW6L4IR$5H\"# M36['EX:)/M/EX7";(*4I"LKIN VC)"5;&,A:Z&F*TNIWNG%_S'8&LO#>9]4U MM K7HUML/;+IJ'P0VUV+8H,((#J#A#6Q@FN)BKP3Q ,*?+#2A;*4"* M92"N2=B:3+K^A!5:R#6Y;NW)RB0J!!0+X#Y >ZGHXIO .[&MNSD':)"_?>LVV_U4TID;H>;DU=:R>VTE'6I^ZH:%MZV;JU+PYW;/*#_ M=ISA!%_[HMV*J7I+N]N8MM)VEV:[NR9M*?"=*F:JW^IUX\R?Z&"-_DNKQ#VE M4Z+_)_@1'?B7C.NGFU SY:'5OKRVF\VNEL96)DR+(7@]@O7 M'5FIY9DJ)-605J9(02YIS=*SIIH,M'?*T4^H\ASE^=JB'#9,T"AL MTMED! N TR7(JWIH&;MNDZ$M@()7,S38SJZABXW, P29#FIR^75;H:/D4E^ M@NKI+YTV5BOJU]TU![DNZY9=J7!,-S?=UNEW'?.L54 MMC@=F]!5>+9([(XP"0ASJ$&5Y_CICH,XZ;PR;?2(R, 98G;D[9RTIW^ JH0" M6R0"JP9'NE$JD;OI&BQ;HK5F<[*-ZC4[FCD,S<>$/\?&2J_ZYY&!$\>ZK);R\@RT!:;T^V7!K<3! ^)+Q_UY;J;C)2MR[ MS7[RYK^BSTJ(+&WD:K3[S7:E5 :Y.%5QJZ(HK>XR"F,=;DQ=Z?GKMOO5$;>8 MM%.)!:S;'!19X:C7JB@M/9OM0:^E;$9K/%%W:"6@RF['T!!0J5*E;900^+L& M*J9!3FK\IC(+;2H0H0JR=C74#0,?MC'4R(K,M?I$XE,VTEW%EO5E_59';56V M]C+4PCE:>4!<4KM/]%"Z^PVO/$L[#SR#20UO:UKX0D_KT[.!M;T8*3GJ%3?5 M5Z^4MGN#.+1^\=ZKI;MT+:UNK].MA.X I^'1'FJP51T&;>@^P=Q4=RIUVJU^ M/$!K59^5$%E:J'6ZB<)6I8ET;(TQG5P7&8(P%QMUW9.^W4[:#(IV7C'=9:>Y MG\@:VH#N')[_ F>\I54N*9J#9K>W>L=E]%XMW:4E1:?7;5=!=GRET/"/!?MN M';YF&1E#%5GO5_=:#9V;6>EW167YW)G'QJ8[E1;]4-6_-7K?3R5G:='^;TK:!(K@^6=%<8[ZUFYG# MO>;V\[3EJ!J;FC :DD"LCO;C*SRU7D;@[92ABX"6$L"U!'NDSWV ML["E-@/$6]W99F2M(>MK=%Y%4'1>YSP>L:IA9P>EKM-S->&H63W'3[!MZ$B]?B\>D;JL MNTU)VX QRI!U-9N;]@MC#\QY,C26;6:[L:\=\Q5_O&]OYD M0)QF3RSCWZF4DO7P,;9&VX(%$^-M>#S:I>_ 19:?73Q.K2IS:UXH8#JRJ3PM M!8=#?OP=&H]+4Y%I6+YS8.D+,U-^FDTS%ZXG,Z>B(,E("SVY_Q M4 H,F->P])"!YA(XJDH4'XE&E8<>O=(X7B'5.YFF?]@@JNA8KW"B6N=*.PYT MLP/*MSI9]X;[\XO#PFR#:GE*B;M_MTYW9<%8R]9F$4%^&:K]7?//U 1LA9XE M :DDEBJL!ME)YI5G=K/E[./M\E- MMIUAEZ:BZM7^BG4!JU_:JKD^2>86=WP*1J'BLV K8F 9R36:J;+7GRI.S2U/ MEKNBWPPY5'C6-D6/*,-K%8]C"_/(6S_T62PQBLKG,"E!=S>!Y39R=:/8[D&9 MZIE^Q.*JH9J^STFL=B2+B&XC[]IR/8<7XX7;8?'+JA*[K"ZVD_#1/# -M#F] M"O#R( 8DK]WE(XP; #;WD.89,GIY$[.L^RP@":K0LD$MCKPZ,QG%+E9UMTF- MF?6["T*$0*'&U(7OL,*::H9Q=44R7)N]+=$DB'GPYW/38$62)9OM[5!RA6Q5 M*%^OU^DHU9#0KVJ!6JU.K[$5FLHOD-)(>ADK(Z7$"C56,0DO],<1>X57"8^" MK**0ZTLQY3P4LKE=K4_0A%R6ST]D(F MJ'-/6$A4?1&?X' $T6%IA><78;KW0#A%2!:>7&6G>V==5FUND557DEF"5?=# MYN:LVNGOA?!RK-HN2F-F>MCP235,//D?[1CRB*B2L0GR:*D,N2)4;&4856;: MK3.(M:^/_'(*/*%-\2>LFHQ?U\]FG$/H/B9B+7#?'AW>@U>TL[#B,WT&PU61Z=. IRT:ZK)+ETME0U M)"]U#E*6)L=YS9OFDKE3.<*HWR@3[QS[Z+.1HN2+(1(1/@<<7FL5=X M E9@\4(@"DI%1;N7Z:/WYL$?N>Q?/@JYZ"VA*V'[=-? MB@-*Y6Q4Q L+,)#E"5S US!-^QDU9#BB+FU_Y(U]Q*M1@JML1 ._EF:ZH9RZRHSB71*3?&/(*V/;BU%G!;@\M-Y[\T7,VT M7:#F$>C_;(+<+.PV^P_3^S277._%9+^_&<-+'R6E,?>D1V,&4W+#GJ5[>Z9: M,O]"EAY \(X_23/5F1C61ZGQ21JIVL^) [)$/]-LTW8^2L]3PV-O_F/B?<+6 ML=&R'80OC_##S>WCU7^HL_FG_ZUT&Y^:Y]'GZ-/5__UQ???]ZN81W_HP"M[_ M@#V&?\SIT_]66N)?!S#VV%B/8F !$Q.=JJ5++$3$P!!?!W:&HS-=4M'*Y,*7 M%MU]70,^VV,);D_2V,;C#!2"CX<\$:F%/=11%*'=XVH,7'KGJHZJ*NHG]+<[ M5[7@;]']"-??03)-=>ZRCU+PZ9/T;.C>%$EK_/9)*D=F2(H3]/,$7(CNN#/5 M-"8P2R/; Z4U>AI%+[VA!V^@/ V>1J4:M-IB6]73@X_5-98B$28)YM+Z_4WO M37X/P =\ +23GOP"2ZMFGH21I K2;E76HI_0>MT%% MAT_NU(N6^K]E">WLZ4V^J>21\'95GTHS]:J#T53T;E,>M-HKW\_K.7L4KW?8 M57#G']%YFIP7_.H?;&IH)G,72"\[N>LN9_9T]AIRL]$O]%*1SHYH,+N65YG4 M_3%ES-2FJN& 6HQ67&ENVV;ETYXGZ)-B?HUE*=1PMRLK Z7PLE5%K%!$PV:@ M@=*2KEX3V>O+K4&S1OR?*Q&7DD20!=)H "=*AI_LPGR ])CX%8'YD(?3?HR.U^\:.O4*/OCVZ20'EL]+8[27L1 MFY^D]&'6Q#L:-8'1P 5E:=[)ȹ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�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htm IDEA: XBRL DOCUMENT v3.20.1

LEASE COMMITMENTS (Details 2)

Dec. 31, 2019

USD ($)

Leases [Abstract]

2020 $ 20,628

Less: Imputed interest/present value discount (1,910)

Present value of lease liability $ 18,718

X

- References
No definition available.
+ Details

Name: cmds_ImputedInterestpresentValueDiscount

Namespace Prefix: cmds_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717

Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 25 R28.htm IDEA: XBRL DOCUMENT v3.20.1

EQUIPMENT (Details 1)
12 Months Ended

Dec. 31, 2019

Office Equipment [Member]

Useful life of asset (in years) 7 years

Vehicles [Member]

Useful life of asset (in years) 5 years

Wheelchair rental pool [Member]

Useful life of asset (in years) 13 months

X

- Definition
Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=cmds_WheelchairRentalPoolMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 26 R24.htm IDEA: XBRL DOCUMENT v3.20.1

ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2) - USD ($)
12 Months Ended

Dec. 31, 2019

Dec. 31, 2018

Accounting Policies [Abstract]

Net income (loss) applicable to common shareholders $ (477,234) $ 68,206

Weighted average common shares outstanding, basic 11,635,534 11,385,693

Stock options 300,000 0

Weighted average common shares outstanding, diluted 11,935,534 11,385,693

Net Income per share - Basic $ (0.04) $ 0.01

Income per shares - Diluted $ (0.04) $ 0.01

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256
+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263
+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1377-109256
+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares purchased for issuance under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256
+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 27 R20.htm IDEA: XBRL DOCUMENT v3.20.1

STOCKHOLDERS' EQUITY (Tables)
12 Months Ended

Dec. 31, 2019

Equity [Abstract]

Schedule of compensation
On the grant date, total recognized compensation of $160,786 was recorded as salaries and wages.

For the year ended

December 31, 2019

Number of shares 300,000

Fair market value per share $ 0.54

Stock based compensation recognized $ 160,786

Schedule of Valuation Assumptions
The fair value of each option award above is estimated using the Black-Scholes option-pricing model with the following assumptions at the measurement date, which was deemed to be the November 26, 2019 grant date:

Measurement date

Dividend yield 0 %

Expected volatility 314.95 %

Risk-free interest rate 1.58 %

Expected life (years) 2

Stock Price $ 0.55

Exercise Price $ 0.55

Schedule of Stock Options Activity
A summary of the activity for the Company's stock options is as follows:

December 31, 2019

Shares Weighted Average
Exercise Price

Outstanding, beginning of year 0 $ 0

Granted 300,000 $ 0.55

Exercised 0 $ 0

Canceled 0 $ 0

Outstanding, end of year 300,000 $ 0.55

Weighted average fair value of options granted $ 0.55

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 28 R41.htm IDEA: XBRL DOCUMENT v3.20.1

LEASE COMMITMENTS (Details Narrative) - USD ($)
12 Months Ended

Dec. 31, 2019

Dec. 31, 2018

Leases [Abstract]

Office space approximate monthly payment $ 2,292

Lease expense $ 27,504 $ 27,504

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of operating lease expense. Excludes sublease income.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 4
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977
+ Details

Name: us-gaap_OperatingLeaseExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Cash payments to lessor's for use of assets under operating leases.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585
+ Details

Name: us-gaap_PaymentsForRent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 29 R6.htm IDEA: XBRL DOCUMENT v3.20.1

STATEMENTS OF CASH FLOWS - USD ($)
12 Months Ended

Dec. 31, 2019

Dec. 31, 2018

Cash Flows From Operating Activities:

Net income (loss) $ (477,234) $ 68,206

Adjustments to reconcile net income (loss) to net cash provided by (used for) operating activities:

Gain on disposal of fixed assets (1,037) (7,246)

Depreciation 63,758 62,825

Stock-based compensation 160,786 0

Changes in current assets and liabilities:

Increase in accounts receivable (8,629) (149,731)

(Increase) decrease in inventory 11,136 (16,486)

Increase in accounts payable and accrued liabilities 22,815 104,824

Net cash provided by (used for) operating activities (228,405) 62,392

Cash Flows From Investing Activities:

Proceeds from sale of fixed assets 6,446 8,064

Purchase of property and equipment (54,385) (75,633)

Net cash provided by (used for) investing activities (47,939) (67,569)

Cash Flows From Financing Activities:

Net borrowings (payments) on line of credit 3,353 3,803

Proceeds from officer 276,550 0

Payments to officer (78,701) 0

Payments on long-term debt (8,523) (11,567)

Proceeds from sales of common stock 100,000 2,000

Net cash provided by (used for) financing activities 292,679 (5,764)

Net Increase (Decrease) in Cash 16,335 (10,941)

Cash at the Beginning of the Period 6,980 17,921

Cash at the End of the Period 23,315 6,980

Schedule Of Non-Cash Investing And Financing Activities

Lease liability and right-of-use-asset 43,677 0

Amortization of right-of-use asset 24,959 0

Supplemental Disclosure

Cash paid for interest 8,376 5,715

Cash paid for income taxes $ 0 $ 0

X

- References
No definition available.
+ Details

Name: cmds_AmortizationOfRightofuseAsset

Namespace Prefix: cmds_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: cmds_LeaseLiabilityAndRightofuseasset

Namespace Prefix: cmds_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdditionalCashFlowElementsFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The current period expense charged against earnings on decontaminating and decommissioning of facilities used in the normal conduct of business and not intended for resale to allocate or recognize the cost of the assets over their useful lives.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_AmortizationAndDepreciationOfDecontaminatingAndDecommissioningAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 210
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 210
-Section 45
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840
+ Details

Name: us-gaap_Cash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in cash. Cash is the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Includes effect from exchange rate changes.
+ References
No definition available.
+ Details

Name: us-gaap_CashPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_GainLossOnSaleOfPropertyPlantEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585
+ Details

Name: us-gaap_IncomeTaxesPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingAssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586
+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireProductiveAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOrSaleOfEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromRelatedPartyDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690
+ Details

Name: us-gaap_ProceedsFromRepaymentsOfLinesOfCredit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585
+ Details

Name: us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585
+ Details

Name: us-gaap_RepaymentsOfOtherLongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585
+ Details

Name: us-gaap_RepaymentsOfRelatedPartyDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of noncash expense for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SupplementalCashFlowElementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 30 R2.htm IDEA: XBRL DOCUMENT v3.20.1

BALANCE SHEETS - USD ($)

Dec. 31, 2019

Dec. 31, 2018

Current Assets

Cash $ 23,315 $ 6,980

Accounts receivable 309,622 300,993

Inventory 30,559 41,695

Right-of-use asset 18,718 0

Total Current Assets 382,214 349,668

Equipment, net of accumulated depreciation of $95,488 and $92,907 43,845 58,627

Total Assets 426,059 408,295

Current Liabilities

Accounts payable and accrued liabilities 353,849 331,034

Line of credit 69,534 66,181

Due from officer 197,849 0

Lease liability 18,718 0

Current portion of long-term debt 3,152 8,241

Total Current liabilities 643,102 405,456

Long-term Liabilities

Long-term debt 2,064 5,498

Total Long-term liabilities 2,064 5,498

Total liabilities 645,166 410,954

Stockholders' Equity (Deficit)

Preferred stock, no par value; 5,000,000 shares authorized; no shares issued and outstanding 0 0

Common stock, no par value; 100,000,000 shares authorized; 11,813,200 (December 31, 2019) and 11,477,200 (December 31, 2018) shares issued and outstanding 345,515 245,515

Additional paid-in capital 160,786 0

Accumulated deficit (725,408) (248,174)

Total Stockholders' Equity (Deficit) (219,107) (2,659)

Total Liabilities and Stockholders' Equity (Deficit) $ 426,059 $ 408,295

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522
+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 210
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 210
-Section 45
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840
+ Details

Name: us-gaap_Cash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DueToRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of obligation due after one year or beyond the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 201.5-02(25))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(23))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 201.5-02(26))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 201.5-02(24))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(16))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910
+ Details

Name: us-gaap_LineOfCredit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19,20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermDebtCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermDebtNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's right to use underlying asset under operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseRightOfUseAsset

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 31 R31.htm IDEA: XBRL DOCUMENT v3.20.1

RELATED PARTY LOAN (Details Narrative) - USD ($)
12 Months Ended

Dec. 31, 2019

Dec. 31, 2018

Related Party Transactions [Abstract]

Term 1 year

Related party loan $ 197,849 $ 0

Repayments of Related Party Loan $ (78,701) $ 0

X

- Definition
Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DueToRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585
+ Details

Name: us-gaap_RepaymentsOfRelatedPartyDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 32 R35.htm IDEA: XBRL DOCUMENT v3.20.1

STOCKHOLDERS' EQUITY (Details 1) - $ / shares
12 Months Ended

Dec. 31, 2019

Dec. 31, 2018

Equity [Abstract]

Dividend yield 0.00%

Expected volatility 314.95%

Risk-free interest rate 1.58%

Expected life (years) 2 years

Stock Price $ 0.55

Exercise Price $ 0.55

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.D.2)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

XML 33 R39.htm IDEA: XBRL DOCUMENT v3.20.1

LEASE COMMITMENTS (Details 1)
12 Months Ended

Dec. 31, 2019

USD ($)

Right-of-Use Asset

ROU Asset, at beginning $ 43,677

Amortization of ROU Asset (24,959)

ROU Asset, at end $ 18,718

X

- References
No definition available.
+ Details

Name: cmds_RightOfUseAsset

Namespace Prefix: cmds_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: cmds_RightofuseAssetAbstract

Namespace Prefix: cmds_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The expense charged against earnings for the periodic recognition of capitalized leases. This element may apply to energy companies that lease mineral producing properties and to other enterprises that capitalize property, plant, or equipment obtained through capital leases.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84164758&loc=d3e45031-112735
+ Details

Name: us-gaap_AmortizationOfLeasedAsset

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 34 R16.htm IDEA: XBRL DOCUMENT v3.20.1

ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Use of Estimates
Use of Estimates

The preparation of financial statements in conformity with U.S. Generally Accepted Accounting Principles (“U.S. GAAP”) requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and Cash Equivalents
Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity of three months or less as cash equivalents.

Accounts Receivable
Accounts Receivable

The majority of the Company’s revenues are received from Medicare, Medicaid, and private insurance companies. As such, the Company records revenues at allowable amounts, net of estimated allowances and discounts based on contracted prices and historical collection rates. The Company reviews accounts receivable periodically for collectability and establishes an allowance for doubtful accounts and records bad debt expense when deemed necessary. At December 30, 2019 and December 31, 2018, the Company has determined that no allowance for doubtful accounts is necessary.

Property and Equipment
Property and Equipment

Property and equipment are recorded at cost and depreciated under straight line methods over each item's estimated useful life.

Inventory
Inventory

The Company carries inventory of durable medical equipment and medical supplies for resale. Inventory is accounted for on a first–in first-out basis. Inventory consists of the following:

December 31, 2019 December 31, 2018

Durable medical equipment $ 22,759 $ 33,570

Medical supplies 249 1,076

Enteral 7,551 7,049

TOTALS $ 30,559 $ 41,695

Revenue recognition
Revenue recognition

It is the Company’s policy that revenues from product sales is recognized in accordance with ASC 606 "Revenue Recognition." Five basic steps must be followed before revenue can be recognized; (1) Identifying the contract(s) with a customer that creates enforceable rights and obligations; (2) Identifying the performance obligations in the contract, such as promising to transfer goods or services to a customer; (3) Determining the transaction price, meaning the amount of consideration in a contract to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer; (4) Allocating the transaction price to the performance obligations in the contract, which requires the company to allocate the transaction price to each performance obligation on the basis of the relative standalone selling prices of each distinct good or services promised in the contract; and (5) Recognizing revenue when (or as) the entity satisfies a performance obligation by transferring a promised good or service to a customer. The amount of revenue recognized is the amount allocated to the satisfied performance obligation. For sales of our Company products, a purchase arrangement is evidenced by a written order, with delivery considered as made after physical customer acceptance. Although rare, defective products may be returned, with other return issues considered on a case by case basis. Services such as periodic scheduled deliveries are contracted in writing, and generally billed monthly. Any service revenue earned by the Company for services such as safety and set up consulting or claims processing is recorded after the service is performed. Rental of durable home medical equipment is evidenced by written contract, with revenue recognized when rent is earned.

The Company’s primary source of revenue is reimbursement from Medicare, Medicaid, and private insurance companies for the procurement and sale of medical equipment and supplies to patients. The amount of revenue earned from each classification as a percent of total revenues is as follows:

December 31,

2019 2018

Medicare 19 % 29 %

Medicaid 7 % 9 %

Private pay/private insurance 73 % 58 %

Other 1 % 4 %

Total

Advertising Costs
Advertising Costs

Advertising costs are expensed as incurred. The Company had advertising costs during the years ended December 31, 2019 and 2018 of $13,453 and $18,129, respectively.

Income Tax
Income Tax

The Company accounts for income taxes pursuant to ASC 740. Under ASC 740, deferred taxes are provided for using the liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss carryforwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

Through February 2012, the Company was an S-Corporation for income tax purposes, and therefore a pass-through entity paying no income tax at the corporate level. The Company had no material loss carryforwards as of December 31, 2011. Included in the Company’s accumulated deficit from February 2012 forward is approximately $99,000 in undistributed S-Corporation losses. At December 31, 2019 and 2018 the Company had net operating loss carryforwards (NOL’s) of approximately $462,000 and $144,000 respectively, which may be applied against future taxable income. However, if certain substantial changes in the Company’s ownership should occur, there could be an annual limitation on the amount of net operating loss carryforwards that can be utilized. The amount of and ultimate realization of the benefits from the operating loss carryforwards for income tax purposes is dependent, in part, upon the tax laws in effect, the future earnings of the Company, and other future events, the effects of which cannot be determined. Because of the uncertainty surrounding the realization of the loss carryforwards, the Company has established a valuation allowance equal to the tax effect (2019 and 2018: 21% federal and 5% state) of the loss carryforwards of approximately $120,000 and $37,440 at December 31, 2019 and 2018, respectively, and therefore, no deferred tax asset has been recognized for the loss carryforwards. The change in valuation allowance is approximately $82,560 and ($19,760) for the periods ended December 31, 2019 and 2018, respectively. The tax effect of remaining NOL’s and resulting deferred tax assets of $120,000 remain fully reserved by valuation allowance, due to continued uncertainty as to their utilization.

Net Income (Loss) per Share
Net Income (Loss) per Share

Basic net income per common share ("Basic EPS'') excludes dilution and is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share ("Diluted EPS'') reflects the potential dilution that could occur if stock options or other contracts to issue shares of common stock were exercised or converted into common stock. The computation of Diluted EPS does not assume exercise or conversion of securities that would have an anti-dilutive effect on net income per common share.

Year Ended
December 31, 2019 Year Ended December 31, 2018

Numerator

Net income (loss) applicable to common shareholders $ (477,234 ) $ 68,206

Denominator

Weighted average common shares outstanding, basic 11,635,534 11,385,693

Stock options 300,000 —

Weighted average common shares outstanding, diluted 11,935,534 11,385,693

Net Income per share - Basic $ (0.04 ) $ 0.01

Income per shares - Diluted $ (0.04 ) $ 0.01

Financial Instruments
Financial Instruments

The carrying value of the Company’s financial instruments, as reported in the accompanying balance sheets, approximates fair value.

Concentrations
Concentrations

Financial instruments that potentially subject the Company to concentrations of credit risk include cash and cash equivalents. The Company places its cash and cash equivalents at well-known financial institutions, where at times, such balances may exceed FDIC insurance limits.

The Company receives a significant amount of its revenues in reimbursements from Medicare and Medicaid thru competitive bidding processes. There is no guarantee that the Company will be selected as a winning contract supplier under future bidding rounds.

Other selling, general and administrative expenses
Other Selling, General and Administrative Expenses

Other selling, general and administrative expenses included the following:

December 31,

2019 2018

Rent $ 27,504 $ 27,504

Office expenses 25,765 40,727

Other SG&A 150,806 126,079

Total $ 204,075 $ 194,310

Long-Lived Assets
Long-Lived Assets

In accordance with ASC 350, the Company regularly reviews the carrying value of intangible and other long-lived assets for the existence of facts or circumstances, both internally and externally, that suggest impairment. If impairment testing indicates a lack of recoverability, an impairment loss is recognized by the Company if the carrying amount of a long-lived asset exceeds its fair value. No impairment was noted during the years ended December 31, 2019 and 2018.

Products and Services, Geographic Areas and Major Customers
Products and Services, Geographic Areas and Major Customers

The Company’s business of medical supply sales constitutes one operating segment. All revenues each year were domestic and to external customers.

Leases
Leases

In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02, “Lease (Topic 842),” a new lease standard requiring lessees to recognize lease assets and lease liabilities for most leases classified as operating leases under previous U.S. GAAP. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset (“ROU” asset) representing its right to use the underlying asset for the lease term. The guidance is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company has adopted this standard effective January 1, 2019. The Company elected the optional transition method that permits adoption of the new standard prospectively, as of the effective date, without adjusting comparative periods presented. See Note 6 for disclosure required by ASC 842.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for advertising cost.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 720
-SubTopic 35
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848
+ Details

Name: us-gaap_AdvertisingCostsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-URI http://asc.fasb.org/topic&trid=2134479
+ Details

Name: us-gaap_ConcentrationRiskDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257
+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.
+ References
No definition available.
+ Details

Name: us-gaap_FinancialInstrumentsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.
+ References
No definition available.
+ Details

Name: us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 740
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=116821951&loc=d3e32247-109318

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=116821951&loc=d3e32280-109318

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 05
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327
+ Details

Name: us-gaap_IncomeTaxPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 6
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for leasing arrangement entered into by lessee.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980
+ Details

Name: us-gaap_LesseeLeasesPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118936363&loc=d3e5033-111524

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534
+ Details

Name: us-gaap_ReceivablesPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph a
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599
+ Details

Name: us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for revenue recognition for sales allowances.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_RevenueRecognitionAllowances

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 720
-SubTopic 35
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592
+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 R12.htm IDEA: XBRL DOCUMENT v3.20.1

STOCKHOLDERS' EQUITY
12 Months Ended

Dec. 31, 2019

Equity [Abstract]

STOCKHOLDERS' EQUITY
NOTE 6. STOCKHOLDERS’ EQUITY

Common Stock

In June 2019, the Company received net proceeds of $100,000 from the sale of 336,000 shares of no-par value common stock at $0.298 per share.

In July 2018, the Company received net proceeds of $2,000 from the sale of 200,000 shares of no-par value common stock at $0.01 per share.

2019 Stock Options Granted

On November 26, 2019, the Board granted stock options to each of two officers, one director, and one advisor for the purchase of 300,000 shares of the common stock of the Company. The options expire in five years from the issuance date, have an exercise price of $0.55, and were immediately vested and exercisable. On the grant date, total recognized compensation of $160,786 was recorded as salaries and wages.

For the year ended

December 31, 2019

Number of shares 300,000

Fair market value per share $ 0.54

Stock based compensation recognized $ 160,786

As of December 31, 2019, total unrecognized compensation remaining to be recognized in future periods totaled $0. The fair value of each option award above is estimated using the Black-Scholes option-pricing model with the following assumptions at the measurement date, which was deemed to be the November 26, 2019 grant date:

Measurement date

Dividend yield 0 %

Expected volatility 314.95 %

Risk-free interest rate 1.58 %

Expected life (years) 2

Stock Price $ 0.55

Exercise Price $ 0.55

A summary of the activity for the Company's stock options is as follows:

December 31, 2019

Shares Weighted Average
Exercise Price

Outstanding, beginning of year 0 $ 0

Granted 300,000 $ 0.55

Exercised 0 $ 0

Canceled 0 $ 0

Outstanding, end of year 300,000 $ 0.55

Weighted average fair value of options granted $ 0.55

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the equity method of accounting for investments in common stock or other interests including unconsolidated domestic subsidiaries, corporate joint ventures, noncontrolling interests in real estate ventures, limited partnerships, and limited liability companies. Additionally, this element describes the entity's application of the cost method to equity investments or other interests that are not consolidated or accounted for under the equity method of accounting. The disclosure provided may include how equity method or cost investments are assessed for impairment.
+ References
No definition available.
+ Details

Name: us-gaap_EquityAndCostMethodInvestmentsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R26.htm IDEA: XBRL DOCUMENT v3.20.1

ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
1 Months Ended 12 Months Ended

Jun. 21, 2019

Dec. 31, 2019

Dec. 31, 2018

Proceeds from sales of common stock $ 100,000 $ 2,000

Number of shares sold for proceeds 336,000 200,000

Allowance for doubtful accounts $ 0 $ 0

Advertising cost 13,453 18,129

Net operating loss carryforwards $ 462,000 $ 144,000

Federal tax rate 21.00% 21.00%

State tax rate 5.00% 5.00%

Loss carryforwards $ 120,000 $ 37,440

Change in valuation allowance 82,560 $ (19,760)

Deferred tax assets $ 120,000

WesBev

Shares Aquired 8,000,000

Percentage of acquisition 69.70%

Proceeds from sales of common stock $ 100,000

Number of shares sold for proceeds 336,000

Total shares 8,336,000

X

- Definition
Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 720
-SubTopic 35
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848
+ Details

Name: us-gaap_AdvertisingExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of allowance for credit loss on accounts receivable.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 20
-Section 50
-Paragraph 13
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118936363&loc=d3e5074-111524

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 20
-Section 50
-Paragraph 13
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118955202&loc=SL82895884-210446
+ Details

Name: us-gaap_AllowanceForDoubtfulAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Percentage of voting equity interests acquired in a business combination achieved in stages, including equity interests in the acquiree held by the acquirer immediately before the acquisition date and acquired at the acquisition date.
+ References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeIncludingSubsequentAcquisitionPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredIncomeTaxAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible loss carryforwards, classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314
+ Details

Name: us-gaap_DeferredTaxAssetsOtherLossCarryforwards

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Percentage of domestic federal statutory tax rate applicable to pretax income (loss).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319
+ Details

Name: us-gaap_OperatingLossCarryforwards

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOrSaleOfEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of shares of stock issued during the period pursuant to acquisitions.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesAcquisitions

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The increase (decrease) during the period in the number of shares issued.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=116821951&loc=d3e32123-109318
+ Details

Name: us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=cmds_WesBevMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 37 R22.htm IDEA: XBRL DOCUMENT v3.20.1

ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)

Dec. 31, 2019

Dec. 31, 2018

Total $ 30,559 $ 41,695

Durable medical equipment

Total 22,759 33,570

Medical supplies

Total 249 1,076

Enteral

Total $ 7,551 $ 7,049

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_PublicUtilitiesInventoryAxis=cmds_DurableMedicalEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PublicUtilitiesInventoryAxis=cmds_MedicalSuppliesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PublicUtilitiesInventoryAxis=cmds_EnteralMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 38 R4.htm IDEA: XBRL DOCUMENT v3.20.1

STATEMENTS OF OPERATIONS - USD ($)
12 Months Ended

Dec. 31, 2019

Dec. 31, 2018

Income Statement [Abstract]

Sales (net of returns) $ 1,017,833 $ 1,309,178

Cost of goods sold 508,874 605,273

Gross profit 508,959 703,905

Operating expenses:

Salaries and wages 517,725 320,470

Professional fees 193,797 59,625

Depreciation 63,758 62,825

Other selling, general and administrative 204,075 194,310

Total operating expenses 979,355 637,230

Income (loss) from operations (470,396) 66,675

Other income (expense):

Interest income 501 0

Interest expense (8,376) (5,715)

Gain on sale of fixed assets 1,037 7,246

Total other income (expense) (6,838) 1,531

Income (loss) before provision for income taxes (477,234) 68,206

Provision for income tax 0 0

Net income (loss) $ (477,234) $ 68,206

Net income (loss) per share applicable to common shareholders - basic $ (0.04) $ 0.01

Net income (loss) per share applicable to common shareholders - diluted $ (0.04) $ 0.01

Weighted average number of common shares outstanding - basic 11,635,534 11,385,693

Weighted average number of common shares outstanding - diluted 11,935,534 11,385,693

X

- Definition
The aggregate cost of goods produced and sold and services rendered during the reporting period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_CostOfRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256
+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263
+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230
+ Details

Name: us-gaap_GainLossOnDispositionOfAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1,2)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h)(1)(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (210.5-03(11))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.9)
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260
+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7(b))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599
+ Details

Name: us-gaap_InvestmentIncomeInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OtherIncomeAndExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of income (expense) related to nonoperating activities, classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.9)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of selling, general and administrative expense classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_OtherSellingGeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07.2(a),(b),(c),(d))
-URI http://asc.fasb.org/extlink&oid=116637345&loc=SL114874292-224272

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 220
-Section 45
-Paragraph 3
-Subparagraph (k)
-URI http://asc.fasb.org/extlink&oid=118262090&loc=SL114874205-224268
+ Details

Name: us-gaap_ProfessionalFees

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(4))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_SalariesAndWages

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256
+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 39 R8.htm IDEA: XBRL DOCUMENT v3.20.1

EQUIPMENT
12 Months Ended

Dec. 31, 2019

Property, Plant and Equipment [Abstract]

EQUIPMENT
NOTE 2. EQUIPMENT

Property and equipment are recorded at cost and consist of the following:

December 31,

2019 2018

Office equipment $ 2,934 $ 2,934

Vehicles 70,208 70,208

Wheelchair rental pool 66,191 78,392

Total property and equipment 139,333 151,534

Accumulated depreciation (95,488 ) (92,907 )

Net property and equipment $ 43,845 $ 58,627



Depreciation is computed using the straight-line method based upon estimated useful lives as follows:

Office equipment 7 years

Vehicles 5 years

Wheelchair rental pool 13 months



Depreciation for 2019 and 2018 was $63,758 and $62,825, respectively.

The wheelchair rental pool consists of wheelchairs rented to customers over the shorter of the 13 month use period as mandated by Medicare and Medicaid, or the period over which the customer requires use of a wheelchair. At the end of the use period, the chair is either returned to the pool to be rented to another customer, or title of the chair is transferred to the customer.

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-URI http://asc.fasb.org/topic&trid=2155823
+ Details

Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 40 R14.htm IDEA: XBRL DOCUMENT v3.20.1

GOING CONCERN
12 Months Ended

Dec. 31, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

GOING CONCERN
NOTE 8. GOING CONCERN

The Company has suffered losses from operations and has working capital and stockholders’ equity deficits. In all likelihood, the Company will be required to make significant future expenditures in connection with marketing efforts along with general administrative expenses. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.

The Company may raise additional capital through the sale of its equity securities, through an offering of debt securities, or through borrowings from financial institutions or related parties. By doing so, the Company hopes to generate sufficient capital to execute its business plan of selling medical supplies on an ongoing basis. Management believes that actions presently being taken to obtain additional funding provide the opportunity for the Company to continue as a going concern.

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 40
-URI http://asc.fasb.org/subtopic&trid=51888271
+ Details

Name: us-gaap_SubstantialDoubtAboutGoingConcernTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 41 R10.htm IDEA: XBRL DOCUMENT v3.20.1

RELATED PARTY LOAN
12 Months Ended

Dec. 31, 2019

Related Party Transactions [Abstract]

RELATED PARTY LOAN
NOTE 4. RELATED PARTY LOAN

On June 21, 2019, the Company entered into a short-term loan with Michael West, an officer of the Company, for $276,550. The loan has a one-year term from June 21, 2019, and is non-interest bearing. The Company made payments of $78,701 on this loan, resulting in a loan balance of $197,849 and $0 as of December 31, 2019 and December 31, 2018, respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-URI http://asc.fasb.org/topic&trid=2122745
+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 42 R18.htm IDEA: XBRL DOCUMENT v3.20.1

EQUIPMENT (Tables)
12 Months Ended

Dec. 31, 2019

Equipment Tables

Schedule of Property and equipment
Property and equipment are recorded at cost and consist of the following:

December 31,

2019 2018

Office equipment $ 2,934 $ 2,934

Vehicles 70,208 70,208

Wheelchair rental pool 66,191 78,392

Total property and equipment 139,333 151,534

Accumulated depreciation (95,488 ) (92,907 )

Net property and equipment $ 43,845 $ 58,627

Schedule of estimated useful lives of equipment
Depreciation is computed using the straight-line method based upon estimated useful lives as follows:

Office equipment 7 years

Vehicles 5 years

Wheelchair rental pool 13 months

X

- References
No definition available.
+ Details

Name: cmds_DisclosureEquipmentTablesAbstract

Namespace Prefix: cmds_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: cmds_ScheduleOfEstimatedUsefulLivesOfEquipmentTableTextBlock

Namespace Prefix: cmds_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 43 R33.htm IDEA: XBRL DOCUMENT v3.20.1

LONG-TERM DEBT (Details 1)

Dec. 31, 2019

USD ($)

Debt Disclosure [Abstract]

2020 $ 3,152

2021 2,064

Total $ 5,216

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of long-term debt and lease obligation, classified as noncurrent.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermDebtAndCapitalLeaseObligations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Principal amount of long-term debt and capital lease obligation maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
No definition available.
+ Details

Name: us-gaap_LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Principal amount of long-term debt and capital lease obligation maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
No definition available.
+ Details

Name: us-gaap_LongTermDebtAndCapitalLeaseObligationsRepaymentsOfPrincipalInNextTwelveMonths

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 44 R37.htm IDEA: XBRL DOCUMENT v3.20.1

STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)
12 Months Ended

Dec. 31, 2019

Dec. 31, 2018

Equity [Abstract]

Proceeds from sales of common stock $ 100,000 $ 2,000

Number of shares sold for proceeds 336,000 200,000

Value of common stock sold (per share) $ 0.298 $ 0.01

Stock based compensation $ 160,786 $ 0

Unrecognized compensation $ 0

X

- Definition
Amount of cost not yet recognized for nonvested award under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOrSaleOfEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of noncash expense for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section S99
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (27)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_TemporaryEquityParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

XML 45 R9.htm IDEA: XBRL DOCUMENT v3.20.1

LINE OF CREDIT
12 Months Ended

Dec. 31, 2019

Debt Disclosure [Abstract]

LINE OF CREDIT
NOTE 3. LINE OF CREDIT

At December 31, 2019 and December 31, 2018, the Company owed a bank $69,534 and $66,181, respectively, under a revolving line of credit. The line of credit is secured by all Company assets, is capped at $100,000, is due on demand, and bears interest at variable rates approximating 7% on average. Interest expense under the note totaled $5,410 and $4,327 during the years ended December 31, 2019 and 2018, respectively. During 2019 and 2018, the Company made net borrowings $3,353 and $3,803, respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI http://asc.fasb.org/topic&trid=2208564
+ Details

Name: us-gaap_DebtDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 46 R5.htm IDEA: XBRL DOCUMENT v3.20.1

STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)

Common Stock (no par)

Additional Paid-In Capital

Accumulated Deficit

Total

Beginning Balance at Dec. 31, 2017 $ 243,515 $ (316,380) $ (72,865)

Beginning Balance, in Shares at Dec. 31, 2017 11,277,200

Common stock issued for cash $ 2,000 2,000

Common stock issued for cash, in Shares 200,000

Net income (loss) for the year 68,206 68,206

Ending Balance at Dec. 31, 2018 $ 245,515 (248,174) (2,659)

Ending Balance, in Shares at Dec. 31, 2018 11,477,200

Common stock issued for cash $ 100,000 100,000

Common stock issued for cash, in Shares 336,000

Stock options granted and vested 160,786 160,786

Net income (loss) for the year (477,234) (477,234)

Ending Balance at Dec. 31, 2019 $ 345,515 $ 160,786 $ (725,408) $ (219,107)

Ending Balance, in Shares at Dec. 31, 2019 11,813,200

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686
+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockConsiderationReceivedPerTransaction

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares issued which are neither cancelled nor held in the treasury.
+ References
No definition available.
+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 47 R1.htm IDEA: XBRL DOCUMENT v3.20.1

Document and Entity Information - USD ($)
12 Months Ended

Dec. 31, 2019

Mar. 27, 2020

Jun. 30, 2019

Document And Entity Information

Entity Registrant Name CANFIELD MEDICAL SUPPLY, INC.

Entity Central Index Key 0001553788

Document Type 10-K

Document Period End Date Dec. 31, 2019

Amendment Flag false

Current Fiscal Year End Date --12-31

Is Entity a Well-known Seasoned Issuer? No

Is Entity a Voluntary Filer? No

Is Entity's Reporting Status Current? Yes

Entity Filer Category Non-accelerated Filer

Entity Emerging Growth Company true

Entity Small Business true

Entity Ex Transition Period true

Entity Shell Company false

Entity Interactive Data Current Yes

Entity File Number 000-55114

Entity Incorporation, State or Country Code CO

Entity Public Float $ 3,683,160

Entity Common Stock, Shares Outstanding 11,813,200

Document Fiscal Period Focus FY

Document Fiscal Year Focus 2019

X

- References
No definition available.
+ Details

Name: cmds_DocumentDocumentAndEntityInformationAbstract

Namespace Prefix: cmds_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityEmergingGrowthCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 7A
-Section B
-Subsection 2
+ Details

Name: dei_EntityExTransitionPeriod

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details

Name: dei_EntityFileNumber

Namespace Prefix: dei_

Data Type: dei:fileNumberItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details

Name: dei_EntityIncorporationStateCountryCode

Namespace Prefix: dei_

Data Type: dei:edgarStateCountryItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-T
-Number 232
-Section 405
+ Details

Name: dei_EntityInteractiveDataCurrent

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.
+ References
No definition available.
+ Details

Name: dei_EntityPublicFloat

Namespace Prefix: dei_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityShellCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicates that the company is a Smaller Reporting Company (SRC).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntitySmallBusiness

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
+ References
No definition available.
+ Details

Name: dei_EntityVoluntaryFilers

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.
+ References
No definition available.
+ Details

Name: dei_EntityWellKnownSeasonedIssuer

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

XML 48 R19.htm IDEA: XBRL DOCUMENT v3.20.1

LONG-TERM DEBT (Tables)
12 Months Ended

Dec. 31, 2019

Debt Disclosure [Abstract]

Schedule of Long Term Debt
Long-term debt consists of the following vehicle loans, which are collateralized by their underlying vehicles with net carrying values exceeding the outstanding loan amounts:

December 31,
2019 December 31,
2018

3.53% installment note payable $352 monthly, including interest, through July 2019 $ — $ 2,782

3.79% installment note payable $299 monthly, including

interest, through July 2021 5,216 8,532

2.99% installment note payable $350 monthly, including interest, through August 2019 — 2,425

Total 5,216 13,739

Less principal due within one year (3,152 ) (8,241 )

 TOTAL LONG-TERM DEBT $ 2,064 $ 5,498

Schedule of Principal amount due to Long Term Assets
Principal payments due on long-term debt subsequent to December 31, 2019, are as follows:

2020 $ 3,152

2021 2,064

TOTAL $ 5,216

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644
+ Details

Name: us-gaap_ScheduleOfDebtInstrumentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of future minimum lease payments as of the date of the latest balance sheet presented, in aggregate and for each of the five years succeeding fiscal years, with separate deductions from the total for the amount representing executor costs, including any profit thereon, included in the minimum lease payments and for the amount of the imputed interest necessary to reduce the net minimum lease payments to present value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84164817&loc=d3e45280-112737
+ Details

Name: us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

EXCEL 49 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 50 R15.htm IDEA: XBRL DOCUMENT v3.20.1

SUBSEQUENT EVENTS
12 Months Ended

Dec. 31, 2019

Subsequent Events [Abstract]

SUBSEQUENT EVENTS
NOTE 9. SUBSEQUENT EVENTS

The Company has evaluated subsequent events through the date these financial statements were issued and determined that there are no reportable subsequent events.

X

- References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 855
-URI http://asc.fasb.org/topic&trid=2122774
+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 51 R11.htm IDEA: XBRL DOCUMENT v3.20.1

LONG-TERM DEBT
12 Months Ended

Dec. 31, 2019

Debt Disclosure [Abstract]

LONG-TERM DEBT
NOTE 5. LONG-TERM DEBT

Long-term debt consists of the following vehicle loans, which are collateralized by their underlying vehicles with net carrying values exceeding the outstanding loan amounts:

December 31,
2019 December 31,
2018

3.53% installment note payable $352 monthly, including interest, through July 2019 $ — $ 2,782

3.79% installment note payable $299 monthly, including

interest, through July 2021 5,216 8,532

2.99% installment note payable $350 monthly, including interest, through August 2019 — 2,425

Total 5,216 13,739

Less principal due within one year (3,152 ) (8,241 )

 TOTAL LONG-TERM DEBT $ 2,064 $ 5,498

Principal payments due on long-term debt subsequent to December 31, 2019, are as follows:

2020 $ 3,152

2021 2,064

TOTAL $ 5,216

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for long-term debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI http://asc.fasb.org/topic&trid=2208564
+ Details

Name: us-gaap_LongTermDebtTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 52 R32.htm IDEA: XBRL DOCUMENT v3.20.1

LONG-TERM DEBT (Details) - USD ($)

Dec. 31, 2019

Dec. 31, 2018

Long Term Gross $ 5,216 $ 13,739

Less principal due within one year (3,152) (8,241)

Total Long Term debt 2,064 5,498

Long-term Debt One [Member]

Note Payable, monthly installment 352

Long Term Gross 0 2,782

Long-term Debt Two [Member]

Note Payable, monthly installment 299

Long Term Gross 5,216 8,532

Long-term Debt Three [Member]

Note Payable, monthly installment 350

Long Term Gross $ 0 $ 2,425

X

- Definition
Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(16))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_DebtInstrumentCarryingAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (b)(3)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_NotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(19)(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16)(a)(1))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(13))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_ShortTermBorrowings

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_ExtinguishmentOfDebtAxis=cmds_LongTermDebtOneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ExtinguishmentOfDebtAxis=cmds_LongTermDebtTwoMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ExtinguishmentOfDebtAxis=cmds_LongTermDebtThreeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 53 R36.htm IDEA: XBRL DOCUMENT v3.20.1

STOCKHOLDERS' EQUITY (Details 2)
12 Months Ended

Dec. 31, 2019

$ / shares

shares

Shares

Shares Outstanding, beginning of year | shares 0

Shares Granted | shares 300,000

Shares Exercised | shares 0

Shares Canceled | shares 0

Shares Outstanding, end of year | shares 300,000

Weighted Average Exercise Price

Weighted average exercise price - Outstanding, beginning of year $ 0

Weighted average exercise price - shares Granted 0.55

Weighted average exercise price - shares Exercised 0

Weighted average exercise price - shares Cancelled 0

Weighted average exercise price - Outstanding, end of year 0.55

Weighted average fair value of options granted $ 0.55

X

- Definition
For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)-(4)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Net number of share options (or share units) granted during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which option holders acquired shares when converting their stock options into shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 54 R27.htm IDEA: XBRL DOCUMENT v3.20.1

EQUIPMENT (Details) - USD ($)

Dec. 31, 2019

Dec. 31, 2018

Property and equipment, gross $ 139,333 $ 151,534

Accumulated depreciation (95,488) (92,907)

Property and equipment, net 43,845 58,627

Office Equipment [Member]

Property and equipment, gross 2,934 2,934

Vehicles [Member]

Property and equipment, gross 70,208 70,208

Wheelchair rental pool [Member]

Property and equipment, gross $ 66,191 $ 78,392

X

- Definition
Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.14)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=cmds_WheelchairRentalPoolMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 55 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 56 R23.htm IDEA: XBRL DOCUMENT v3.20.1

ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)
12 Months Ended

Dec. 31, 2019

Dec. 31, 2018

Revenue recognition percent 100.00% 100.00%

Medicare

Revenue recognition percent 19.00% 29.00%

Medicaid

Revenue recognition percent 7.00% 9.00%

Private pay/private insurance

Revenue recognition percent 73.00% 58.00%

Other

Revenue recognition percent 1.00% 4.00%

X

- References
No definition available.
+ Details

Name: cmds_RevenueRecognitionPercent

Namespace Prefix: cmds_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ConcentrationRiskByTypeAxis=cmds_MedicareMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByTypeAxis=cmds_MedicaidMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByTypeAxis=cmds_PrivatePayPrivateInsuranceMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByTypeAxis=cmds_OtherMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 57 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 52 276 1 false 17 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://canfieldmedical.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - BALANCE SHEETS Sheet http://canfieldmedical.com/role/BalanceSheets BALANCE SHEETS Statements 2 false false R3.htm 00000003 - Statement - BALANCE SHEETS (Parenthetical) Sheet http://canfieldmedical.com/role/BalanceSheetsParenthetical BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - STATEMENTS OF OPERATIONS Sheet http://canfieldmedical.com/role/StatementsOfOperations STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 00000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) Sheet http://canfieldmedical.com/role/StatementsOfStockholdersEquityDeficit STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) Statements 5 false false R6.htm 00000006 - Statement - STATEMENTS OF CASH FLOWS Sheet http://canfieldmedical.com/role/StatementsOfCashFlows STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 00000007 - Disclosure - ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://canfieldmedical.com/role/OrganizationOperationsAndSummaryOfSignificantAccountingPolicies ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 7 false false R8.htm 00000008 - Disclosure - EQUIPMENT Sheet http://canfieldmedical.com/role/Equipment EQUIPMENT Notes 8 false false R9.htm 00000009 - Disclosure - LINE OF CREDIT Sheet http://canfieldmedical.com/role/LineOfCredit LINE OF CREDIT Notes 9 false false R10.htm 00000010 - Disclosure - RELATED PARTY LOAN Sheet http://canfieldmedical.com/role/RelatedPartyLoan RELATED PARTY LOAN Notes 10 false false R11.htm 00000011 - Disclosure - LONG-TERM DEBT Sheet http://canfieldmedical.com/role/Long-termDebt LONG-TERM DEBT Notes 11 false false R12.htm 00000012 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://canfieldmedical.com/role/StockholdersEquity STOCKHOLDERS' EQUITY Notes 12 false false R13.htm 00000013 - Disclosure - LEASE COMMITMENTS Sheet http://canfieldmedical.com/role/LeaseCommitments LEASE COMMITMENTS Notes 13 false false R14.htm 00000014 - Disclosure - GOING CONCERN Sheet http://canfieldmedical.com/role/GoingConcern GOING CONCERN Notes 14 false false R15.htm 00000015 - Disclosure - SUBSEQUENT EVENTS Sheet http://canfieldmedical.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 15 false false R16.htm 00000016 - Disclosure - ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://canfieldmedical.com/role/OrganizationOperationsAndSummaryOfSignificantAccountingPoliciesPolicies ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 16 false false R17.htm 00000017 - Disclosure - ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://canfieldmedical.com/role/OrganizationOperationsAndSummaryOfSignificantAccountingPoliciesTables ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://canfieldmedical.com/role/OrganizationOperationsAndSummaryOfSignificantAccountingPolicies 17 false false R18.htm 00000018 - Disclosure - EQUIPMENT (Tables) Sheet http://canfieldmedical.com/role/EquipmentTables EQUIPMENT (Tables) Tables http://canfieldmedical.com/role/Equipment 18 false false R19.htm 00000019 - Disclosure - LONG-TERM DEBT (Tables) Sheet http://canfieldmedical.com/role/Long-termDebtTables LONG-TERM DEBT (Tables) Tables http://canfieldmedical.com/role/Long-termDebt 19 false false R20.htm 00000020 - Disclosure - STOCKHOLDERS' EQUITY (Tables) Sheet http://canfieldmedical.com/role/StockholdersEquityTables STOCKHOLDERS' EQUITY (Tables) Tables http://canfieldmedical.com/role/StockholdersEquity 20 false false R21.htm 00000021 - Disclosure - LEASE COMMITMENTS (Tables) Sheet http://canfieldmedical.com/role/LeaseCommitmentsTables LEASE COMMITMENTS (Tables) Tables http://canfieldmedical.com/role/LeaseCommitments 21 false false R22.htm 00000022 - Disclosure - ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Sheet http://canfieldmedical.com/role/OrganizationOperationsAndSummaryOfSignificantAccountingPoliciesDetails ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Details http://canfieldmedical.com/role/OrganizationOperationsAndSummaryOfSignificantAccountingPoliciesTables 22 false false R23.htm 00000023 - Disclosure - ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) Sheet http://canfieldmedical.com/role/OrganizationOperationsAndSummaryOfSignificantAccountingPoliciesDetails1 ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) Details http://canfieldmedical.com/role/OrganizationOperationsAndSummaryOfSignificantAccountingPoliciesTables 23 false false R24.htm 00000024 - Disclosure - ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2) Sheet http://canfieldmedical.com/role/OrganizationOperationsAndSummaryOfSignificantAccountingPoliciesDetails2 ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2) Details http://canfieldmedical.com/role/OrganizationOperationsAndSummaryOfSignificantAccountingPoliciesTables 24 false false R25.htm 00000025 - Disclosure - ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3) Sheet http://canfieldmedical.com/role/OrganizationOperationsAndSummaryOfSignificantAccountingPoliciesDetails3 ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3) Details http://canfieldmedical.com/role/OrganizationOperationsAndSummaryOfSignificantAccountingPoliciesTables 25 false false R26.htm 00000026 - Disclosure - ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://canfieldmedical.com/role/OrganizationOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://canfieldmedical.com/role/OrganizationOperationsAndSummaryOfSignificantAccountingPoliciesTables 26 false false R27.htm 00000027 - Disclosure - EQUIPMENT (Details) Sheet http://canfieldmedical.com/role/EquipmentDetails EQUIPMENT (Details) Details http://canfieldmedical.com/role/EquipmentTables 27 false false R28.htm 00000028 - Disclosure - EQUIPMENT (Details 1) Sheet http://canfieldmedical.com/role/EquipmentDetails1 EQUIPMENT (Details 1) Details http://canfieldmedical.com/role/EquipmentTables 28 false false R29.htm 00000029 - Disclosure - EQUIPMENT (Details Narrative) Sheet http://canfieldmedical.com/role/EquipmentDetailsNarrative EQUIPMENT (Details Narrative) Details http://canfieldmedical.com/role/EquipmentTables 29 false false R30.htm 00000030 - Disclosure - LINE OF CREDIT (Details Narrative) Sheet http://canfieldmedical.com/role/LineOfCreditDetailsNarrative LINE OF CREDIT (Details Narrative) Details http://canfieldmedical.com/role/LineOfCredit 30 false false R31.htm 00000031 - Disclosure - RELATED PARTY LOAN (Details Narrative) Sheet http://canfieldmedical.com/role/RelatedPartyLoanDetailsNarrative RELATED PARTY LOAN (Details Narrative) Details http://canfieldmedical.com/role/RelatedPartyLoan 31 false false R32.htm 00000032 - Disclosure - LONG-TERM DEBT (Details) Sheet http://canfieldmedical.com/role/Long-termDebtDetails LONG-TERM DEBT (Details) Details http://canfieldmedical.com/role/Long-termDebtTables 32 false false R33.htm 00000033 - Disclosure - LONG-TERM DEBT (Details 1) Sheet http://canfieldmedical.com/role/Long-termDebtDetails1 LONG-TERM DEBT (Details 1) Details http://canfieldmedical.com/role/Long-termDebtTables 33 false false R34.htm 00000034 - Disclosure - STOCKHOLDERS' EQUITY (Details) Sheet http://canfieldmedical.com/role/StockholdersEquityDetails STOCKHOLDERS' EQUITY (Details) Details http://canfieldmedical.com/role/StockholdersEquityTables 34 false false R35.htm 00000035 - Disclosure - STOCKHOLDERS' EQUITY (Details 1) Sheet http://canfieldmedical.com/role/StockholdersEquityDetails1 STOCKHOLDERS' EQUITY (Details 1) Details http://canfieldmedical.com/role/StockholdersEquityTables 35 false false R36.htm 00000036 - Disclosure - STOCKHOLDERS' EQUITY (Details 2) Sheet http://canfieldmedical.com/role/StockholdersEquityDetails2 STOCKHOLDERS' EQUITY (Details 2) Details http://canfieldmedical.com/role/StockholdersEquityTables 36 false false R37.htm 00000037 - Disclosure - STOCKHOLDERS??? EQUITY (Details Narrative) Sheet http://canfieldmedical.com/role/StockholdersEquityDetailsNarrative STOCKHOLDERS??? EQUITY (Details Narrative) Details 37 false false R38.htm 00000038 - Disclosure - LEASE COMMITMENTS (Details) Sheet http://canfieldmedical.com/role/LeaseCommitmentsDetails LEASE COMMITMENTS (Details) Details http://canfieldmedical.com/role/LeaseCommitmentsTables 38 false false R39.htm 00000039 - Disclosure - LEASE COMMITMENTS (Details 1) Sheet http://canfieldmedical.com/role/LeaseCommitmentsDetails1 LEASE COMMITMENTS (Details 1) Details http://canfieldmedical.com/role/LeaseCommitmentsTables 39 false false R40.htm 00000040 - Disclosure - LEASE COMMITMENTS (Details 2) Sheet http://canfieldmedical.com/role/LeaseCommitmentsDetails2 LEASE COMMITMENTS (Details 2) Details http://canfieldmedical.com/role/LeaseCommitmentsTables 40 false false R41.htm 00000041 - Disclosure - LEASE COMMITMENTS (Details Narrative) Sheet http://canfieldmedical.com/role/LeaseCommitmentsDetailsNarrative LEASE COMMITMENTS (Details Narrative) Details http://canfieldmedical.com/role/LeaseCommitmentsTables 41 false false All Reports Book All Reports cmds-20191231.xml cmds-20191231.xsd cmds-20191231_cal.xml cmds-20191231_def.xml cmds-20191231_lab.xml cmds-20191231_pre.xml http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2019-01-31 true true XML 58 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}

LEASE COMMITMENTS (Details 2)	Dec. 31, 2019 USD ($)
Leases [Abstract]
2020	$ 20,628
Less: Imputed interest/present value discount	(1,910)
Present value of lease liability	$ 18,718

EQUIPMENT (Details 1)	12 Months Ended
EQUIPMENT (Details 1)	Dec. 31, 2019
Office Equipment [Member]
Useful life of asset (in years)	7 years
Vehicles [Member]
Useful life of asset (in years)	5 years
Wheelchair rental pool [Member]
Useful life of asset (in years)	13 months

LEASE COMMITMENTS (Details Narrative) - USD ($)	12 Months Ended
LEASE COMMITMENTS (Details Narrative) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Leases [Abstract]
Office space approximate monthly payment	$ 2,292
Lease expense	$ 27,504	$ 27,504

STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
STATEMENTS OF CASH FLOWS - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Cash Flows From Operating Activities:
Net income (loss)	$ (477,234)	$ 68,206
Adjustments to reconcile net income (loss) to net cash provided by (used for) operating activities:
Gain on disposal of fixed assets	(1,037)	(7,246)
Depreciation	63,758	62,825
Stock-based compensation	160,786	0
Changes in current assets and liabilities:
Increase in accounts receivable	(8,629)	(149,731)
(Increase) decrease in inventory	11,136	(16,486)
Increase in accounts payable and accrued liabilities	22,815	104,824
Net cash provided by (used for) operating activities	(228,405)	62,392
Cash Flows From Investing Activities:
Proceeds from sale of fixed assets	6,446	8,064
Purchase of property and equipment	(54,385)	(75,633)
Net cash provided by (used for) investing activities	(47,939)	(67,569)
Cash Flows From Financing Activities:
Net borrowings (payments) on line of credit	3,353	3,803
Proceeds from officer	276,550	0
Payments to officer	(78,701)	0
Payments on long-term debt	(8,523)	(11,567)
Proceeds from sales of common stock	100,000	2,000
Net cash provided by (used for) financing activities	292,679	(5,764)
Net Increase (Decrease) in Cash	16,335	(10,941)
Cash at the Beginning of the Period	6,980	17,921
Cash at the End of the Period	23,315	6,980
Schedule Of Non-Cash Investing And Financing Activities
Lease liability and right-of-use-asset	43,677	0
Amortization of right-of-use asset	24,959	0
Supplemental Disclosure
Cash paid for interest	8,376	5,715
Cash paid for income taxes	$ 0	$ 0

BALANCE SHEETS - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Current Assets
Cash	$ 23,315	$ 6,980
Accounts receivable	309,622	300,993
Inventory	30,559	41,695
Right-of-use asset	18,718	0
Total Current Assets	382,214	349,668
Equipment, net of accumulated depreciation of $95,488 and $92,907	43,845	58,627
Total Assets	426,059	408,295
Current Liabilities
Accounts payable and accrued liabilities	353,849	331,034
Line of credit	69,534	66,181
Due from officer	197,849	0
Lease liability	18,718	0
Current portion of long-term debt	3,152	8,241
Total Current liabilities	643,102	405,456
Long-term Liabilities
Long-term debt	2,064	5,498
Total Long-term liabilities	2,064	5,498
Total liabilities	645,166	410,954
Stockholders' Equity (Deficit)
Preferred stock, no par value; 5,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock, no par value; 100,000,000 shares authorized; 11,813,200 (December 31, 2019) and 11,477,200 (December 31, 2018) shares issued and outstanding	345,515	245,515
Additional paid-in capital	160,786	0
Accumulated deficit	(725,408)	(248,174)
Total Stockholders' Equity (Deficit)	(219,107)	(2,659)
Total Liabilities and Stockholders' Equity (Deficit)	$ 426,059	$ 408,295

RELATED PARTY LOAN (Details Narrative) - USD ($)	12 Months Ended
RELATED PARTY LOAN (Details Narrative) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Related Party Transactions [Abstract]
Term	1 year
Related party loan	$ 197,849	$ 0
Repayments of Related Party Loan	$ (78,701)	$ 0

STOCKHOLDERS' EQUITY (Details 1) - $ / shares	12 Months Ended
STOCKHOLDERS' EQUITY (Details 1) - $ / shares	Dec. 31, 2019	Dec. 31, 2018
Equity [Abstract]
Dividend yield	0.00%
Expected volatility	314.95%
Risk-free interest rate	1.58%
Expected life (years)	2 years
Stock Price		$ 0.55
Exercise Price		$ 0.55

LEASE COMMITMENTS (Details 1)	12 Months Ended
LEASE COMMITMENTS (Details 1)	Dec. 31, 2019 USD ($)
Right-of-Use Asset
ROU Asset, at beginning	$ 43,677
Amortization of ROU Asset	(24,959)
ROU Asset, at end	$ 18,718

ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
	Jun. 21, 2019	Dec. 31, 2019	Dec. 31, 2018
Proceeds from sales of common stock		$ 100,000	$ 2,000
Number of shares sold for proceeds		336,000	200,000
Allowance for doubtful accounts		$ 0	$ 0
Advertising cost		13,453	18,129
Net operating loss carryforwards		$ 462,000	$ 144,000
Federal tax rate		21.00%	21.00%
State tax rate		5.00%	5.00%
Loss carryforwards		$ 120,000	$ 37,440
Change in valuation allowance		82,560	$ (19,760)
Deferred tax assets		$ 120,000
WesBev
Shares Aquired	8,000,000
Percentage of acquisition	69.70%
Proceeds from sales of common stock	$ 100,000
Number of shares sold for proceeds	336,000
Total shares	8,336,000

ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Total	$ 30,559	$ 41,695
Durable medical equipment
Total	22,759	33,570
Medical supplies
Total	249	1,076
Enteral
Total	$ 7,551	$ 7,049

STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
STATEMENTS OF OPERATIONS - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Income Statement [Abstract]
Sales (net of returns)	$ 1,017,833	$ 1,309,178
Cost of goods sold	508,874	605,273
Gross profit	508,959	703,905
Operating expenses:
Salaries and wages	517,725	320,470
Professional fees	193,797	59,625
Depreciation	63,758	62,825
Other selling, general and administrative	204,075	194,310
Total operating expenses	979,355	637,230
Income (loss) from operations	(470,396)	66,675
Other income (expense):
Interest income	501	0
Interest expense	(8,376)	(5,715)
Gain on sale of fixed assets	1,037	7,246
Total other income (expense)	(6,838)	1,531
Income (loss) before provision for income taxes	(477,234)	68,206
Provision for income tax	0	0
Net income (loss)	$ (477,234)	$ 68,206
Net income (loss) per share applicable to common shareholders - basic	$ (0.04)	$ 0.01
Net income (loss) per share applicable to common shareholders - diluted	$ (0.04)	$ 0.01
Weighted average number of common shares outstanding - basic	11,635,534	11,385,693
Weighted average number of common shares outstanding - diluted	11,935,534	11,385,693

LONG-TERM DEBT (Details 1)	Dec. 31, 2019 USD ($)
Debt Disclosure [Abstract]
2020	$ 3,152
2021	2,064
Total	$ 5,216

STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)	12 Months Ended
STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Equity [Abstract]
Proceeds from sales of common stock	$ 100,000	$ 2,000
Number of shares sold for proceeds	336,000	200,000
Value of common stock sold (per share)	$ 0.298	$ 0.01
Stock based compensation	$ 160,786	$ 0
Unrecognized compensation	$ 0

STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)	Common Stock (no par)	Additional Paid-In Capital	Accumulated Deficit	Total
Beginning Balance at Dec. 31, 2017	$ 243,515		$ (316,380)	$ (72,865)
Beginning Balance, in Shares at Dec. 31, 2017	11,277,200
Common stock issued for cash	$ 2,000			2,000
Common stock issued for cash, in Shares	200,000
Net income (loss) for the year			68,206	68,206
Ending Balance at Dec. 31, 2018	$ 245,515		(248,174)	(2,659)
Ending Balance, in Shares at Dec. 31, 2018	11,477,200
Common stock issued for cash	$ 100,000			100,000
Common stock issued for cash, in Shares	336,000
Stock options granted and vested		160,786		160,786
Net income (loss) for the year			(477,234)	(477,234)
Ending Balance at Dec. 31, 2019	$ 345,515	$ 160,786	$ (725,408)	$ (219,107)
Ending Balance, in Shares at Dec. 31, 2019	11,813,200

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2019	Mar. 27, 2020	Jun. 30, 2019
Document And Entity Information
Entity Registrant Name	CANFIELD MEDICAL SUPPLY, INC.
Entity Central Index Key	0001553788
Document Type	10-K
Document Period End Date	Dec. 31, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	true
Entity Small Business	true
Entity Ex Transition Period	true
Entity Shell Company	false
Entity Interactive Data Current	Yes
Entity File Number	000-55114
Entity Incorporation, State or Country Code	CO
Entity Public Float			$ 3,683,160
Entity Common Stock, Shares Outstanding		11,813,200
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2019

LONG-TERM DEBT (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Long Term Gross	$ 5,216	$ 13,739
Less principal due within one year	(3,152)	(8,241)
Total Long Term debt	2,064	5,498
Long-term Debt One [Member]
Note Payable, monthly installment	352
Long Term Gross	0	2,782
Long-term Debt Two [Member]
Note Payable, monthly installment	299
Long Term Gross	5,216	8,532
Long-term Debt Three [Member]
Note Payable, monthly installment	350
Long Term Gross	$ 0	$ 2,425

STOCKHOLDERS' EQUITY (Details 2)	12 Months Ended
STOCKHOLDERS' EQUITY (Details 2)	Dec. 31, 2019 $ / shares shares
Shares
Shares Outstanding, beginning of year \| shares	0
Shares Granted \| shares	300,000
Shares Exercised \| shares	0
Shares Canceled \| shares	0
Shares Outstanding, end of year \| shares	300,000
Weighted Average Exercise Price
Weighted average exercise price - Outstanding, beginning of year	$ 0
Weighted average exercise price - shares Granted	0.55
Weighted average exercise price - shares Exercised	0
Weighted average exercise price - shares Cancelled	0
Weighted average exercise price - Outstanding, end of year	0.55
Weighted average fair value of options granted	$ 0.55

EQUIPMENT (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Property and equipment, gross	$ 139,333	$ 151,534
Accumulated depreciation	(95,488)	(92,907)
Property and equipment, net	43,845	58,627
Office Equipment [Member]
Property and equipment, gross	2,934	2,934
Vehicles [Member]
Property and equipment, gross	70,208	70,208
Wheelchair rental pool [Member]
Property and equipment, gross	$ 66,191	$ 78,392

ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Revenue recognition percent	100.00%	100.00%
Medicare
Revenue recognition percent	19.00%	29.00%
Medicaid
Revenue recognition percent	7.00%	9.00%
Private pay/private insurance
Revenue recognition percent	73.00%	58.00%
Other
Revenue recognition percent	1.00%	4.00%